KOL | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
के लिए फिर से शुरू Harry Roger Büller
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Harry Roger Büller: आँकड़ों को प्रभावित करें
रिपोर्ट चलाएं
| Concept | World rank |
|---|---|
| age∗10μg | #1 |
| deep vein thrombosis | #1 |
| relevant major | #1 |
| ultrasonography dvt | #1 |
| perfusion scan | #1 |
| pyridines recurrence | #1 |
| somittrial | #1 |
| animal female heparin | #1 |
| baseline characteristics duration | #1 |
| fibrinolysis levels | #1 |
| lmwh rtap | #1 |
| coagulation fibrinolytic proteins | #1 |
| respondents 60 | #1 |
| cancer patients cvcs | #1 |
| relative risks carriers | #1 |
| vivo coagulation factor | #1 |
| oral rivaroxaban treatment | #1 |
| severity clinical presentation | #1 |
| risk homozygous women | #1 |
| uesvt patients | #1 |
| lowmolecularweight heparin treatment | #1 |
| study centre duration | #1 |
| time recombinant | #1 |
| anticoagulants double | #1 |
| single dose tb402 | #1 |
| lmwh users incidence | #1 |
| safety 60 dose | #1 |
| treatment venous | #1 |
| idraparinux versus | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| placebo 25mg apixaban | #1 |
| vte study | #1 |
| symptomatic legs dvt | #1 |
| relatives normal levels | #1 |
| ultrasonography diagnostic | #1 |
| vitamin antagonist patients | #1 |
| clinically relevant disease | #1 |
| vitamin antagonists treatment | #1 |
| 12 kg1 enoxaparin | #1 |
| smoking patency | #1 |
| anticoagulation period | #1 |
| dose response apixaban | #1 |
| lowmolecularweight heparin 95 | #1 |
| quantitative ddimer tests | #1 |
| absolute thrombotic risk | #1 |
| timeperiod | #1 |
| failure rate efficiency | #1 |
| smoking graft patency | #1 |
| combination cdrs | #1 |
| women elevated levels | #1 |
| dose rnapc2 | #1 |
| silent dvt | #1 |
| probability categories | #1 |
| suspected deep | #1 |
| anticoagulant treatment vte | #1 |
| association protein levels | #1 |
| uedvt recurrent vte | #1 |
| tomography angiography vte | #1 |
| rivaroxaban standard therapy | #1 |
| 8h flight | #1 |
| embolism randomized | #1 |
| cdrscore | #1 |
| heparins cancer patients | #1 |
| carriers recurrence | #1 |
| rtap lmwh | #1 |
| suspected symptomatic | #1 |
| revascularisation procedures patients | #1 |
| ili score | #1 |
| screening carriers | #1 |
| protein levels mortality | #1 |
| randomized studies efficacy | #1 |
| ldf diagnosis | #1 |
| relatives normal fviii | #1 |
| method factor | #1 |
| reduceddose noacs warfarin | #1 |
| ankle brachial prevalence | #1 |
| elevated cardiac troponins | #1 |
| category perelated death | #1 |
| heparin vitamin antagonist | #1 |
| 2479 relatives | #1 |
| embolism radionuclide | #1 |
| leg veins patients | #1 |
| patients khorana | #1 |
| tests venography | #1 |
| coagulationinhibiting | #1 |
| compression ultrasonography detection | #1 |
| diagnostic strategies patients | #1 |
| 250 patients cancer | #1 |
| death category | #1 |
| vitamin antagonists time | #1 |
| recurrence major bleeding | #1 |
| quantitative ddimer test | #1 |
| levels procoagulant factors | #1 |
| initial heparin patients | #1 |
| chest perfusion scintigraphy | #1 |
| normal ddimer concentration | #1 |
| infections gentamicin | #1 |
| crptest | #1 |
| selective ddimer thresholds | #1 |
| pulmonary angiography strategies | #1 |
| pulmonary embolism studies | #1 |
| doac recipients | #1 |
| standard therapy months | #1 |
| idraparinux 25 | #1 |
| doubleheterozygotes | #1 |
| ventilation scan chest | #1 |
| fviii women | #1 |
| venography tests | #1 |
| evaluable patients 95 | #1 |
| patients initial heparin | #1 |
| probabilityscan | #1 |
| 53 amputations | #1 |
| thromboembolism relatives | #1 |
| orthopedic surgery netherlands | #1 |
| desogestrelcontaining coagulation factors | #1 |
| incidence venous | #1 |
| cus strategies | #1 |
| 50 rivaroxaban | #1 |
| progression vte | #1 |
| vte day | #1 |
| qscan | #1 |
| enoxaparin vkas | #1 |
| preference doacs | #1 |
| patients malignancy | #1 |
| 3 idraparinux | #1 |
| isolated deficiencies proteins | #1 |
| thromboembolism 3 | #1 |
| endotoxemia tests | #1 |
| members symptomatic carriers | #1 |
| safety outcome | #1 |
| 378 patients edoxaban | #1 |
| deepvein thrombosis incidence | #1 |
| diagnostic management patients | #1 |
| analysis hokusai | #1 |
| predefined outcomes vte | #1 |
| 95 elevated ctni | #1 |
| 3 rfviia | #1 |
| lmwh delivery | #1 |
| idrabiotaparinux idraparinux | #1 |
| crp test patients | #1 |
| category death | #1 |
| hyperhomocysteinemia relatives | #1 |
| aptt org 10172 | #1 |
| plateletactivating antibodies risk | #1 |
| intestinal microbiota coagulation | #1 |
| obese controls difference | #1 |
| clinical presentation category | #1 |
| platelets iqr | #1 |
| combined training gps | #1 |
| coagulation clinical | #1 |
| constans score | #1 |
| heparin org 10172 | #1 |
| frequency venous thromboembolism | #1 |
| patients mismatched scan | #1 |
| scenarioanalysis | #1 |
| prophylaxis crt | #1 |
| thrombo‐embolic events | #1 |
| laalleles | #1 |
| normal levels fviii | #1 |
| pulmonary angiography ultrasonography | #1 |
| normal lung scan | #1 |
| early time recurrence | #1 |
| warfarin cancer patients | #1 |
| procoagulant factors levels | #1 |
| idraparinux vitamin antagonist | #1 |
| matisse clinical trials | #1 |
| decisions duration | #1 |
| tb402 12 kg1 | #1 |
| rule cdr | #1 |
| fetal loss stillbirth | #1 |
| travel venous thromboembolism | #1 |
| elevated fviii patients | #1 |
| probability lung scan | #1 |
| rnapc2 groups placebo | #1 |
| antidote vitamin | #1 |
| equinox study | #1 |
| prophylaxis idraparinux | #1 |
| rnapc2 groups | #1 |
| unexplained dvt patients | #1 |
| venous thrombosis recurrence | #1 |
| symptomatic recurrent vte | #1 |
| older patients cdr | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| heparins vitamin antagonists | #1 |
| subsequent diagnosis malignancy | #1 |
| einsteindvt | #1 |
| idraparinux standard therapy | #1 |
| 50 years combination | #1 |
| vte occurred | #1 |
| rate recurrent | #1 |
| malignancy achieved inr | #1 |
| preferred oral anticoagulant | #1 |
| graft patency patency | #1 |
| 0·620·74 | #1 |
| failure diagnostic management | #1 |
| mdct expert radiologist | #1 |
| dalteparin vte treatment | #1 |
| intracranial clinical presentation | #1 |
| 25mg apixaban | #1 |
| ft4 level patients | #1 |
| death vte studies | #1 |
| subsequent symptomatic cancer | #1 |
| venography feasibility | #1 |
| oral apixaban treatment | #1 |
| elevated levels fviii | #1 |
| scan pulmonary embolism | #1 |
| consensus strategy strategy | #1 |
| sgs pretest probability | #1 |
| synthetic selective factor | #1 |
| symptomatic recurrent | #1 |
| hellp syndrome mutations | #1 |
| clinically suspected dvt | #1 |
| management study | #1 |
| patients unexplained dvt | #1 |
| simplified wells rule | #1 |
| obstetric complications relatives | #1 |
| cancer patients cdr | #1 |
| local radiologist experts | #1 |
| dvt 56 | #1 |
| administration lmwh | #1 |
| patients normal tests | #1 |
| patency smokers | #1 |
| pulmonary embolism basis | #1 |
| sspe proximal | #1 |
| tests pulmonary embolism | #1 |
| embolism wells | #1 |
| dvt 3 | #1 |
| popliteal veins sensitivity | #1 |
| uesvt median | #1 |
| atherosclerosis hemophilia patients | #1 |
| cdr ddimer levels | #1 |
| united states rnapc2 | #1 |
| flebography | #1 |
| combination ddimer testing | #1 |
| amplify trial apixaban | #1 |
| loss subsequent pregnancy | #1 |
| protein mortality | #1 |
| followup overt cancer | #1 |
| ddimer test | #1 |
| normal ddimer result | #1 |
| patients artificial graft | #1 |
| bleeding risk lmwh | #1 |
| ctscan qscan | #1 |
| initial treatment dvt | #1 |
| lmwh plasma levels | #1 |
| treatment idraparinux | #1 |
| rhir lmwh | #1 |
| feasibility venography | #1 |
| pulmonary embolism life | #1 |
| cdr normal | #1 |
| duration heparin treatment | #1 |
| apixaban extended treatment | #1 |
| relevant bleeding | #1 |
| pulmonary embolism fondaparinux | #1 |
| annual incidence patients | #1 |
| strategy abdominal pelvic | #1 |
| aptt org | #1 |
| strategies abdominal pelvic | #1 |
| absolute annual incidences | #1 |
| ddimer levels cdr | #1 |
| variable d‐dimer thresholds | #1 |
| total vte patients | #1 |
| venous thromboembolism episode | #1 |
| 95 3633 patients | #1 |
| compression ultrasonography presentation | #1 |
| cancer patients patients | #1 |
| cancer patients ufh | #1 |
| protecht shr | #1 |
| asymptomatic extension | #1 |
| khorana | #1 |
| bmi fondaparinux | #1 |
| efficacy vte | #1 |
| beta thromboglobulin org | #1 |
| einstein dvt patients | #1 |
| uesvt mortality | #1 |
| wells simplified | #1 |
| symptomatic venous | #1 |
| departments pharmacological prophylaxis | #1 |
| 5 avidin infusion | #1 |
| casedescription | #1 |
| cancer cdr | #1 |
| acenocoumarol efficacy | #1 |
| perelated death category | #1 |
| ldf cus | #1 |
| scores occult cancer | #1 |
| individualized duration | #1 |
| probability cdr | #1 |
| lmwh immobilization | #1 |
| 750 μg l1 | #1 |
| extended anticoagulation doacs | #1 |
| tb402 prevention | #1 |
| fviii normal levels | #1 |
| previous surveys netherlands | #1 |
| ambulatory computers | #1 |
| clinical uedvt | #1 |
| apc resistance factor | #1 |
| lmwh acute treatment | #1 |
| falsenormal | #1 |
| avidin vte | #1 |
| doses 75 microg | #1 |
| puerperium diagnostic suspicion | #1 |
| inr studies | #1 |
| patients uedvt uesvt | #1 |
| increasing levels ft4 | #1 |
| enoxaparin primary efficacy | #1 |
| vte fatal | #1 |
| recommendations dvt | #1 |
| heparin initial treatment | #1 |
| edoxaban risk factors | #1 |
| principal safety | #1 |
| departments orthopedic surgery | #1 |
| obese hemophilic patients | #1 |
| rule exclusion | #1 |
| ccus 4 | #1 |
| prolactin venous thrombosis | #1 |
| thrice daily gentamicin | #1 |
| outpatients symptomatic dvt | #1 |
| recurrent vte statin | #1 |
| enoxaparin tb402 | #1 |
| patients ivte | #1 |
| apixaban randomized patients | #1 |
| 6 months avidin | #1 |
| axa activity 5 | #1 |
| anticoagulant fondaparinux | #1 |
| thrombophilia late loss | #1 |
| 0·2 3633 patients | #1 |
| exclusion pulmonary | #1 |
| uesvt recurrent vte | #1 |
| cancer patients cancer | #1 |
| d‐dimer test | #1 |
| clinical probability patients | #1 |
| level loss patency | #1 |
| patients antithrombotic prescriptions | #1 |
| excluded pulmonary | #1 |
| inr range ttr | #1 |
| anticoagulants probability | #1 |
| 20210a mutation | #1 |
| vka treatment treatment | #1 |
| intravenous unfractionated | #1 |
| vte addition | #1 |
| wells cdr | #1 |
| prothrombin individuals | #1 |
| wells rules | #1 |
| coagulation factors markers | #1 |
| rivaroxaban acute dvt | #1 |
| laalleles platelets | #1 |
| prevalence coagulation | #1 |
| pvo qscan | #1 |
| survival fondaparinux | #1 |
| fviii venous thromboembolism | #1 |
| withheld | #1 |
| ufh grade | #1 |
| bleeding rates quality | #1 |
| proportion 75 years | #1 |
| alternative diagnoses patients | #1 |
| upper extremity uedvt | #1 |
| predefined outcomes | #1 |
| 36 papers | #1 |
| simplified geneva score | #1 |
| cancer edoxaban | #1 |
| vka share | #1 |
| uesvt uedvt | #1 |
| recurrent thrombosis pts | #1 |
| distal clots | #1 |
| ml1 ctpa | #1 |
| thiazoles venous | #1 |
| patients compression ultrasonography | #1 |
| pregnancyrelated complications relatives | #1 |
| efficacy outcome | #1 |
| 7268 patients suspected | #1 |
| matisse trials | #1 |
| nonhigh cdr | #1 |
| gogh dvt trial | #1 |
| bleeding clinically | #1 |
| vka netherlands | #1 |
| replacement vka | #1 |
| thromboembolism treated | #1 |
| incidence ctni | #1 |
| 9 incidence | #1 |
| patients enoxaparin vkas | #1 |
| outcome clinically | #1 |
| aged nadroparin | #1 |
| strategies ultrasonography | #1 |
| subcutaneous nadroparin placebo | #1 |
| svt lmwh | #1 |
| dalteparin major bleeding | #1 |
| failure cip | #1 |
| proportion pulmonary embolism | #1 |
| lmwh edoxaban | #1 |
| ventricular dysfunction edoxaban | #1 |
| pvo ctscan | #1 |
| ddimer test combination | #1 |
| 393 patients warfarin | #1 |
| rivaroxaban dvt treatment | #1 |
| matisse dvt | #1 |
| suspected perfusion scan | #1 |
| cdr ddimer test | #1 |
| individuals air travel | #1 |
| p0001 saline | #1 |
| travel‐related venous thrombosis | #1 |
| patients tb402 | #1 |
| idraparinux vte | #1 |
| edoxaban cancer patients | #1 |
| studies ttr | #1 |
| inherited thrombophilia patients | #1 |
| systematic search cteph | #1 |
| fetal loss carriers | #1 |
| limited screening 95 | #1 |
| uesvt | #1 |
| uedvt clinical | #1 |
| heparin acenocoumarol | #1 |
| residual thrombotic mass | #1 |
| proximal extent ipe | #1 |
| patients advanced malignancy | #1 |
| factor viii homocysteine | #1 |
| molecular weight fondaparinux | #1 |
| adjusted dose ufh | #1 |
| qscan 3 weeks | #1 |
| cancer 145 patients | #1 |
| calfvein thrombi | #1 |
| hokusaivte trial | #1 |
| recurrence bleeding risk | #1 |
| 023 relatives | #1 |
| embolism sensitivity | #1 |
| chromogenic endotoxin | #1 |
| fondaparinux rfviia injection | #1 |
| ctscanreading | #1 |
| poc test patients | #1 |
| polyethylenglycolhirudin | #1 |
| enoxaparin vkas treatment | #1 |
| rfviia idraparinux | #1 |
| pvoq | #1 |
| normotensive patients studies | #1 |
| original wells | #1 |
| plasma concentration fviii | #1 |
| fxainhibitors vka recipients | #1 |
| false normal | #1 |
| rfviia 3 | #1 |
| bleeding einstein | #1 |
| suspected cdr | #1 |
| embolism suspected | #1 |
| positive vte | #1 |
| noncarriers annual incidence | #1 |
| pulmonary embolism metaanalysis | #1 |
| 15 lmwh | #1 |
| combination cdr | #1 |
| vte airline pilots | #1 |
| doacs initial heparin | #1 |
| presentation major | #1 |
| timerequirement | #1 |
| patients idraparinux | #1 |
| control anticardiolipin antibodies | #1 |
| vte risk coc | #1 |
| patients deep | #1 |
| risk percentage points | #1 |
| oral edoxaban dose | #1 |
| treatment experimental thrombosis | #1 |
| org aptt | #1 |
| oral anticoagulants phase | #1 |
| compression ultrasonography patients | #1 |
| non‐invasive diagnostic work‐up | #1 |
| topic thrombophlebitis | #1 |
| association travel | #1 |
| months standard therapy | #1 |
| weight heparinoid | #1 |
| 5 years lmwh | #1 |
| extended anticoagulation apixaban | #1 |
| guideline adherence justification | #1 |
| anticoagulant treatment patients | #1 |
| elevated ctni patients | #1 |
| cart lower levels | #1 |
| activecontrol placebo | #1 |
| xageneration | #1 |
| heparins cancer spread | #1 |
| 7268 patients | #1 |
| pulmonary embolism carriers | #1 |
| cstatistic major bleeding | #1 |
| reduceddose noacs stroke | #1 |
| lmwh replacement | #1 |
| 5395 patients | #1 |
| prescriptionbased | #1 |
| cancer patients uedvt | #1 |
| clinically suspected cancer | #1 |
| early discharge strategies | #1 |
| doacs cirrhosis patients | #1 |
| gentamicin patients netilmicin | #1 |
| diagnostic strategies strategies | #1 |
| placebo rnapc2 | #1 |
| factor viii relatives | #1 |
| vka recipients | #1 |
| international thrombosis experts | #1 |
| wellscdr | #1 |
| dimer clinical | #1 |
| submassive elevated ctni | #1 |
| adjunct thrombolysis | #1 |
| abelacimab | #1 |
| dvt anticoagulants | #1 |
| venous thrombosis pregnancy | #1 |
| patients protein deficiencies | #1 |
| beneficial lmwh | #1 |
| presenting location women | #1 |
| prospective management study | #1 |
| risk pulmonary embolism | #1 |
| 97 compression ultrasonography | #1 |
| cdrscore combination | #1 |
| rabinov | #1 |
| cancer clinical presentation | #1 |
| selective beta‐blocker treatment | #1 |
| local radiologist | #1 |
| venous thromboembolism idraparinux | #1 |
| guidelines abi | #1 |
| lmwhmediated | #1 |
| conventional therapy enoxaparin | #1 |
| clinically suspected uedvt | #1 |
| pulmonary angiography study | #1 |
| evaluable patients apixaban | #1 |
| edoxabantreated | #1 |
| acute treatment lmwh | #1 |
| wells clinical | #1 |
| 5‐snp scores | #1 |
| relatives mutation | #1 |
| patients clinical probability | #1 |
| lmwh departments | #1 |
| elderly outpatients combination | #1 |
| intensity vkas doacs | #1 |
| heparins data | #1 |
| studies 3 months | #1 |
| avws prevalence | #1 |
| prediction models recurrence | #1 |
| vte risk day | #1 |
| patients laalleles | #1 |
| heparin vitamin | #1 |
| apc resistance tests | #1 |
| efficiency subgroups | #1 |
| 95 intracranial | #1 |
| controlled trials thrombophilia | #1 |
| ipe expert radiologists | #1 |
| recurrent vte doacs | #1 |
| hokusai‐vte trial | #1 |
| thrombophilia patients doacs | #1 |
| fviii homocysteine | #1 |
| edoxaban dalteparin | #1 |
| apixaban conventional therapy | #1 |
| venous thrombosis vwf | #1 |
| safety clinical utility | #1 |
| doacs factor | #1 |
| outcome recurrent | #1 |
| advanced malignancy | #1 |
| fviii vte | #1 |
| hokusaivte trial patients | #1 |
| cdrs patients | #1 |
| superficial thrombophlebitis incidence | #1 |
| xainhibitors | #1 |
| vte arterial | #1 |
| standardintensity vkas | #1 |
| tb402 enoxaparin | #1 |
| pulmonary embolism cdr | #1 |
| subcutaneous length life | #1 |
| year prophylaxis | #1 |
| dimer test | #1 |
| antithrombotic prescriptions adherence | #1 |
| longhaul flight | #1 |
| proximal location ipe | #1 |
| ddimer test patients | #1 |
| venous thromboembolism edoxaban | #1 |
| echocardiography normotensive patients | #1 |
| controlledstudy | #1 |
| idraparinux recurrent thromboembolism | #1 |
| reported incidence vte | #1 |
| ultrasonography leg veins | #1 |
| presenting vte location | #1 |
| cdr dimer | #1 |
| therapeutic doses lmwh | #1 |
| —brachial | #1 |
| study ecq | #1 |
| anticoagulants chemotherapy | #1 |
| cip diagnostic management | #1 |
| combination cdrscore | #1 |
| quantitative dimer | #1 |
| postthrombotic symptoms patients | #1 |
| fondaparinux unfractionated | #1 |
| deficiency proteins | #1 |
| heparinoid | #1 |
| carriers relative risks | #1 |
| fxiaso enoxaparin | #1 |
| standalone ddimer testing | #1 |
| patients treatment duration | #1 |
| relatives tafi levels | #1 |
| elevated fviii | #1 |
| abnormal ipg | #1 |
| perelated death classification | #1 |
| initial treatment patients | #1 |
| ultrasound strategies patients | #1 |
| lmprovement | #1 |
| clinical probability risk | #1 |
| venous thrombosis mutations | #1 |
| models development studies | #1 |
| quantitative ddimer testing | #1 |
| comparison vidas assay | #1 |
| idraparinux placebo | #1 |
| age multiple comorbidities | #1 |
| ivte clinical practice | #1 |
| ddimer test result | #1 |
| tinaquant assay comparison | #1 |
| pharmacological methods prophylaxis | #1 |
| protein resistance control | #1 |
| influenza case patients | #1 |
| hokusai‐vte cancer study | #1 |
| extended treatment edoxaban | #1 |
| intrinsic coagulation vivo | #1 |
| avidin placebo | #1 |
| double heterozygous carriers | #1 |
| mutation relatives | #1 |
| recurrent vte immobilization | #1 |
| dvt 69 | #1 |
| daily dalteparin treatment | #1 |
| abnormal vaginal bleeding | #1 |
| ddimer result | #1 |
| lmwhs 95 | #1 |
| mutation arg506 | #1 |
| successful attenuation | #1 |
| ldfr symptomatic legs | #1 |
| 5mg apixaban | #1 |
| presentation category | #1 |
| pulmonary embolism tests | #1 |
| prevention topic guidelines | #1 |
| rnapc2 patients | #1 |
| reocclusion antithrombotic drug | #1 |
| severe presentation patients | #1 |
| monoclonal antibodies apc | #1 |
| combination nonhigh cdr | #1 |
| thrombosis vte | #1 |
| 560 pharmacies | #1 |
| d‐dimer level | #1 |
| clinical probability exclusion | #1 |
| relatives elevated levels | #1 |
| recurrent dvt dvt | #1 |
| edoxaban warfarin groups | #1 |
| symptomatic pts | #1 |
| standard treatment idraparinux | #1 |
| wellsrule | #1 |
| wells rule primary | #1 |
| dvt symptomatic | #1 |
| patients acute recurrent | #1 |
| respondents lmwh | #1 |
| acenocoumarol initial treatment | #1 |
| noacs prevention | #1 |
| p0424 | #1 |
| elderly patients dvt | #1 |
| impedance thrombophlebitis | #1 |
| death venous thromboembolism | #1 |
| thrombosis vitamin | #1 |
| pulmonary embolism | #1 |
| elevated fviii age | #1 |
| 547253 | #1 |
| 65±9years | #1 |
| lowmolecularweight heparin category | #1 |
| aged venous | #1 |
| long haul flights | #1 |
| practiceassistants | #1 |
| ivte | #1 |
| sustained antithrombotic effects | #1 |
| pioped study study | #1 |
| diagnostic strategy primary | #1 |
| realtime bmode ultrasonography | #1 |
| dose daily edoxaban | #1 |
| messages justification | #1 |
| patients inherited thrombophilia | #1 |
| rule dimer | #1 |
| dalteparin 6 months | #1 |
| pulmonary embolism idraparinux | #1 |
| abdominal pelvic strategies | #1 |
| venous thrombus growth | #1 |
| mortality postthrombotic symptoms | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| compression ultrasonography | #1 |
| 0·2 edoxabantreated | #1 |
| ifngamma pselectin | #1 |
| fviii concentration | #1 |
| neoplasms heparin | #1 |
| low levels ft4 | #1 |
| vitamin anticoagulants | #1 |
| major bleeding cancer | #1 |
| women edoxaban | #1 |
| dvt costs | #1 |
| bleeding risk treatment | #1 |
| calf dvt ultrasound | #1 |
| efficacy heparin therapy | #1 |
| types major bleeding | #1 |
| fviii hyperhomocysteinemia | #1 |
| acquired atiii deficiency | #1 |
| category fxainhibitors | #1 |
| acenocoumarol heparin | #1 |
| 69 conclusions | #1 |
| extra hospital visits | #1 |
| threemonth incidence | #1 |
| vte procoagulant activity | #1 |
| idraparinux patients | #1 |
| normal venogram | #1 |
| enoxaparin heparin treatment | #1 |
| segmental subsegmental | #1 |
| single‐detector row | #1 |
| intravenous injections lmwh | #1 |
| vkas lmwh | #1 |
| rnapc2 inhibition | #1 |
| amplify trial | #1 |
| sensitivity 100 percent | #1 |
| undvt | #1 |
| 95ci tb402 | #1 |
| phase doacs | #1 |
| ultrasound compression ultrasound | #1 |
| hokusai vte cancer | #1 |
| efficacy conventional treatment | #1 |
| heparin initial | #1 |
| oral administration bsf | #1 |
| diagnosis deepvein thrombosis | #1 |
| reduceddose noacs | #1 |
| nadroparin patients | #1 |
| presenting location vte | #1 |
| rnapc2 united states | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| nadroparin therapeutic dose | #1 |
| dimer result | #1 |
| safety idraparinux | #1 |
| venous thrombosis hyperglycemia | #1 |
| 2 diagnostic management | #1 |
| achieved inr patients | #1 |
| normal dimer | #1 |
| included patients study | #1 |
| extensive screening cancer | #1 |
| progression svt | #1 |
| iii plg | #1 |
| simple diagnostic strategy | #1 |
| carriers pulmonary embolism | #1 |
| riskstroponin | #1 |
| elevated biomarkers hospital | #1 |
| double reports | #1 |
| specificity pulmonary embolism | #1 |
| presence venous thrombosis | #1 |
| baseline pvo | #1 |
| 208791 | #1 |
| idraparinux months | #1 |
| ventilation lung scanning | #1 |
| 500 org | #1 |
| milliliter enoxaparin | #1 |
| fetal loss miscarriage | #1 |
| hemorrhage heparin | #1 |
| treated vka | #1 |
| scores riete score | #1 |
| patients advanced prostate | #1 |
| cvc crt | #1 |
| netherlands 5 years | #1 |
| rivaroxaban lmwh vka | #1 |
| travellers thrombosis | #1 |
| rfviia fondaparinux | #1 |
| excluding pulmonary | #1 |
| carriers thrombophilic defects | #1 |
| chest perfusion scan | #1 |
| referral basis | #1 |
| idraparinux | #1 |
| nadroparin aspirin | #1 |
| rivaroxaban replacement | #1 |
| vte location | #1 |
| tsh antitpo | #1 |
| pulmonary embolism role | #1 |
| rabinovpaulin | #1 |
| major bleeds vka | #1 |
| clinical decision rule | #1 |
| strategies diagnostic management | #1 |
| leg ultrasonography patients | #1 |
| idraparinux 6 months | #1 |
| lmwh venous thrombosis | #1 |
| vte trial | #1 |
| 3633 patients edoxaban | #1 |
| heparin survival | #1 |
| prothrombin 20210a mutation | #1 |
| nondiagnostic lung scan | #1 |
| standard therapy rivaroxaban | #1 |
| thrombophlebitis tomography | #1 |
| relatives antithrombin | #1 |
| role exclusion | #1 |
| doacs anatomical extent | #1 |
| questionnaires thrombosis | #1 |
| presentation 1 week | #1 |
| 12 months edoxaban | #1 |
| studies doac treatment | #1 |
| crt cvc | #1 |
| uedvt terms | #1 |
| vte difference | #1 |
| simplified rule proportion | #1 |
| enoxaparin initial treatment | #1 |
| current practise | #1 |
| 00515 | #1 |
| 2630 pilots | #1 |
| treat thrombosis | #1 |
| incidental symptomatic vte | #1 |
| women factor leiden | #1 |
| tb402 50 | #1 |
| patients tests prevalence | #1 |
| s1p1activation | #1 |
| cdr physicians | #1 |
| orthopedic thromboprophylaxis | #1 |
| standardintensity vkas doacs | #1 |
| avidin idrabiotaparinux | #1 |
| compression ultrasound dvt | #1 |
| patients reduceddose noacs | #1 |
| ecq ankle brachial | #1 |
| ufh grade 1a | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| 3633 patients edoxabantreated | #1 |
| wellscdrscore | #1 |
| subcutaneous idraparinux | #1 |
| current comprehensions | #1 |
| tests prevalence abi | #1 |
| treatment cumulative incidence | #1 |
| gastrointestinal cancer edoxaban | #1 |
| org heparin | #1 |
| 123362 | #1 |
| fxainhibitors | #1 |
| wells rule exclusion | #1 |
| test venography | #1 |
| dvt impedance plethysmography | #1 |
| patients wells rule | #1 |
| probability ventilation | #1 |
| submassive incidence | #1 |
| einsteinextension | #1 |
| wound haematoma | #1 |
| probability normal | #1 |
| netherlands lmwh | #1 |
| factual hemorrhage heparin | #1 |
| botticelli dvt dose‐ranging | #1 |
| cstatistic model discrimination | #1 |
| edoxaban east asian | #1 |
| warfarin cstatistic | #1 |
| initial heparin edoxaban | #1 |
| acute recurrent patients | #1 |
| easier monitoring | #1 |
| patients examiner | #1 |
| survival lmwh | #1 |
| hokusaivte study | #1 |
| unexplained dvt | #1 |
| patients retropubic prostatectomy | #1 |
| vkas efficacy | #1 |
| age recurrent vte | #1 |
| heparins inhibition | #1 |
| netherlands vka | #1 |
| vte elevated fviii | #2 |
| secondary efficiency | #2 |
| lmwh users | #2 |
| events severe | #2 |
| nematode anticoagulant | #2 |
| clinically suspected | #2 |
| central localization | #2 |
| heparin effective | #2 |
| 17 apixaban | #2 |
| angioplasty clopidogrel | #2 |
| mutations cleavage sites | #2 |
| symptomatic outpatients | #2 |
| pulmonary embolism purpose | #2 |
| rnapc2 doses | #2 |
| fibrinolysis influenza | #2 |
| 6 months scores | #2 |
| mdct reference standard | #2 |
| bleeding rate patients | #2 |
| venous thrombophlebitis | #2 |
| idraparinux vitamin | #2 |
| employees longhaul flight | #2 |
| thyroid hormone coagulation | #2 |
| pharmacological strategies | #2 |
| interleukin‐10 response | #2 |
| vidas assay | #2 |
| 95 dvt | #2 |
| extended constans score | #2 |
| sr34006 | #2 |
| major bleeding recurrent | #2 |
| common alternative diagnoses | #2 |
| fvl carriers carriers | #2 |
| influenza coagulation | #2 |
| months 25 | #2 |
| primary efficacy outcome | #2 |
| major clinically | #2 |
| venographically | #2 |
| coagulation factors prolactin | #2 |
| mutations propeptide | #2 |
| clinical pretest probability | #2 |
| resource utilisation treatment | #2 |
| enoxaparin difference | #2 |
| thrombophilic defects risk | #2 |
| embolism safely | #2 |
| fibrinolytic proteins | #2 |
| 95 0·2 | #2 |
| efficiency original score | #2 |
| crnm bleeds | #2 |
| performance constans rule | #2 |
| vte 1000 personyears | #2 |
| antagonists vka | #2 |
| referred patients secondary | #2 |
| cancer addition | #2 |
| vitamin antagonists quality | #2 |
| composite scores area | #2 |
| incidence recurrent | #2 |
| recombinant nematode | #2 |
| inflammation neutrophils thrombosis | #2 |
| raskob | #2 |
| computerized impedance | #2 |
| safety pravastatin therapy | #2 |
| secondary strategies | #2 |
| statins recurrent vte | #2 |
| ventilation scanning | #2 |
| adapted ddimer thresholds | #2 |
| euro138 | #2 |
| rule proportion | #2 |
| current clinical challenges | #2 |
| absolute incidence | #2 |
| gcpg | #2 |
| administration rviia | #2 |
| ageadjusted ddimer testing | #2 |
| years 36 | #2 |
| efficiency strategy | #2 |
| global public awareness | #2 |
| n832 | #2 |
| 8292 patients | #2 |
| pravastatin therapy children | #2 |
| computed venous | #2 |
| amuse strategy | #2 |
| standardised time intervals | #2 |
| protein rnapc2 | #2 |
| warfarintreated | #2 |
| rfviia injection rfviia | #2 |
| presentation dvt | #2 |
| subcutaneous length | #2 |
| amadeus study | #2 |
| normal ddimer test | #2 |
| thrombophilic disorders | #2 |
| 3306 patients | #2 |
| cdr variables cdr | #2 |
| thrombosis normal | #2 |
| ufh survival | #2 |
| exposure flights | #2 |
| anticoagulated patients permanent | #2 |
| lower clinical utility | #2 |
| endogenous activated protein | #2 |
| ddimer determination | #2 |
| exclude pulmonary | #2 |
| tinaquant vidas | #2 |
| uedvt performance | #2 |
| duration anticoagulant | #2 |
| outcome symptomatic | #2 |
| patients prior vte | #2 |
| lowmolecularweight heparin women | #2 |
| embolism primary | #2 |
| biomarkers casecontrol studies | #2 |
| received edoxaban | #2 |
| thromboembolism thrombophilia | #2 |
| intrinsic cascade | #2 |
| intermediate phenotype vte | #2 |
| negative ageadjusted ddimer | #2 |
| model cancer patients | #2 |
| sspe patients patients | #2 |
| recurrent deep | #2 |
| 20210a mutations | #2 |
| rivaroxaban thiazoles | #2 |
| relation coagulation factors | #2 |
| quality warfarin treatment | #2 |
| pulmonary embolism efficacy | #2 |
| primary hospitalbased strategies | #2 |
| fviii increased risk | #2 |
| patients peripheral graft | #2 |
| uptake noacs | #2 |
| vein compressibility | #2 |
| sustained antithrombotic | #2 |
| 8 wk risk | #2 |
| efficiency diagnostic strategies | #2 |
| 95 comparator individuals | #2 |
| compression doppler | #2 |
| cdr wells cdr | #2 |
| incidental vte | #2 |
| beta‐receptor blockade | #2 |
| hyperglycemia diagnosis | #2 |
| treatment deep | #2 |
| hellp syndrome prevalence | #2 |
| test cancer | #2 |
| venous thromboembolism enoxaparin | #2 |
| cancer recurrent vte | #2 |
| uedvt efficiency | #2 |
| scan normal | #2 |
| 95 cancer patients | #2 |
| vte svt | #2 |
| ultrasonography patients | #2 |
| life treatment duration | #2 |
| hemorr2hages atria scores | #2 |
| wells cdr patients | #2 |
| endotoxininduced activation coagulation | #2 |
| principal safety outcome | #2 |
| patients abi measurement | #2 |
| pulmonary embolism asthma | #2 |
| major bleeding cindexes | #2 |
| failure rate strategy | #2 |
| ddimer assay | #2 |
| graft occlusion patients | #2 |
| score dimer | #2 |
| plasmin activity inhibition | #2 |
| women therapeutic doses | #2 |
| gauge plethysmography | #2 |
| major bleeding intermediate | #2 |
| arterial thrombotic disease | #2 |
| undiagnosed malignancy | #2 |
| suspected pulmonary embolism | #2 |
| simplired test | #2 |
| plasma d‐dimer concentration | #2 |
| cha2ds2vasc nri | #2 |
| major bleeding edoxaban | #2 |
| vte orthopedic surgery | #2 |
| patients low probability | #2 |
| heparin compounds | #2 |
| khorana protecht | #2 |
| rnapc2 | #2 |
| analysis venous | #2 |
| alife study | #2 |
| single administration tb402 | #2 |
| pregnancy coc | #2 |
| limits cancer | #2 |
| deficiencies proteins | #2 |
| bleeding complications treatment | #2 |
| heparin administered | #2 |
| clinical prediction model | #2 |
| prothrombin pulmonary embolism | #2 |
| impedance plethysmography patients | #2 |
| relevant patient subgroups | #2 |
| coumarin sensitivity | #2 |
| blood coagulation rnapc2 | #2 |
| apixaban enoxaparin warfarin | #2 |
| uedvt cancer patients | #2 |
| treated anticoagulants | #2 |
| apixaban lmwh vka | #2 |
| brain metastases doacs | #2 |
| wells cdr cdr | #2 |
| decision rule | #2 |
| fibrinolysis pentoxifylline | #2 |
| rule combined | #2 |
| low‐molecular‐weight heparin | #2 |
| influenza prothrombotic state | #2 |
| treated edoxaban | #2 |
| plasma concentrations endotoxin | #2 |
| serum tnf activity | #2 |
| subsegmental emboli | #2 |
| f5 r506q | #2 |
| risk khorana | #2 |
| recurrent vte risk | #2 |
| incidental venous | #2 |
| concomitant thrombophilic | #2 |
| mutation 35 | #2 |
| comparator individuals 95 | #2 |
| regression pravastatin | #2 |
| enoxaparin warfarin | #2 |
| levels coagulation factors | #2 |
| hokusai vte | #2 |
| n1423 | #2 |
| pregnancy venous thrombosis | #2 |
| screening fvl | #2 |
| pentasaccharide fondaparinux | #2 |
| patients khorana score | #2 |
| travel venous | #2 |
| mild risk factor | #2 |
| factor iia | #2 |
| clinical probability estimate | #2 |
| blood coagulation inhibition | #2 |
| patients oral factor | #2 |
| ate cancer patients | #2 |
| heparin nadroparin | #2 |
| vte 12 | #2 |
| medscape | #2 |
| healthcare settings findings | #2 |
| recurrence thromboembolism | #2 |
| bleeding edoxaban | #2 |
| venous | #2 |
| normohomocysteinemic relatives | #2 |
| simplified wells | #2 |
| suspected upper | #2 |
| hokusai vtecancer study | #2 |
| exclusion pulmonary embolism | #2 |
| rivaroxaban 30 bid | #2 |
| age‐adjusted d‐dimer testing | #2 |
| heparin treatment influenza | #2 |
| crd42017056309 | #2 |
| dimer thresholds | #2 |
| hasbled score hemorr2hages | #2 |
| thromboinflammation cardiovascular disease | #2 |
| ufh 6 months | #2 |
| c1173t dimorphism | #2 |
| prolactin relation | #2 |
| primary healthcare secondary | #2 |
| acquired antithrombin | #2 |
| embolism deep | #2 |
| measurement ankle brachial | #2 |
| annual incidences | #2 |
| nonpermanent heart failure | #2 |
| suspected pulmonary | #2 |
| surgical casts | #2 |
| coagulation fibrinolytic | #2 |
| nct00633893 | #2 |
| impedance plethysmography diagnosis | #2 |
| recombinant hirudin cgp | #2 |
| duration anticoagulant treatment | #2 |
| risk anticoagulation therapy | #2 |
| risk deep | #2 |
| diagnostic lung | #2 |
| vitamin antagonist rivaroxaban | #2 |
| treatment ttr | #2 |
| lmwh efficacy | #2 |
| levothyroxine exposure | #2 |
| hmb primary outcome | #2 |
| oral direct inhibitors | #2 |
| hospitalbased strategies | #2 |
| bleeding occurred | #2 |
| death vte | #2 |
| patients hemorr2hages | #2 |
| intravenous loading dose | #3 |
| activecontrol | #3 |
| prevalence avws | #3 |
| protein thrombophilia | #3 |
| vte performance | #3 |
| knee factor | #3 |
| travel venous thrombosis | #3 |
| cardiac troponine | #3 |
| pulmonary embolism models | #3 |
| 12month study period | #3 |
| 3633 patients | #3 |
| ddimer threshold | #3 |
| time venous thrombosis | #3 |
| thiophenes venous | #3 |
| coagulation air travel | #3 |
| idrabiotaparinux | #3 |
| patients 6575 years | #3 |
| negative predictive proportion | #3 |
| female hemorrhage humans | #3 |
| gestalt 95 | #3 |
| products follow | #3 |
| definition perelated death | #3 |
| idrabiotaparinux warfarin | #3 |
| composite stroke | #3 |
| venous thromboembolism | #3 |
| enoxaparin follow | #3 |
| diagnosis pulmonary embolism | #3 |
| crt cancer patients | #3 |
| safely exclude | #3 |
| 02011 | #3 |
| heparin heparin | #3 |
| extensive screening | #3 |
| dvt primary | #3 |
| prolactin controls | #3 |
| chemotherapy prophylaxis | #3 |
| apc protective | #3 |
| 3month incidence | #3 |
| alternative diagnoses | #3 |
| death clinical studies | #3 |
| detection dvt | #3 |
| female humans inhibitors | #3 |
| primary wells rule | #3 |
| patients proximalvein thrombosis | #3 |
| venous thrombosis travel | #3 |
| treatment low | #3 |
| mechanisms heparin | #3 |
| platelet agents | #3 |
| pph lmwh | #3 |
| administration rnapc2 | #3 |
| incidence enoxaparin | #3 |
| patients 6 months | #3 |
| venous thromboembolism thrombophilia | #3 |
| ctnt risk stratification | #3 |
| dvt major | #3 |
| gestalt probability | #3 |
| bleeding 3 | #3 |
| dimer blood | #3 |
| topic heparin heparin | #3 |
| multiple comorbidities polypharmacy | #3 |
| studies hemorrhage | #3 |
| presenting location | #3 |
| treatment lowmolecularweight heparin | #3 |
| ft4 risk | #3 |
| cancer patients ate | #3 |
| proximalvein thrombosis | #3 |
| thrombophlebitis treatment | #3 |
| approaches primary | #3 |
| outpatient treatment dvt | #3 |
| subcutaneous fondaparinux | #3 |
| patients ft4 level | #3 |
| axa activity | #3 |
| simplified wells specificity | #3 |
| recombinant hirudin rhir | #3 |
| pulmonary embolism‐related death | #3 |
| monoclonal replacement | #3 |
| factors prothrombin | #3 |
| outcome venous | #3 |
| einstein dvt | #3 |
| wells rule dvt | #3 |
| “gestalt | #3 |
| dvt einstein | #3 |
| outpatients dvt | #3 |
| failurerate | #3 |
| dip placebo | #3 |
| diagnosis pulmonary | #3 |
| revised geneva efficiency | #3 |
| patients gastrointestinal cancer | #3 |
| primary rule | #3 |
| wells rule gestalt | #3 |
| treatment vte recurrence | #3 |
| thrombophilic defect | #3 |
| recurrence thrombophlebitis | #3 |
| rnapc2 fviia | #3 |
| therapy venous | #3 |
| influence heparins | #3 |
| 20210ga | #3 |
| standard therapy treatment | #3 |
| capillary blood sample | #3 |
| warfarin subgroup | #3 |
| prevalence hemostatic abnormalities | #3 |
| einstein studies | #3 |
| 95 wells rule | #3 |
| ultrasonography strategies | #3 |
| single diagnostic | #3 |
| impedance predictive | #3 |
| efficacy heparin | #3 |
| nct00643201 | #3 |
| cohort study employees | #3 |
| lmwh pph | #3 |
| low probability models | #3 |
| healthy donor fmt | #3 |
| strategies efficiency | #3 |
| patients venous | #3 |
| probability dimer | #3 |
| pad smokers | #3 |
| cancer patients ipe | #3 |
| cancer randomised trials | #3 |
| venous thrombosis cancer | #3 |
| vte venous thrombosis | #3 |
| safely excluded | #3 |
| plethysmography impedance | #3 |
| svt vte | #3 |
| patients incidental vte | #3 |
| incidence total vte | #3 |
| normal result | #3 |
| subcutaneous lmwh | #3 |
| vein thrombosis | #3 |
| older children vte | #3 |
| tinaquant assay | #3 |
| fxiaso | #3 |
| einstein patients | #3 |
| predictable pharmacokinetics | #3 |
| 100 years year | #3 |
| 3month vte incidence | #3 |
| vte denmark | #3 |
| lowmolecularweight humans length | #3 |
| dvt hip | #3 |
| endogenous apc | #3 |
| venous thrombosis positive | #3 |
| safety acenocoumarol | #3 |
| thombosis | #3 |
| lowmolecularweight heparin placebo | #3 |
| clinical models patients | #3 |
| hasbled | #3 |
| dose reduction edoxaban | #3 |
| dvt systematic differences | #3 |
| ipe cancer patients | #3 |
| ddimer assays | #3 |
| thromboembolism low | #3 |
| favour lmwh | #3 |
| patients venography | #3 |
| oral hormonal cross | #3 |
| introduction mdct | #3 |
| factor viiic | #3 |
| cancer active cancer | #3 |
| desogestrelcontaining | #3 |
| heparin edoxaban | #3 |
| ventilation scan | #3 |
| 6575 years | #3 |
| heparins cancer | #3 |
| pulmonary embolism primary | #3 |
| tfindependent | #3 |
| embolism‐related | #3 |
| hokusai‐vte | #3 |
| baseline values placebo | #3 |
| users incidence | #3 |
| placebo n4 | #3 |
| nadroparin placebo | #3 |
| recurrent thromboembolic | #3 |
| vte major burden | #3 |
| cdr combination | #3 |
| age annual incidence | #3 |
| studies cus strategies | #3 |
| vte low | #3 |
| pulmonary embolism gestalt | #3 |
| venous thromboembolism apixaban | #3 |
| thromboembolism background | #3 |
| patients wells | #3 |
| compensated dic | #3 |
| inhibition blood coagulation | #3 |
| normal ctnt presentation | #3 |
| incidental pulmonary embolism | #3 |
| sensitivity compression | #3 |
| iii deficiency | #3 |
| vte 3 | #3 |
| treatment vitamin antagonists | #3 |
| diagnosis deep | #3 |
| adult patients vte | #3 |
| safely | #3 |
| bleeding major | #3 |
| dalteparin difference | #3 |
| atria hemorr2hages | #3 |
| hf severity risk | #3 |
| treatment vka | #3 |
| deep vein | #3 |
| stable acute | #3 |
| tb‐402 | #3 |
| selectine | #3 |
| venous arterial | #3 |
| antithrombin iii concentrate | #3 |
| lmwh | #3 |
| mutation venous | #3 |
| discontinuation ufh | #3 |
| idiopathic venous | #3 |
| combination wells score | #3 |
| coagulation influence | #3 |
| patients ultrasonography | #3 |
| refuted | #4 |
| embolism tomography | #4 |
| predilution postdilution | #4 |
| point dimer | #4 |
| thrombophilic families | #4 |
| 3587 | #4 |
| disease vte | #4 |
| criteria dose reduction | #4 |
| venous thrombosis levels | #4 |
| diagnostic prediction models | #4 |
| impedance plethysmography | #4 |
| vte global burden | #4 |
| women normal levels | #4 |
| 35±4 | #4 |
| extended treatment | #4 |
| chinese korean ethnicity | #4 |
| postthrombotic symptoms | #4 |
| apixaban efficacy | #4 |
| rviia thrombin generation | #4 |
| vitamin antagonists | #4 |
| risk occult cancer | #4 |
| episode venous | #4 |
| questionnaires venous | #4 |
| thrombosis air | #4 |
| noacs netherlands | #4 |
| death survey | #4 |
| embolism dimer | #4 |
| patients submassive | #4 |
| arterial thrombotic | #4 |
| thromboembolism occurred | #4 |
| diagnostic management strategies | #4 |
| recurrent vte months | #4 |
| thromboembolism systematic | #4 |
| patients crcl 60 | #4 |
| bleeding anticoagulants | #4 |
| estrogen therapy patients | #4 |
| primary failure rate | #4 |
| patients fondaparinux | #4 |
| lowmolecularweight heparin | #4 |
| vitamin antagonist treatment | #4 |
| levels ft4 | #4 |
| series venograms | #4 |
| patients clinically | #4 |
| safety pravastatin | #4 |
| diagnostic management | #4 |
| ageadjusted cutoff patients | #4 |
| patients edoxaban | #4 |
| measurement abi | #4 |
| preexisting heparin | #4 |
| travel thrombosis | #4 |
| embolism background | #4 |
| netherlands pulmonary | #4 |
| thrombosis deep | #4 |
| tinaquant | #4 |
| contraindications treatment | #4 |
| proximal patients | #4 |
| enoxaparin female humans | #4 |
| hemostatic profile | #4 |
| women apc resistance | #4 |
| patients primary healthcare | #4 |
| chromogenic compounds | #4 |
| coagulation endotoxin | #4 |
| vte global | #4 |
| leiden carriers | #4 |
| lmwhs standard heparin | #4 |
| global disease burden | #4 |
| idiopathic venous thrombosis | #4 |
| fibrin generation test | #4 |
| disease burden vte | #4 |
| patients venous thromboembolism | #4 |
| patients dimer | #4 |
| chemotherapy shr | #4 |
| mbe patients | #4 |
| hyperhomocysteinemic relatives | #4 |
| patient category | #4 |
| rivaroxaban 20 | #4 |
| venous thromboembolism patients | #4 |
| abdomen relationship | #4 |
| patient education treatment | #4 |
| thrombosis symptomatic | #4 |
| embolism roc | #4 |
| nct00571649 | #4 |
| vte netherlands | #4 |
| control anticoagulation | #4 |
| dutch orthopedic | #4 |
| pregnancies carriers | #4 |
| 0651 | #4 |
| thromboembolism treatment | #4 |
| patients nonpermanent | #4 |
| venography patients | #4 |
| vte treatment patients | #4 |
| serial impedance | #4 |
| treatment unfractionated heparin | #4 |
| total vte | #4 |
| ultrasonography venous | #4 |
| global burden vte | #4 |
| gramnegative bacteria humans | #4 |
| serial impedance plethysmography | #4 |
| thromboembolism study | #4 |
| sankyo | #4 |
| oral rivaroxaban | #4 |
| thromboembolism vitamin | #4 |
| dimer assays | #4 |
| cleavage sites apc | #4 |
| daily netilmicin | #4 |
| activation fibrinolytic | #4 |
| negative point | #4 |
| chads2 p0001 | #4 |
| received warfarin | #4 |
| rule pulmonary | #4 |
| primary pulmonary embolism | #4 |
| protecht | #4 |
| vte highincome countries | #4 |
| chemotherapy vte prophylaxis | #4 |
| vitamin antagonists patients | #4 |
| amadeus trial | #4 |
| lmwh female heparin | #4 |
| dose noacs | #4 |
| doac studies | #4 |
| cancer vwf | #4 |
| probability prospective | #4 |
| thromboembolism factor | #4 |
| clot resolution | #4 |
| warfarin 3 months | #4 |
| 150 microg levonorgestrel | #4 |
| diagnosis uedvt | #4 |
| clinically relevant bleeding | #4 |
| vte total | #4 |
| 10172 | #4 |
| patients alternative diagnosis | #4 |
| thrombosis ischemic stroke | #4 |
| 335 patients | #4 |
| noacs cancer patients | #4 |
| coagulation factors risk | #4 |
| advanced cancer 95 | #4 |
| edoxaban patients | #4 |
| life duration | #4 |
| thrombosis uedvt | #4 |
| population rivaroxaban | #4 |
| 6 months prophylaxis | #4 |
| risk vkas | #4 |
| procoagulant factors | #4 |
| prophylaxis lmwh | #4 |
| symptomatic deep | #4 |
| ddimer assay patients | #4 |
| “reversal | #4 |
| lmwh cancer patients | #4 |
| rfviia injection | #4 |
| vka treatment | #4 |
| enoxaparin day | #4 |
| lowmolecular weight heparins | #4 |
| 150 microg desogestrel | #4 |
| hemorr2hages | #4 |
| thromboembolism arterial | #4 |
| clot lysis patients | #4 |
| thrombophilia 95 | #4 |
| netilmicin patients | #5 |
| treatment fondaparinux | #5 |
| compression ultrasound | #5 |
| predilution | #5 |
| thrombosis primary | #5 |
| patients wells score | #5 |
| outcome major | #5 |
| medea study | #5 |
| clinical presentation clinical | #5 |
| patients recurrent dvt | #5 |
| pulmonary embolism patients | #5 |
| bleeding cancer | #5 |
| endogenous activated | #5 |
| 2 rules | #5 |
| molecularweight heparin | #5 |
| thromboembolism | #5 |
| efficiency patients | #5 |
| dvt prevalence | #5 |
| cdr patients | #5 |
| southern latin america | #5 |
| thrombosis upper | #5 |
| previous venous thromboembolism | #5 |
| thromboembolism idraparinux | #5 |
| gestalt | #5 |
| isolated calfvein thrombosis | #5 |
| preschool contraceptives | #5 |
| heparin compared | #5 |
| outpatients hospital | #5 |
| factor leiden 95 | #5 |
| ventricular dysfunction echocardiography | #5 |
| consensus strategy | #5 |
| rivaroxaban enoxaparin vka | #5 |
| thromboembolism thrombosis | #5 |
| phlebography plethysmography | #5 |
| secondary venous thrombosis | #5 |
| antithrombotic drug treatment | #5 |
| vka patients | #5 |
| coronary angioplasty angioplasty | #5 |
| iii plasminogen | #5 |
| pregnancy pph | #5 |
| burden vte | #5 |
| ft4 level | #5 |
| diagnosis questionnaire | #5 |
| hirudin treatment | #5 |
| patients superficial thrombophlebitis | #5 |
| day rivaroxaban | #5 |
| risk prediction scores | #5 |
| low‐molecular‐weight | #5 |
| fh patients cvd | #5 |
| patients parenteral anticoagulants | #5 |
| vte factor | #5 |
| low molecularweight humans | #5 |
| pad smoking | #5 |
| asymptomatic carriers mutation | #5 |
| thrombophlebitis ultrasonography | #5 |
| secondary dvt | #5 |
| incidence prognostic significance | #5 |
| vte 6 | #5 |
| treatment acute dvt | #5 |
| clinical probability assessment | #5 |
| repeated ultrasonography | #5 |
| suspected uedvt | #5 |
| dimer combination | #5 |
| cgp 39393 | #5 |
| recurrent dvt patients | #5 |
| 8292 | #5 |
| clinical probability | #5 |
| vte patients cancer | #5 |
| panwards | #5 |
| specificity thrombophlebitis | #5 |
| fviii families | #5 |
| normal ctpa | #5 |
| venous thromboembolism studies | #5 |
| endotoxin testing | #5 |
| upper extremity thrombosis | #5 |
| embolism reproducibility | #5 |
| sensitivity negative predictive | #5 |
| elevated plasma level | #5 |
| women warfarin | #5 |
| adjusted dimer | #5 |
| transfusion blood loss | #5 |
| lmwh recommended | #5 |
| exclusion venous thromboembolism | #5 |
| daiichi sankyo | #5 |
| patients pulmonary embolism | #5 |
| thrombosis leg | #5 |
| coc pregnancy | #5 |
| inhibition plasminogen activation | #5 |
| thromboembolism studies | #5 |
| severe pph women | #5 |
| patients subtherapeutic | #5 |
| deepvein thrombosis | #5 |
| diagnostic strategies | #5 |
| 8491 | #5 |
| endotoxin chimpanzees | #5 |
| lmwh incidence | #5 |
| cancer strategy | #5 |
| hokusai | #5 |
| fviia rnapc2 | #5 |
| 12month cumulative incidence | #6 |
| embolism pulmonary | #6 |
| incidence recurrence | #6 |
| patients uedvt | #6 |
| subcutaneous low | #6 |
| clinically relevant subgroups | #6 |
| pulmonary embolism presence | #6 |
| isolated deficiencies | #6 |
| antagonists treatment | #6 |
| effects levonorgestrel | #6 |
| patients anticoagulation clinic | #6 |
| apixaban treatment dose | #6 |
| prevalence vte | #6 |
| svt extension | #6 |
| duration rivaroxaban | #6 |
| synthetic pentasaccharides | #6 |
| thrombophilic defects | #6 |
| patients tests | #6 |
| c1173 | #6 |
| standardized morbidity ratio | #6 |
| subcutaneous nadroparin | #6 |
| combined utility | #6 |
| 049 95 | #6 |
| stressinduced hyperglycaemia | #6 |
| fixeddose regimen | #6 |
| risk khorana score | #6 |
| anticoagulants female | #6 |
| patients pulmonary angiography | #6 |
| patients iohexol | #6 |
| thromboembolism bleeding | #6 |
| conventional therapy treatment | #6 |
| patients lowmolecularweight heparin | #6 |
| neoplasms pulmonary embolism | #6 |
| outcome occurred | #6 |
| d‐dimer testing | #6 |
| perioperative blood loss | #6 |
| repeatedly normal | #6 |
| treatment svt | #6 |
| 10±4 | #6 |
| venograms | #6 |
| endotoxin assays | #6 |
| simplired dimer | #6 |
| treatment intermittent claudication | #6 |
| treatment pulmonary embolism | #6 |
| vka | #6 |
| dalteparin dose | #6 |
| dabigatran etexilate dabigatran | #6 |
| patients suspected | #6 |
| 39393 | #6 |
| risk increasing levels | #6 |
| daily gentamicin | #6 |
| vte controls | #6 |
| funding bayer | #6 |
| amplify | #6 |
| patients factor mutation | #6 |
| severe antithrombin | #6 |
| cancer primary patients | #6 |
| symptomatic legs | #6 |
| fviia inhibition | #6 |
| dimer cut | #6 |
| women hyperhomocysteinemia | #6 |
| patients diagnostic | #6 |
| vte cancer | #6 |
| severe dic | #6 |
| blood coagulation mechanism | #6 |
| probability pulmonary | #6 |
| embolism ventricular | #6 |
| proportion cancer patients | #6 |
| arterial cardiovascular | #6 |
| grade 1a ufh | #6 |
| effects ufh | #6 |
| vte anticoagulant treatment | #6 |
| diagnostic workup | #6 |
| symptoms intermittent claudication | #6 |
| treatment ufh | #6 |
| leiden | #6 |
| ft4 patients | #6 |
| elisapositive | #6 |
| enoxaparin incidence | #6 |
| rate major bleeding | #6 |
| dvt trial | #6 |
| compression stockings patients | #6 |
| lmwh users users | #6 |
| thrombosis guidelines | #6 |
| ultrasonography normal | #6 |
| wells rule | #6 |
| endotoxininduced activation | #6 |
| oral edoxaban | #6 |
| lmwh cancer | #6 |
| anticoagulant treatment | #6 |
| pembqol questionnaire | #6 |
| edoxaban efficacy | #6 |
| selective beta | #6 |
| oral anticoagulants dabigatran | #6 |
| 393 patients | #6 |
| initial heparin treatment | #6 |
| recurrent pulmonary | #6 |
| levonorgestrel desogestrel | #6 |
| low absolute risk | #6 |
| patients proximal | #6 |
| anticoagulants hemorrhage | #6 |
| efficiency proportion | #6 |
| warfarin venous thromboembolism | #6 |
| assay fibrin | #6 |
| subjects vte | #6 |
| myocardial infarction ctni | #6 |
| factor leiden carriers | #6 |
| 597939 | #7 |
| tnf injection | #7 |
| rates edoxaban | #7 |
| ufh treatment | #7 |
| presence cteph | #7 |
| primary dvt | #7 |
| relation prolactin levels | #7 |
| silent pulmonary embolism | #7 |
| thrombophilia pregnancy loss | #7 |
| general practitioners guideline | #7 |
| antithrombin protein | #7 |
| negative ddimer test | #7 |
| vka therapy | #7 |
| mpc1609 | #7 |
| thromboembolism adult | #7 |
| coagulation humans | #7 |
| spiral sensitivity | #7 |
| doppler skin | #7 |
| levels factor viii | #7 |
| pulmonary embolism sensitivity | #7 |
| diagnostic suspicion | #7 |
| relation levels | #7 |
| anticoagulant parameters | #7 |
| factor female humans | #7 |
| ottawa score | #7 |
| 680 | #7 |
| stockings control | #7 |
| nondiagnostic lung scans | #7 |
| 220 dabigatran | #7 |
| administration bsf | #7 |
| unselected women | #7 |
| major bleeding rate | #7 |
| dvt ipg | #7 |
| statin treatment risk | #7 |
| perelated death | #7 |
| carriers defects | #7 |
| embolism prospective | #7 |
| etexilate oral | #7 |
| tb402 | #7 |
| heparin org | #7 |
| arterial cardiovascular disease | #7 |
| lung scan | #7 |
| placebo rivaroxaban | #7 |
| proportion older patients | #7 |
| combination ipg | #7 |
| diagnosis venous thrombosis | #7 |
| patients standard heparin | #7 |
| venous thrombosis treatment | #7 |
| phenprocoumon polymorphism | #7 |
| day initial treatment | #7 |
| neoplasms pulmonary | #7 |
| inhibitor apixaban | #7 |
| thromboembolism total | #7 |
| prothrombin risk | #7 |
| treatment doac | #7 |
| deepvein thrombosis patients | #7 |
| major bleeding vkas | #7 |
| specific antidotes | #7 |
| blood coagulation humans | #7 |
| vitamin antagonists vka | #7 |
| negative predictive npv | #7 |
| noncompressibility | #7 |
| aspirin combined | #7 |
| carriers venous thromboembolism | #7 |
| thrombophlebitis adolescent | #7 |
| leg ultrasonography | #7 |
| mutations factor viii | #7 |
| vte cancer diagnosis | #7 |
| major bleeding | #7 |
| recurrent dvt | #7 |
| protein protein deficiencies | #7 |
| thromboembolism vte | #7 |
| rivaroxaban 10 | #7 |
| primary efficacy | #7 |
| plasma levels ifngamma | #7 |
| incidence recurrent vte | #7 |
| thrombosis prophylaxis | #8 |
| occult cancer patients | #8 |
| discontinuation anticoagulant treatment | #8 |
| thrombosis adolescent | #8 |
| compression surveys | #8 |
| treatment venous thrombosis | #8 |
| oral glucocorticoids risk | #8 |
| testing rule | #8 |
| aged phlebography | #8 |
| symptomatic deepvein thrombosis | #8 |
| enoxaparin vka | #8 |
| arg506 factor | #8 |
| p0001 hasbled score | #8 |
| vka lmwh | #8 |
| vitamin antagonists vkas | #8 |
| deficiency antithrombin | #8 |
| agnelli | #8 |
| comorbidity polypharmacy | #8 |
| probability lung | #8 |
| patients extended anticoagulation | #8 |
| apixaban enoxaparin | #8 |
| nondiagnostic scan | #8 |
| recurrent vte bleeding | #8 |
| low clinical probability | #8 |
| risk employees | #8 |
| oac adherence | #8 |
| increased fibrinolytic | #8 |
| normal computed | #8 |
| cancer pulmonary embolism | #8 |
| recurrent vte mb | #8 |
| years cumulative incidence | #8 |
| pvoct | #8 |
| inherited thrombophilic | #8 |
| physicians stockings | #8 |
| products humans | #8 |
| contrast venography | #8 |
| initial heparin | #8 |
| heparin vitamin antagonists | #8 |
| leiden prothrombin | #8 |
| warfarin hazard ratio | #8 |
| international organisations | #8 |
| inr values patients | #8 |
| current approach | #8 |
| duration treatment | #8 |
| administration low | #8 |
| tests pulmonary | #8 |
| vascular endothelial barrier | #8 |
| analysis apixaban | #8 |
| carriers fvl | #8 |
| vte score | #8 |
| 150 enoxaparin | #8 |
| v617f jak2 | #8 |
| objectively confirmed | #8 |
| oral apixaban | #8 |
| 0·2 | #8 |
| unprovoked vte patients | #8 |
| risks dvt | #8 |
| nafronyl | #8 |
| inr determination | #8 |
| lmwh grade 1a | #8 |
| patients symptomatic vte | #8 |
| structured algorithm | #8 |
| acute symptomatic vte | #8 |
| fxi aso | #8 |
| chemotherapy low risk | #8 |
| prevention vte | #8 |
| 97 95 | #8 |
| prospective management | #8 |
| homocysteine markers | #8 |
| point ultrasonography | #8 |
| euro55 | #8 |
| xii deficient | #8 |
| dimer tests | #8 |
| funding daiichi | #8 |
| overt cancer | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| optimal intensity | #8 |
| patients excluded | #8 |
| anticoagulation unprovoked vte | #8 |
| wells scores | #8 |
| proximal deep | #8 |
| levonorgestrelcontaining | #8 |
| ufh initial treatment | #8 |
| dimer concentration | #8 |
| bnp ctnt | #8 |
| ageadjusted ddimer cutoff | #8 |
| consecutive outpatients | #8 |
| persistent risk factors | #8 |
| proximal deepvein thrombosis | #8 |
| anticoagulants antineoplastic | #8 |
| severe preeclampsia patients | #8 |
| 1599 patients | #8 |
| placebo plasma levels | #9 |
| oral antithrombins | #9 |
| factors thrombophlebitis | #9 |
| months efficacy | #9 |
| embolism venous | #9 |
| fxa inhibitor | #9 |
| apixaban oral factor | #9 |
| cancer factor | #9 |
| atiii concentrates | #9 |
| patients active cancer | #9 |
| edoxaban major bleeding | #9 |
| thromboembolism cancer | #9 |
| longterm treatment vte | #9 |
| tafi levels | #9 |
| oral contraceptive pregnancy | #9 |
| heparin therapy patients | #9 |
| discontinuing anticoagulation | #9 |
| homocysteine women | #9 |
| weight heparin | #9 |
| male oligosaccharides | #9 |
| diagnosis mdct | #9 |
| cancer cell extravasation | #9 |
| diagnostic prediction model | #9 |
| vte relatives | #9 |
| combination stroke | #9 |
| thrombosis venous thromboembolism | #9 |
| incidence postthrombotic syndrome | #9 |
| cancer episode | #9 |
| fondaparinux cancer patients | #9 |
| prothrombin 20210a | #9 |
| lipoproteina women | #9 |
| compression stockings prevention | #9 |
| comorbidities polypharmacy | #9 |
| normal ddimer | #9 |
| incidental pulmonary | #9 |
| acute medical illnesses | #9 |
| generation pill | #9 |
| thrombosis thromboinflammation | #9 |
| characteristics severity | #9 |
| postdilution | #9 |
| serotonin platelet | #9 |
| strategies dimer | #9 |
| concomitant cancer | #9 |
| büller | #9 |
| vte rcts | #9 |
| ultrasonogram | #9 |
| crcl 60 | #9 |
| bled bleeding | #9 |
| iii concentrate | #9 |
| treatment prophylaxis | #9 |
| carriers factor leiden | #9 |
| hemorr2hages atria | #9 |
| abnormal vaginal | #9 |
| treatment edoxaban | #9 |
| enoxaparin factor | #9 |
| daiichisankyo | #9 |
| cofact | #9 |
| lmwh mortality | #9 |
| major bleeding treatment | #9 |
| independent committee | #9 |
| thrombosis compared | #9 |
| therapeutic dose patients | #9 |
| nonpermanent | #9 |
| anticoagulant pathways | #9 |
| patients fxa inhibitors | #9 |
| method enoxaparin | #9 |
| animal heparin | #10 |
| asymptomatic pulmonary embolism | #10 |
| cus diagnosis | #10 |
| normohomocysteinemic | #10 |
| rates recurrent vte | #10 |
| induced coagulation | #10 |
| deficiencies antithrombin | #10 |
| incidence 1000 personyears | #10 |
| rfviia blood loss | #10 |
| factor prevention | #10 |
| cvd fh patients | #10 |
| inr cases | #10 |
| ageadjusted cutoff | #10 |
| incidence major bleeding | #10 |
| ddimer concentration | #10 |
| heparin nomogram | #10 |
| vte efficacy | #10 |
| rabbits administration | #10 |
| thrombophlebitis adult | #10 |
| treatment aprotinin | #10 |
| oral thrombin inhibitor | #10 |
| embolism patients | #10 |
| thrombosis background | #10 |
| injection avidin | #10 |
| dvt lower extremity | #10 |
| 4470 | #10 |
| single loss | #10 |
| treatment uedvt | #10 |
| fii mutation | #10 |
| probability pulmonary embolism | #10 |
| thr incidence | #10 |
| bled scores | #10 |
| gramnegative septicemia | #10 |
| 1215 patients | #10 |
| patients endotoxemia | #10 |
| anticoagulants | #10 |
| fondaparinux risk | #10 |
| factor levels patients | #10 |
| retrospective study efficacy | #10 |
| patients venous thrombosis | #10 |
| inherited thrombophilic factors | #10 |
| severity clinical | #10 |
| venous thrombosis | #10 |
| crp test | #10 |
| snp scores | #10 |
| nadroparine | #10 |
| oral administration dabigatran | #10 |
| hypocoagulable state | #10 |
| lmwh studies | #10 |
| 598 patients | #10 |
| vnv | #10 |
| intimamedia thickness imt | #10 |
| cancer patients lmwh | #10 |
| leg veins | #10 |
| aged antithrombin | #10 |
| year years | #10 |
| simplified geneva | #10 |
| 100 years discontinuation | #10 |
| cancer patients vte | #10 |
| venous thromboembolic event | #10 |
| magellan study | #10 |
| subcutaneous metaanalysis | #10 |
| embolism clinical | #10 |
| extremity deep | #10 |
| magellan trial | #10 |
| wells | #10 |
| schedule heparin | #10 |
| major bleeding crnmb | #10 |
| pregnancy carriers | #10 |
| treatment vitamin | #10 |
| protein dic | #10 |
| dvt | #11 |
| pyridines thiazoles | #11 |
| air travel | #11 |
| weight humans | #11 |
| vte vwf | #11 |
| intensity anticoagulation | #11 |
| gps training | #11 |
| pulmonary embolism incidence | #11 |
| 30 microg ethinylestradiol | #11 |
| recombinant human tnf | #11 |
| patients cancer vte | #11 |
| patients anticoagulant treatment | #11 |
| pregnancyrelated complications | #11 |
| cancer patients dvt | #11 |
| mutations prevalence | #11 |
| clinical pretest | #11 |
| endotoxin assay | #11 |
| screening cancer | #11 |
| carriers factor | #11 |
| edoxaban | #11 |
| knee clinical trials | #11 |
| fondaparinux hemorrhage | #11 |
| haemophilia vwd | #11 |
| gentamicin treatment patients | #11 |
| cancer patients evidence | #11 |
| 880 patients | #11 |
| adult anticoagulants | #11 |
| variation inr | #11 |
| lmwh pregnancy | #11 |
| inhibitors hemorrhage | #11 |
| combination dimer | #11 |
| crnmb 95 | #11 |
| heparinoid org | #11 |
| ldfr | #11 |
| patients probability | #11 |
| factor venous | #11 |
| medical conferences | #11 |
| pcc dabigatran | #11 |
| sulfates dermatan | #11 |
| patients cvcs | #11 |
| pulmonary angiography venography | #11 |
| embolism recurrence | #11 |
| ufh studies | #11 |
| embolism prevalence | #11 |
| lmwh pregnancies | #11 |
| incidence major | #11 |
| levels prolactin | #11 |
| endotoxin pentoxifylline | #11 |
| oral dabigatran | #11 |
| org 10172 | #11 |
| reference testing | #11 |
| thromboembolism major | #11 |
| previous venous | #11 |
| dabigatran enoxaparin | #11 |
| hospital lmwh | #11 |
| 750 μg | #11 |
| d‐dimer levels | #11 |
| vte recurrence risk | #12 |
| topic venous | #12 |
| months primary | #12 |
| warfarin recurrent vte | #12 |
| factor leiden prothrombin | #12 |
| 72 children | #12 |
| venous thromboembolism incidence | #12 |
| prevention venous thrombosis | #12 |
| annual incidence vte | #12 |
| event recurrence | #12 |
| treatment crt | #12 |
| humanized arthroplasty | #12 |
| warfarin treated | #12 |
| bnp cardiac troponin | #12 |
| risk venous | #12 |
| control metaanalysis | #12 |
| vka noacs | #12 |
| anticoagulation unprovoked | #12 |
| peghirudin | #12 |
| observation risk | #12 |
| bayer schering pharma | #12 |
| ageadjusted ddimer | #12 |
| subsegmental pulmonary emboli | #12 |
| nephro | #12 |
| deficient women | #12 |
| perelated | #12 |
| outpatient management patients | #12 |
| female heparin humans | #12 |
| thrombosis dvt | #12 |
| thrombin generation fibrinolysis | #12 |
| hirulog1 | #12 |
| livebirth rate | #12 |
| geneva score | #12 |
| women factor | #12 |
| outcomes venous thromboembolism | #12 |
| safety efficiency | #12 |
| dvt treatment | #12 |
| proximal vein | #12 |
| recurrent vte anticoagulation | #12 |
| patients lupus anticoagulant | #12 |
| noacs vka | #12 |
| concomitant disorders | #12 |
| pioped study | #12 |
| paulin | #12 |
| recurrent vte | #12 |
| crd42013003526 | #12 |
| patients lmwhs | #12 |
| proximal veins | #12 |
| anticoagulant factor | #12 |
| 9702 | #12 |
| doseadjustment | #12 |
| warfarin therapy inr | #12 |
| stopping anticoagulation | #12 |
| fondaparinux unfractionated heparin | #12 |
| 9295 | #12 |
| thrombophilic | #12 |
| hemodynamically stable | #12 |
| patients incidental | #12 |
| 86 percent | #13 |
| arixtra | #13 |
| dabigatran 220 | #13 |
| pselectin patients | #13 |
| major hip | #13 |
| indication anticoagulation | #13 |
| clinical decision rules | #13 |
| groups inr | #13 |
| dimer testing | #13 |
| 95 carriers | #13 |
| uedvt | #13 |
| concomitant antiplatelet therapy | #13 |
| safety oral | #13 |
| arterial thromboembolism ate | #13 |
| factor viii apc | #13 |
| strain gauge plethysmography | #13 |
| factor leiden mutation | #13 |
| occult cancer | #13 |
| safety doacs | #13 |
| thrombosis young | #13 |
| ufh dalteparin | #13 |
| association venous thrombosis | #13 |
| levels factor | #13 |
| nct00986154 | #13 |
| hematologic pregnancy trimester | #13 |
| recombinant hirudin rhirudin | #13 |
| bleeding events edoxaban | #13 |
| thrombosis acute | #13 |
| time prothrombin | #13 |
| vte recurrence 95 | #13 |
| treatment venous thromboembolism | #13 |
| daily subcutaneous | #13 |
| vte major | #13 |
| obesity haemophilia patients | #13 |
| deepvein thrombosis dvt | #13 |
| patients anticoagulant | #13 |
| selective testing | #13 |
| heparin low | #13 |
| superficial thrombophlebitis | #13 |
| bayer healthcare | #13 |
| randomized cross | #13 |
| conventional anticoagulants | #13 |
| category studies | #13 |
| inhibition tnf | #13 |
| dimer threshold | #13 |
| vte female humans | #13 |
| vte 64 | #13 |
| continuous intravenous heparin | #13 |
| plethysmography | #13 |
| inferiority efficacy | #13 |
| vte | #13 |
| dvt lower | #13 |
| rivaroxaban thiophenes | #13 |
| spiral computed tomography | #13 |
| vte groups | #13 |
| dabigatran vte | #13 |
| marder score | #13 |
| patients thrombophilia | #13 |
| prevention venous thromboembolism | #13 |
| plethysmograms | #13 |
| antithrombin iii activity | #13 |
| edoxaban oral factor | #14 |
| unprovoked vte vte | #14 |
| female fibrin | #14 |
| fvl carriers | #14 |
| higher ddimer levels | #14 |
| cadherins endothelium | #14 |
| loss women | #14 |
| thrombosis | #14 |
| obstetric complications women | #14 |
| thrombophilia patients | #14 |
| awareness pad | #14 |
| gastrointestinal bleeding patients | #14 |
| experimental endotoxaemia | #14 |
| aged anticoagulants | #14 |
| lmwh vka | #14 |
| plasminogen apoa | #14 |
| dvt lower extremities | #14 |
| edoxaban warfarin | #14 |
| anticoagulant rivaroxaban | #14 |
| aged plethysmography | #14 |
| crnm | #14 |
| low molecular | #14 |
| ultrasound strategies | #14 |
| recurrent venous | #14 |
| patients outpatients | #14 |
| limited screening | #14 |
| standard heparin | #14 |
| aspirin women | #14 |
| vte months | #14 |
| costs dvt | #14 |
| atiii deficiency | #14 |
| placebo rfviia | #14 |
| effects hyperthyroidism | #14 |
| incidence severe pph | #14 |
| patients dvt | #14 |
| patients vka therapy | #14 |
| thromboembolism age | #14 |
| acute deep | #14 |
| cancer patients anticoagulation | #14 |
| 17 placebo | #14 |
| treated lmwh | #14 |
| riete score | #14 |
| treatment duration patients | #14 |
| vte statin | #14 |
| revised geneva | #14 |
| safety edoxaban | #14 |
| recurrent venous thromboembolism | #14 |
| factor viii levels | #14 |
| symptomatic pulmonary | #14 |
| conventionaltherapy | #14 |
| bolus intravenous injection | #14 |
| doseranging study | #14 |
| patients acute vte | #14 |
| 12 kg1 | #14 |
| pregnancy venous | #14 |
| oral direct factor | #15 |
| diagnosis venous | #15 |
| antagonist vka | #15 |
| treatment 12 months | #15 |
| subcutaneous regimen | #15 |
| coc vte | #15 |
| thrombosis diagnosis | #15 |
| pregnancy outcome pregnancy | #15 |
| patients ctpa | #15 |
| prior venous thromboembolism | #15 |
| generation oral | #15 |
| clinically relevant endpoints | #15 |
| vitaminkantagonists | #15 |
| doacs aspirin | #15 |
| edoxaban treatment | #15 |
| thrombinography | #15 |
| enoxaparin vte | #15 |
| activation contact | #15 |
| prophylaxis venous thromboembolism | #15 |
| thrombus growth | #15 |
| abdominal pelvic | #15 |
| lmwh ufh | #15 |
| arg562 | #15 |
| primary safety outcome | #15 |
| khorana score | #15 |
| fondaparinux efficacy | #15 |
| cteph incidence | #15 |
| cardiovascular diseases thrombosis | #15 |
| anticoagulants patients | #15 |
| experimental thrombosis | #15 |
| control subjects prevalence | #15 |
| patients vitamin antagonists | #15 |
| studies pulmonary | #15 |
| arg506 | #15 |
| inr range | #15 |
| recombinant factor viia | #15 |
| probability assessment | #15 |
| established vte | #15 |
| thyroid hormone excess | #15 |
| symptomatic events | #15 |
| 500 pg | #15 |
| coagulation | #15 |
| lomoparan | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| subcutaneous enoxaparin | #15 |
| factor leiden | #15 |
| inr patient | #15 |
| warfarin acenocoumarol | #16 |
| major bleeding events | #16 |
| venous thrombosis warfarin | #16 |
| vterelated death | #16 |
| deep venous thrombosis | #16 |
| arterial vascular events | #16 |
| women unexplained | #16 |
| recurrent symptomatic | #16 |
| risk clinically | #16 |
| thromboembolism time | #16 |
| bleeding aged | #16 |
| major bleeding anticoagulation | #16 |
| vte khorana score | #16 |
| thrombosis haemostasis | #16 |
| thrombosis association | #16 |
| analysis rivaroxaban | #16 |
| combination clinical | #16 |
| 6 months placebo | #16 |
| avws patients | #16 |
| abdomino | #16 |
| viia activity | #16 |
| netilmicin gentamicin | #16 |
| test clinical | #16 |
| positivity threshold | #16 |
| patients acenocoumarol | #16 |
| subsequent pregnancy loss | #16 |
| ddimer levels patients | #16 |
| thrombosis low | #16 |
| postthrombotic syndrome children | #16 |
| 100 95 | #16 |
| cancer cancer patients | #16 |
| dvt lmwh | #16 |
| occult cancer detection | #16 |
| factors major | #16 |
| impaired fibrinolysis | #16 |
| factor inhibitor | #16 |
| thrombosis adult | #16 |
| cancer screening patients | #16 |
| vte edoxaban | #17 |
| scan classification | #17 |
| fragment f1 | #17 |
| mutation women | #17 |
| 12 months patients | #17 |
| vkorc1 gene | #17 |
| factor monoclonal | #17 |
| prohemostatic | #17 |
| thromboembolism patients | #17 |
| female humans vte | #17 |
| 516 patients | #17 |
| rivaroxaban oral factor | #17 |
| gentamicin netilmicin | #17 |
| permanent patients | #17 |
| excessive blood loss | #17 |
| diagnosis svt | #17 |
| anticoagulant therapy patients | #17 |
| ctscans | #17 |
| pharmo record linkage | #17 |
| patients impedance | #17 |
| factors venous | #17 |
| dimer assay | #17 |
| thrombosis clinical | #17 |
| management crt | #17 |
| dvt prevention | #17 |
| topic hemorrhage humans | #17 |
| patients overt hypothyroidism | #17 |
| recurrent vte events | #17 |
| lower specificity | #17 |
| anticoagulants clinical | #17 |
| women mutation | #17 |
| incidence pts | #17 |
| endotoxemia bacteremia | #17 |
| 2688 | #17 |
| fibrinolysis treatment | #17 |
| anticoagulants drug | #17 |
| compared enoxaparin | #17 |
| lmwhs patients | #17 |
| hematoma heparin | #17 |
| thromboembolism venous | #18 |
| aptt heparin | #18 |
| warfarin hazard | #18 |
| treatment vkas | #18 |
| intravenous heparin therapy | #18 |
| commercial airline pilots | #18 |
| proximal vein thrombosis | #18 |
| stable anticoagulation | #18 |
| combined form | #18 |
| flight hours | #18 |
| apc thrombin generation | #18 |
| vka edoxaban | #18 |
| relevant nonmajor | #18 |
| antithrombotic treatment patients | #18 |
| patients strategy | #18 |
| outcome events | #18 |
| prothrombin g20210a | #18 |
| hivinfected patients cart | #18 |
| lmwh doacs | #18 |
| diagnostic strategy | #18 |
| simplired | #18 |
| poc test | #18 |
| 4 clinical | #18 |
| vka vte | #18 |
| weight adjusted | #18 |
| sanofi aventis | #18 |
| 023 | #18 |
| thrombosis pulmonary | #18 |
| venous thromboembolism rivaroxaban | #18 |
| cancer vte | #18 |
| women pregnancy loss | #18 |
| annual incidence | #18 |
| thrombosis total | #18 |
| favor lmwh | #18 |
| edoxaban vte | #18 |
| 35 women | #19 |
| doubleblinding | #19 |
| adjusted dose | #19 |
| local angiogenesis | #19 |
| acute recurrent | #19 |
| patients sspe | #19 |
| lmwh patients | #19 |
| endogenous fibrinolysis | #19 |
| studies factor | #19 |
| vitamin antagonist | #19 |
| abnormal ultrasound | #19 |
| objective testing | #19 |
| active search | #19 |
| thromboembolism administration | #19 |
| fibrinolytic response | #19 |
| patients prevalence | #19 |
| increased risk relatives | #19 |
| dvt rivaroxaban | #19 |
| versions version | #19 |
| recurrence vte | #19 |
| venography sensitivity | #19 |
| subcutaneous dalteparin | #19 |
| patients major bleeding | #19 |
| low platelets | #19 |
| increased fibrinolytic activity | #19 |
| coagulation studies | #19 |
| prognostic echocardiography | #19 |
| ufh lmwh | #19 |
| systemic activation coagulation | #19 |
| patients derivation | #19 |
| edoxaban dose | #19 |
| antibodynegative | #19 |
| oral dabigatran enoxaparin | #19 |
| ddimer tests | #19 |
| symptomatic dvt | #19 |
| recurrent venous thrombosis | #19 |
| treatment heparin | #19 |
| venous thromboembolism relatives | #19 |
| patients elevated biomarkers | #19 |
| 56 95 | #19 |
| extended oral | #19 |
| ipdma | #19 |
| fondaparinux enoxaparin | #19 |
| retropubic prostatectomy | #19 |
| vwf vte | #19 |
| recurrence bleeding | #20 |
| blindly | #20 |
| shr 95 | #20 |
| standardtherapy hazard ratio | #20 |
| abi measurement | #20 |
| new agent | #20 |
| excluded patients | #20 |
| thrombophilia vte | #20 |
| antitpo | #20 |
| thrombosis ultrasonography | #20 |
| treatment vte | #20 |
| life venous thrombosis | #20 |
| incidences death | #20 |
| cancer severity | #20 |
| carriers prothrombin | #20 |
| versions questionnaire | #20 |
| antagonists vkas | #20 |
| pregnancyrelated vte | #20 |
| impedance plethysmography ipg | #20 |
| risk thrombophilia | #20 |
| established atherosclerosis | #20 |
| anticoagulation clinic | #20 |
| absolute risk | #20 |
| residual venous | #20 |
| ctnt bnp | #20 |
| diagnostic workup patients | #20 |
| dabigatran 150 | #20 |
| patients ddimer testing | #20 |
| warfarin edoxaban | #20 |
| statin vte | #20 |
| subsegmental | #20 |
| symptomatic venous thrombosis | #20 |
| prothrombin mutation | #20 |
| control situation | #20 |
| therapy rivaroxaban | #20 |
| malignancy time | #20 |
| compared ufh | #20 |
| guidance ssc | #20 |
| intravenous injections | #20 |
| injections subcutaneous | #20 |
| single criterion | #20 |
| nadroparin | #20 |
| calf veins | #20 |
| abi risk factors | #20 |
| synthetic cross | #20 |
| portola | #20 |
| proteins thrombin | #20 |
| distance treatment | #20 |
| hemodynamically stable patients | #21 |
| hemostatic abnormalities | #21 |
| treatment apixaban | #21 |
| carriers noncarriers | #21 |
| internists cardiologists | #21 |
| concomitant anti | #21 |
| current standard treatment | #21 |
| outcome incidence | #21 |
| doacs lmwhs | #21 |
| fibrinolysis inflammation | #21 |
| major bleeding patients | #21 |
| disease ischemic | #21 |
| treatment acenocoumarol | #21 |
| thrombosis anticoagulants | #21 |
| occult malignancy | #21 |
| patients 3 months | #21 |
| vte patients | #21 |
| d‐dimer | #21 |
| distance quality | #21 |
| thromb | #21 |
| risk cohort study | #21 |
| ddimer concentrations | #21 |
| deep venous | #21 |
| discriminatory performance | #21 |
| venogram | #21 |
| prothrombin 20210 | #21 |
| bleeding treatment | #22 |
| treatment dvt | #22 |
| thrombophilia screening | #22 |
| patients immobilization | #22 |
| riskbenefit ratio | #22 |
| doppler venous thrombosis | #22 |
| lpa plasminogen | #22 |
| cttr | #22 |
| hormonal cross | #22 |
| time inr | #22 |
| anticoagulants heparin | #22 |
| dimer age | #22 |
| public awareness | #22 |
| host defense response | #22 |
| safety treatment | #22 |
| patients recurrent symptoms | #22 |
| vascular endotoxins | #22 |
| dichotomously | #22 |
| venous thromboembolic | #22 |
| alternative anticoagulation | #22 |
| recurrent thromboembolism | #22 |
| ttr inr | #22 |
| dose subcutaneous | #22 |
| cmax ctrough | #22 |
| anticoagulants humans | #22 |
| acute vte | #22 |
| patientyears | #22 |
| daily enoxaparin | #22 |
| patients severe hf | #22 |
| 5392 | #23 |
| fondaparinux | #23 |
| time platelet | #23 |
| cancer patients risk | #23 |
| odis | #23 |
| rivaroxaban dosing | #23 |
| development dic | #23 |
| clotbound thrombin | #23 |
| n1157 | #23 |
| hasbled score | #23 |
| vte studies | #23 |
| lower extremity amputation | #23 |
| percentage increase | #23 |
| prevalence venous thromboembolism | #23 |
| elevated ctni | #23 |
| ambulatory cancer patients | #23 |
| standardduration | #23 |
| gentamicin patients | #23 |
| direct factor inhibitors | #23 |
| patients coagulation disorders | #23 |
| 011 | #23 |
| kakkar | #23 |
| 2 investigators | #23 |
| bidirectional relation | #23 |
| life pulmonary embolism | #23 |
| recurrence venous | #23 |
| normal angiogram | #23 |
| enoxaparin 40 | #23 |
| venous arterial thrombosis | #23 |
| thromboembolism anticoagulants | #23 |
| followup incidence | #24 |
| fondaparinux placebo | #24 |
| 049 | #24 |
| food drugs | #24 |
| subtherapeutic | #24 |
| rates venous thromboembolism | #24 |
| therapy heparin | #24 |
| safety fondaparinux | #24 |
| years episode | #24 |
| levels fviii | #24 |
| overt hyperthyroidism | #24 |
| thrombosis carriers | #24 |
| recurrent thromboembolism patients | #24 |
| viiic | #24 |
| patients acute treatment | #24 |
| parameters fibrinolysis | #24 |
| specific antidote | #24 |
| desogestrel levonorgestrel | #24 |
| lowmolecularweight humans | #24 |
| bleeding complication | #24 |
| ufh patients | #24 |
| patients severe bleeding | #24 |
| predefined criteria | #24 |
| presence dvt | #24 |
| recurrent pulmonary embolism | #24 |
| ddimer testing | #24 |
| month incidence | #24 |
| prevalence deficiencies | #24 |
| independent external validation | #24 |
| a21gly | #24 |
| patients abnormal perfusion | #24 |
| fatima | #25 |
| expert radiologists | #25 |
| suggestions improvement | #25 |
| factors anticoagulants | #25 |
| thromboembolism acute | #25 |
| specificity efficiency | #25 |
| willebrand factor adamts13 | #25 |
| cha2ds2vasc chads2 | #25 |
| xii activity | #25 |
| studies lmwh | #25 |
| treatment symptomatic | #25 |
| f1 2 levels | #25 |
| amadeus | #25 |
| anatomical extent | #25 |
| fibrinogen degradation | #25 |
| influence smoking | #25 |
| patients gastrointestinal bleeding | #25 |
| middeldorp | #25 |
| perfusion lung scan | #25 |
| vte clinical | #25 |
| sepsis intravascular coagulation | #25 |
| lmwh treatment | #25 |
| rethoracotomy | #26 |
| failure rate | #26 |
| patients symptomatic dvt | #26 |
| edoxaban vka | #26 |
| specificity negative predictive | #26 |
| viia complex | #26 |
| parameters risk | #26 |
| treatment lmwh | #26 |
| 9715 | #26 |
| doacs vitamin antagonists | #26 |
| venous thromboemboli | #26 |
| miscarriage stillbirth | #26 |
| patients cdr | #26 |
| asymptomatic carriers | #26 |
| patients essential thrombocythaemia | #26 |
| unprovoked vte | #26 |
| events year | #26 |
| homozygous carriers | #26 |
| dalteparin ufh | #26 |
| ecq | #26 |
| major bleeding bleeding | #26 |
| hormonal manipulation | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| edoxaban versus | #26 |
| rate recurrent vte | #26 |
| patients major hemorrhage | #27 |
| combined training | #27 |
| thrombophlebitis | #27 |
| treating physician | #27 |
| current guidance | #27 |
| patients elevated levels | #27 |
| perfusion lung | #27 |
| female heterozygote | #27 |
| 0·63 | #27 |
| lowmolecularweight heparin patients | #27 |
| anticoagulants blood | #27 |
| thrombosis venous | #27 |
| noncarriers 95 | #27 |
| enoxaparin female | #27 |
| extremity venous | #27 |
| airline pilots | #27 |
| training gps | #27 |
| cancer spread | #27 |
| vte thr | #27 |
| thrombocytopenia antibodies | #27 |
| unprovoked venous | #27 |
| venous thromboembolism carriers | #27 |
| lmwh prophylaxis | #27 |
| anticoagulants factor | #27 |
| low molecularweight heparin | #27 |
| months studies | #27 |
| vte doacs | #27 |
| day 35 | #27 |
| npv patients | #27 |
| nonmajor | #27 |
| patients 50 | #27 |
| presentation followup | #28 |
| pph severe pph | #28 |
| objective tests | #28 |
| acutely medical patients | #28 |
| unexplained | #28 |
| 4650 | #28 |
| cancer venous thromboembolism | #28 |
| patients unprovoked | #28 |
| vte 6 months | #28 |
| coagulation tissue factor | #28 |
| hirudin therapy | #28 |
| 2½ | #28 |
| specific reversal agent | #28 |
| pembqol | #28 |
| therapeutic doses | #28 |
| rfviia placebo | #28 |
| vitamin aged | #28 |
| factors recurrent | #28 |
| anticoagulation women | #28 |
| tests diagnostic | #28 |
| apc plasma | #28 |
| embolism retrospective | #28 |
| receiving rivaroxaban | #28 |
| monitoring therapy | #28 |
| anticoagulants compared | #28 |
| dvt pulmonary embolism | #29 |
| pulmonary angiography | #29 |
| thrombosis treatment | #29 |
| spread cancer | #29 |
| g20210a mutation | #29 |
| prediction scores | #29 |
| aged morpholines | #29 |
| direct oral anticoagulants | #29 |
| 1000 individuals | #29 |
| diagnosis dvt | #29 |
| patients standard therapy | #29 |
| 8240 | #29 |
| oral glucocorticoids | #29 |
| bleeding increased | #29 |
| heparin versus | #29 |
| pulmonary embolism recurrence | #29 |
| dabigatran pcc | #29 |
| pulmonary embolism death | #29 |
| cindexes | #29 |
| recurrence svt | #29 |
| dutch famine | #29 |
| acenocoumarol patients | #29 |
| sex‐specific differences | #29 |
| patients avws | #29 |
| years year | #29 |
| pbac score | #29 |
| plateletactivating antibodies | #29 |
| septicemia | #29 |
| major bleeding rivaroxaban | #29 |
| resistance activated protein | #29 |
| thrombo | #29 |
| aspirin placebo | #29 |
| authors incidence | #29 |
| thrombosis 95 | #29 |
| blind trials | #29 |
| aminoglycoside therapy | #29 |
| current management strategies | #29 |
| embolism risk | #30 |
| patients vte | #30 |
| new anticoagulants | #30 |
| xii factor | #30 |
| 1000 personyears incidence | #30 |
| markers coagulation activation | #30 |
| doac vka | #30 |
| f1 2 | #30 |
| cancer venous | #30 |
| residual thrombosis | #30 |
| subcutaneous heparin | #30 |
| thromboembolism warfarin | #30 |
| prevention venous | #30 |
| ufh vte | #30 |
| rule patients | #30 |
| administration pentoxifylline | #30 |
| vte coc | #30 |
| 95 risk | #30 |
| support techniques | #30 |
| direct oral factor | #30 |
| costs diagnosis | #30 |
| recurrent patients | #31 |
| rfviia novoseven | #31 |
| 8755 | #31 |
| 2 antiplasmin | #31 |
| activation blood coagulation | #31 |
| placebo observation | #31 |
| iii activity | #31 |
| prevalence probability | #31 |
| ufh fondaparinux | #31 |
| recurrent vte patients | #31 |
| incidence pph | #31 |
| recurrent episode | #31 |
| antithrombotic therapies | #31 |
| pharmacological prophylaxis | #31 |
| dvt pulmonary | #31 |
| bled | #31 |
| rhir | #31 |
| incidence cteph | #31 |
| inhibitor edoxaban | #31 |
| thromboprophylaxis risk | #31 |
| experimental endotoxemia | #31 |
| ventilation scintigraphy | #31 |
| standardtherapy | #31 |
| apixaban placebo | #31 |
| women recurrent miscarriage | #31 |
| dimer cutoff | #31 |
| patients deepvein thrombosis | #31 |
| events 95 | #31 |
| 0206 | #31 |
| thromboembolism adolescent | #31 |
| imaging sensitivity specificity | #31 |
| term risk | #31 |
| vte ufh | #31 |
| analysis reviewers | #31 |
| extended prophylaxis | #31 |
| international society thrombosis | #32 |
| factor female | #32 |
| parenteral anticoagulants | #32 |
| low clinical | #32 |
| ufh | #32 |
| negative septicemia | #32 |
| negative dimer | #32 |
| leiden mutation | #32 |
| generation patients | #32 |
| treatment anticoagulants | #32 |
| warfarin vte | #32 |
| resistance activated | #32 |
| age adjusted | #32 |
| normal genotype | #32 |
| factors thrombolytic | #32 |
| varicosis | #32 |
| parenteral anticoagulation | #32 |
| khorana score patients | #32 |
| suspected patients | #32 |
| netherlands predictive | #32 |
| year 95 | #32 |
| cancer patients diagnosis | #33 |
| activation factors | #33 |
| unitage | #33 |
| apixaban treatment | #33 |
| additional tests | #33 |
| rhirudin | #33 |
| warfarin risks | #33 |
| prophylaxis vte | #33 |
| subcutaneous male | #33 |
| low probability | #33 |
| data meta | #33 |
| pulmonary angiogram | #33 |
| nephrotoxicity gentamicin | #33 |
| active implementation | #33 |
| thromboembolism young | #33 |
| mega study | #33 |
| anticoagulant protein | #33 |
| chapter patients | #33 |
| factor viii patients | #33 |
| heparin lmwh | #33 |
| vte thrombophilia | #34 |
| anticoagulant | #34 |
| bilateral venography | #34 |
| 10 95 | #34 |
| plasmin alpha | #34 |
| subsegmental pulmonary embolism | #34 |
| 590 | #34 |
| warfarin adult | #34 |
| deficiency protein | #34 |
| phytonadione | #34 |
| grade 1a | #34 |
| lmwh unfractionated heparin | #34 |
| apcsr | #34 |
| compare efficacy | #34 |
| 3 months treatment | #34 |
| control trials | #34 |
| reocclusion patients | #34 |
| hemorrhage heparin humans | #34 |
| vte compared | #34 |
| thrombosis lower | #34 |
| pregnancy loss women | #34 |
| 9241 | #34 |
| surgery hip | #35 |
| weekly subcutaneous | #35 |
| statin association | #35 |
| anticoagulants benzimidazoles | #35 |
| neoplasms venous | #35 |
| enoxaparin prevention | #35 |
| embolism | #35 |
| radiologists diagnosis | #35 |
| lung scanning | #35 |
| rviia | #35 |
| 36 95 | #35 |
| risk members | #35 |
| pph blood loss | #35 |
| patients efficiency | #35 |
| activation coagulation | #35 |
| prevention model | #35 |
| fibrinolytic activation | #36 |
| thrombophilia venous | #36 |
| acute symptomatic | #36 |
| peripheral endovascular | #36 |
| 1698 | #36 |
| venous thromboembolism dabigatran | #36 |
| catheterrelated infection | #36 |
| treatment acute vte | #36 |
| hellp patients | #36 |
| viii levels | #36 |
| dose reduction patients | #36 |
| levels coagulation | #36 |
| fibrinogen depletion | #36 |
| inherited risk factors | #36 |
| factors travel | #36 |
| novoseven | #36 |
| regular monitoring | #36 |
| riskbenefit | #36 |
| iii antithrombin | #36 |
| 4139 | #36 |
| studies echocardiography | #36 |
| 287 patients | #36 |
| venous thromboembolic disease | #36 |
| factors thrombophilia | #37 |
| screening occult | #37 |
| outcome composite | #37 |
| recombinant hirudin | #37 |
| ctpa patients | #37 |
| vte increased | #37 |
| magellan | #37 |
| cumulative incidence vte | #37 |
| excluding | #37 |
| anticoagulant action | #37 |
| bagsvaerd | #37 |
| suspected venous | #37 |
| prophylactic heparin | #37 |
| ototoxicity nephrotoxicity | #37 |
| tat complexes | #37 |
| venography | #37 |
| warfarin 95 | #37 |
| risk venous thrombosis | #37 |
| pad studies | #37 |
| thrombosis humans | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| lwmh | #37 |
| anticoagulants prevention | #37 |
| risk factors pts | #37 |
| genotype 95 | #37 |
| perelated mortality | #37 |
| patients ddimer levels | #38 |
| doac lmwh | #38 |
| 2835 | #38 |
| recurrence day | #38 |
| catheterrelated thrombosis | #38 |
| rivaroxaban placebo | #38 |
| nonmajor bleeding | #38 |
| submassive pulmonary | #38 |
| vte cancer patients | #38 |
| restenosis reocclusion | #38 |
| sensitivity biomarkers | #38 |
| 10 total | #38 |
| anticoagulants female humans | #38 |
| coagulation protein | #38 |
| vte bleeding | #38 |
| age recurrence | #38 |
| congenital deficiencies | #38 |
| 3306 | #38 |
| fetal loss women | #38 |
| children familial hypercholesterolemia | #39 |
| submassive | #39 |
| 277 patients | #39 |
| compression stocking | #39 |
| septic syndrome | #39 |
| enoxaparin placebo | #39 |
| heparins lmwhs | #39 |
| doacs | #39 |
| embolus | #39 |
| incidence patients | #39 |
| incidence cancer | #39 |
| systemic inflammatory responses | #39 |
| time compression | #39 |
| fibrin fibrinogen | #39 |
| subcutaneous intention | #39 |
| low molecular weight | #39 |
| continued treatment | #39 |
| superficial vein thrombosis | #39 |
| diagnostic prediction | #39 |
| specificity patients | #39 |
| standardized definition | #40 |
| episode venous thromboembolism | #40 |
| therapeutic dosages | #40 |
| thrombinantithrombin complexes | #40 |
| day 6 months | #40 |
| anticoagulant therapy | #40 |
| activatable fibrinolysis | #40 |
| endotoxininduced | #40 |
| patients normal | #40 |
| clotting activation | #40 |
| tfmp | #40 |
| common femoral vein | #40 |
| anticoagulation therapy patients | #40 |
| dalteparin treatment | #40 |
| arterial vascular | #40 |
| grade 1a patients | #40 |
| pemb | #40 |
| ambulatory cancer | #40 |
| fviiic | #40 |
| bleeding | #40 |
| international clinical | #40 |
| lung scintigraphy | #41 |
| submassive pulmonary embolism | #41 |
| lowmolecularweight heparins | #41 |
| placebo 6 months | #41 |
| endotoxin induced | #41 |
| heparin therapy | #41 |
| calf vein thrombosis | #41 |
| cancer lmwh | #41 |
| anticoagulated patients | #41 |
| risk recurrent vte | #41 |
| triage tests | #41 |
| 7268 | #41 |
| 95 genotype | #41 |
| pentasaccharides | #41 |
| dabigatran etexilate | #41 |
| prophylaxis venous | #42 |
| patients prospective | #42 |
| patients silent | #42 |
| thrombosis administration | #42 |
| netilmicin | #42 |
| major contributor | #42 |
| stroke thrombosis | #42 |
| standardization committee | #42 |
| anticoagulation risk | #42 |
| patients vasopressors | #42 |
| neoplasms thrombosis | #42 |
| cell extravasation | #42 |
| 8101 | #42 |
| type graft | #42 |
| post‐thrombotic syndrome | #43 |
| rtap | #43 |
| venous thromboembolism vte | #43 |
| patients vte risk | #43 |
| 543 patients | #43 |
| ischemic events | #43 |
| probability patients | #43 |
| venous thrombosis thrombophilia | #43 |
| draft document | #43 |
| heparin risk | #43 |
| fetal loss | #43 |
| cancer adjusted | #43 |
| monthly incidence | #43 |
| vkas patients | #43 |
| warfarin anticoagulants | #43 |
| initial treatment | #43 |
| factors thromboembolism | #44 |
| edoxaban therapy | #44 |
| patients tinzaparin | #44 |
| recurrent vte 95 | #44 |
| 95 pulmonary embolism | #44 |
| expert physicians | #44 |
| enoxaparin risk | #44 |
| mild hyperhomocysteinaemia | #44 |
| experimental venous thrombosis | #44 |
| restoration euthyroidism | #44 |
| indications patients | #44 |
| 10–14 | #44 |
| nonvka oral anticoagulants | #44 |
| efficiency models | #44 |
| 20 30 | #44 |
| uedvt patients | #44 |
| role coagulation | #44 |
| protein sepsis | #44 |
| rate venous | #44 |
| coagulation activation | #45 |
| 95 warfarin | #45 |
| fondaparinux patients | #45 |
| revascularisation procedures | #45 |
| dose lmwh | #45 |
| patients bnp | #45 |
| venous thrombotic | #45 |
| years algorithm | #45 |
| dose adjusted | #45 |
| treated warfarin | #45 |
| wells score | #45 |
| coumarin therapy | #45 |
| oral direct | #45 |
| dvt patients | #45 |
| daily rivaroxaban | #46 |
| treatment model | #46 |
| prothrombin fragment f1 | #46 |
| abtpo | #46 |
| extended duration | #46 |
| day levels | #46 |
| major bleeding placebo | #46 |
| ssc isth | #46 |
| standard therapy | #46 |
| healthcare settings | #46 |
| ruling | #46 |
| percent confidence | #46 |
| bleeding rivaroxaban | #46 |
| management venous | #46 |
| patients unprovoked vte | #46 |
| hospital outpatients | #46 |
| pioped | #46 |
| stroke risk assessment | #46 |
| outcome vitamin | #47 |
| iiia receptors | #47 |
| mechanical prophylaxis | #47 |
| episode vte | #47 |
| central venous lines | #47 |
| plasma ddimer levels | #47 |
| male methimazole | #47 |
| boehringer ingelheim | #47 |
| ambulatory anticoagulants | #47 |
| bristol myers squibb | #47 |
| roccurve | #47 |
| mutation pregnancy | #47 |
| new oral anticoagulant | #47 |
| factors rivaroxaban | #48 |
| recurrence venous thromboembolism | #48 |
| subcommittee | #48 |
| small studies | #48 |
| patients acute dvt | #48 |
| thromboprophylactic | #48 |
| thrombotic burden | #48 |
| daiichi | #48 |
| travel risk | #48 |
| elevated plasma levels | #48 |
| fondaparinux heparin | #48 |
| rivaroxaban compared | #48 |
| risk recurrent | #48 |
| diagnosis physicians | #48 |
| intermediate risk risk | #48 |
| patients pulmonary | #48 |
| factor viii deficiency | #49 |
| enoxaparin | #49 |
| lowmolecularweight heparin lmwh | #49 |
| levels protein | #49 |
| vte diagnosis | #49 |
| calf vein | #49 |
| women aspirin | #49 |
| rivaroxaban prevention | #49 |
| incidence venous thromboembolism | #50 |
| thromboembolism aged | #50 |
| etexilate | #50 |
| transient risk factor | #50 |
| prospective diagnostic | #50 |
| dvt diagnosis | #50 |
| treatment threshold | #50 |
| vitamink antagonists | #50 |
| nonselective betablockers | #50 |
| intensity treatment | #50 |
| acute respiratory insufficiency | #50 |
| cardiac surgery mortality | #50 |
| buller | #50 |
| outpatient therapy | #50 |
| atria patients | #50 |
| factor vte | #51 |
| patients 11 | #51 |
| previous survey | #51 |
| acenocoumarol | #51 |
| 95 apixaban | #51 |
| tomography pulmonary | #51 |
| discrimination model | #51 |
| normal perfusion | #51 |
| strategies treatment | #51 |
| protein deficiencies | #51 |
| effects coagulation | #51 |
| global disease | #51 |
| risk venous thromboembolism | #52 |
| lung scans | #52 |
| pdvt | #52 |
| doacs vka | #52 |
| hematologic malignancies patients | #52 |
| patients comorbid conditions | #52 |
| apixaban vte | #52 |
| 3 month | #52 |
| svt patients | #52 |
| free thyroxine ft4 | #52 |
| lmwh fondaparinux | #52 |
| vte major bleeding | #52 |
| unnecessarily | #52 |
| 1·12 | #52 |
| inhibitors heparin | #52 |
| 1522 | #53 |
| 40 daily | #53 |
| absolute risks | #53 |
| thromboembolism prevention | #53 |
| patients initially | #53 |
| thrombophilic factors | #53 |
| versus enoxaparin | #53 |
| warfarintreated patients | #53 |
| preference patients | #53 |
| suspected venous thromboembolism | #53 |
| cross study | #53 |
| hemostatic balance | #53 |
| 479 patients | #53 |
| postthrombotic syndrome | #53 |
| reported incidence | #53 |
| 034 | #54 |
| patients incidence | #54 |
| patients obese | #54 |
| thromboembolism death | #54 |
| pai1 levels patients | #54 |
| bled score | #54 |
| chads2 cha2ds2vasc | #54 |
| vte mortality | #54 |
| prethrombotic | #54 |
| acquired risk factors | #54 |
| major bleeds | #54 |
| 2537 | #54 |
| endocrine disorders | #54 |
| familial thrombophilia | #54 |
| antithrombotic drug | #54 |
| male pulmonary embolism | #54 |
| 378 patients | #54 |
| legs patients | #55 |
| proximal extent | #55 |
| insurances | #55 |
| biological pan | #55 |
| long term risk | #55 |
| dosereduction | #55 |
| methods randomized | #55 |
| nondeficient | #55 |
| unfractionated heparin | #55 |
| rivaroxaban | #55 |
| unfractionated heparin ufh | #55 |
| anticoagulants arthroplasty replacement | #55 |
| compared lmwh | #55 |
| treatment thresholds | #55 |
| preeclampsia hellp syndrome | #56 |
| seventh accp conference | #56 |
| 20210a | #56 |
| level mortality | #56 |
| vte death | #56 |
| tromboembólica | #56 |
| time event | #56 |
| reduced capacity | #56 |
| venous outflow obstruction | #56 |
| vitamin warfarin | #56 |
| enoxaparin rivaroxaban | #56 |
| vasopressors | #56 |
| risk major bleeding | #56 |
| deficiency prevalence | #56 |
| major bleeding apixaban | #56 |
| enoxaparin patients | #56 |
| inr values | #56 |
| physicians guidelines | #56 |
| weight heparins | #56 |
| risk factors vte | #57 |
| ctscan | #57 |
| levels survival | #57 |
| antithrombin iii heparin | #57 |
| calf dvt | #57 |
| clinical models | #57 |
| inhibitors female humans | #57 |
| subsegmental pulmonary | #57 |
| pharmo | #58 |
| doacs patients | #58 |
| inhibitors female | #58 |
| fibrinolysis humans | #58 |
| lowmolecular weight heparin | #58 |
| ruled | #58 |
| spiral computed | #58 |
| malignancy mortality | #58 |
| unfractionated heparin patients | #58 |
| thrombin activatable | #58 |
| clot lysis time | #59 |
| safety warfarin | #59 |
| risk vte | #59 |
| mutation prothrombin | #59 |
| warfarin treatment | #59 |
| bias trial | #59 |
| acute venous thromboembolism | #59 |
| risk periods | #59 |
| factor generation | #59 |
| direct oral | #59 |
| risk factors sensitivity | #59 |
| aventis | #59 |
| incidence symptomatic | #59 |
| thrombosis aged | #59 |
| heterozygous factor | #59 |
| women difference | #60 |
| target inr | #60 |
| pediatric venous thromboembolism | #60 |
| fixeddose | #60 |
| 079 95 | #60 |
| constans | #60 |
| atrial fibrillation metaanalysis | #60 |
| prevalence pulmonary | #60 |
| anticoagulants treatment | #60 |
| awareness risk factors | #60 |
| hemorrhage humans | #60 |
| pulmonary embolism 95 | #60 |
| acute pulmonary embolism | #60 |
| dvt 95 | #61 |
| association protein | #61 |
| benzimidazoles dabigatran | #61 |
| 3633 | #61 |
| hypocoagulable | #61 |
| tests prevalence | #61 |
| month surgery | #61 |
| cdr score | #61 |
| perfusion ventilation | #61 |
| long‐term treatment | #61 |
| rosendaal | #61 |
| amuse | #61 |
| free thyroxine | #61 |
| general practitioners patients | #62 |
| protein fibrinogen | #62 |
| post thrombotic | #62 |
| 273 patients | #62 |
| human endotoxemia | #62 |
| ttr patients | #62 |
| patients administration | #62 |
| combined contraceptives oral | #62 |
| procoagulant state | #62 |
| informatizado | #62 |
| 250 patients | #62 |
| activated partial | #62 |
| women mutations | #63 |
| revised geneva score | #63 |
| rivaroxaban lmwh | #63 |
| injection endotoxin | #63 |
| cvrs | #63 |
| symptoms dvt | #63 |
| quantitative test | #63 |
| vte thromboprophylaxis | #63 |
| physicians predictive | #63 |
| venous thromboembolisms | #63 |
| management anticoagulation | #63 |
| common odds ratio | #63 |
| treatment network | #63 |
| factor leiden risk | #63 |
| smoking smoking cessation | #63 |
| 33 women | #63 |
| cancer noncancer patients | #64 |
| heparin fondaparinux | #64 |
| superficial vein | #64 |
| vkas treatment | #64 |
| blinded trial | #64 |
| acute pulmonary | #64 |
| decision rules | #64 |
| factor inhibitors | #64 |
| prior vte | #64 |
| oral thrombin | #64 |
| bleeding events patients | #64 |
| thrombophilic risk | #64 |
| dvts | #64 |
| postthrombotic | #64 |
| selfadjustment | #64 |
| patients aortic valve | #64 |
| ultrasonograms | #65 |
| prothrombin g20210a mutation | #65 |
| accuracy diagnostic tests | #65 |
| fvl vte | #65 |
| prevalence abnormalities | #65 |
| stroke thromboembolism | #65 |
| treatment pad | #65 |
| 0 points | #66 |
| elfa | #66 |
| statin therapy risk | #66 |
| death classification | #66 |
| 95 bleeding | #66 |
| axa | #66 |
| dvt sensitivity | #66 |
| female heparin | #66 |
| rapid triage | #66 |
| risk factor thrombosis | #66 |
| newer anticoagulants | #66 |
| 1127 | #67 |
| rate major | #67 |
| apixaban | #67 |
| patients tertiles | #67 |
| patients factor | #67 |
| standard therapy patients | #67 |
| atrial fibrillation stroke | #67 |
| 1894 | #68 |
| patients bnp levels | #68 |
| 20210g | #68 |
| coagulation fibrinolysis | #68 |
| fibrinolytic | #68 |
| perioperative blood | #68 |
| 3594 | #68 |
| patients benefits | #68 |
| academic medical centre | #68 |
| 05 95 | #68 |
| ranging study | #68 |
| thrombosis blood | #69 |
| ionis | #69 |
| justify | #69 |
| certoparin | #69 |
| recurrent thrombosis patients | #69 |
| enfermedad tromboembólica | #69 |
| suspected | #69 |
| heparin ufh | #69 |
| postphlebitic | #69 |
| plasma interleukin | #69 |
| fixed dose | #70 |
| α2ap | #70 |
| vwfrco | #70 |
| test patients | #70 |
| elevated cardiac | #70 |
| 8190 | #70 |
| cutoff levels | #70 |
| major bleeding complications | #70 |
| mantelhaenszel | #70 |
| patients protein | #70 |
| gramnegative sepsis | #70 |
| thrombosis recurrence | #70 |
| rivaroxaban treatment | #70 |
| withhold | #70 |
| ischemic events patients | #70 |
| aged predictive | #70 |
| vte vka | #71 |
| clopidogrel placebo | #71 |
| thromboprophylaxis | #71 |
| plasminogen plg | #71 |
| asymptomatic atherosclerosis | #71 |
| levels vwf | #71 |
| topic costs | #71 |
| tests prospective | #71 |
| diagnostic sensitivity specificity | #71 |
| unfractionated | #71 |
| overt hypothyroidism | #72 |
| elevated factor | #72 |
| pooled rate | #72 |
| activation prothrombin | #72 |
| new anticoagulant | #72 |
| hf studies | #72 |
| complications hematologic | #72 |
| antithrombin iii iii | #72 |
| viia factor | #72 |
| patients lmwh | #72 |
| trifurcation | #72 |
| ddimer values | #72 |
| versus vitamin | #72 |
| ingelheim | #73 |
| tomography spiral | #73 |
| 12 months 95 | #73 |
| noacs | #73 |
| analysis diagnostic | #73 |
| reversal agent | #73 |
| soluble fibrin | #73 |
| ddimer measurement | #73 |
| prolongations | #73 |
| suspected dvt | #74 |
| prethrombotic state | #74 |
| proteins patients | #74 |
| dvt study | #74 |
| carriers | #74 |
| 1732 | #74 |
| 2124 | #74 |
| 2550 | #74 |
| soluble thrombomodulin | #74 |
| 5395 | #74 |
| experimental metastasis | #74 |
| female hemorrhage | #74 |
| longterm risk | #74 |
| study selection | #74 |
| thrombolytic therapy patients | #75 |
| 2904 | #75 |
| retrospective follow | #75 |
| carotid femoral arteries | #75 |
| 8492 | #75 |
| incidence bleeding events | #75 |
| 1334 | #75 |
| postoperative dvt | #75 |
| selective factor | #75 |
| extended anticoagulation | #76 |
| oral combined contraceptives | #76 |
| combined contraceptives | #76 |
| tests primary | #76 |
| early time | #76 |
| angiography ctpa | #76 |
| factor xii deficiency | #76 |
| duration thromboprophylaxis | #76 |
| risk thrombosis | #76 |
| social aspects | #77 |
| p023 | #77 |
| patients secondary | #77 |
| thrombosis pregnancy | #77 |
| boehringer | #77 |
| individual patient | #77 |
| arterial wall thickness | #78 |
| unprovoked | #78 |
| female fibrinolysis | #78 |
| ipg | #78 |
| arterial thromboembolism | #78 |
| women thrombophilia | #78 |
| 20 daily | #78 |
| elevated dimer | #78 |
| suspected acute | #79 |
| vte fvl | #79 |
| 2486 | #79 |
| topic heparin | #79 |
| time therapeutic | #79 |
| factor adult | #79 |
| vkas | #79 |
| efficacy agents | #79 |
| limulus test | #79 |
| humans pulmonary | #79 |
| suspected cancer | #80 |
| vte rate | #80 |
| subhazard ratio | #80 |
| daily bid | #80 |
| heterozygous deficiency | #80 |
| thromboembolism incidence | #80 |
| sspe patients | #80 |
| alife | #80 |
| patient data | #80 |
| bleeding mortality | #80 |
| 95 05 | #80 |
| validation models | #80 |
| topic risk | #81 |
| test evaluation | #81 |
| walking distance | #81 |
| systemic inflammatory | #81 |
| vascular events | #81 |
| knee arthroplasty patients | #81 |
| outpatient basis | #81 |
| lmwh vte | #81 |
| weitz | #81 |
| prothrombin complex concentrate | #81 |
| thrombolytic drugs | #82 |
| 50 micrograms | #82 |
| placebo women | #82 |
| prospective validation | #82 |
| heparin prevention | #82 |
| thrombosis thrombophilia | #82 |
| symptomatic carriers | #82 |
| clinical sign | #82 |
| 3month followup | #82 |
| thrombosis incidence | #82 |
| posthoc analysis | #82 |
| crnmb | #82 |
| common practice | #82 |
| mammography patients | #82 |
| timeperiods | #82 |
| dimer patients | #83 |
| patients thrombi | #83 |
| elective coronary | #83 |
| inhibitor dabigatran | #83 |
| 287 | #83 |
| 2213 | #83 |
| bistro | #83 |
| bleeding women | #83 |
| prophylactic dose | #84 |
| healthcare setting | #84 |
| normotensive patients | #84 |
| screening humans | #84 |
| diagnostic outcome | #84 |
| inhibitor rivaroxaban | #84 |
| inherited thrombophilia | #84 |
| heparin treatment | #84 |
| duration therapy | #84 |
| venous thrombosis patients | #85 |
| endotoxins | #85 |
| antithrombin iii protein | #85 |
| peripheral vascular diseases | #85 |
| thrombosis svt | #85 |
| asymptomatic dvt | #85 |
| anticoagulants antiphospholipid | #85 |
| normal levels | #85 |
| dabigatran vka | #86 |
| 75 microg | #86 |
| elevated ddimer levels | #86 |
| venovenous hemofiltration | #86 |
| major bleeding warfarin | #86 |
| rhapc | #86 |
| 4576 | #86 |
| 10⁶ | #86 |
| obstetric patients | #87 |
| acute venous | #87 |
| ≤50 | #87 |
| post‐hoc analysis | #87 |
| patients 28 | #87 |
| avws | #87 |
| vidas | #87 |
| clinical impact | #87 |
| 95 100 | #87 |
| contact activation | #87 |
| treatment statins | #88 |
| internist | #88 |
| treatment incidence | #88 |
| 4 points | #88 |
| activation factor | #88 |
| venographic | #88 |
| cdr | #88 |
| aged multicenter | #88 |
| lmwhs | #88 |
| 3319 | #88 |
| washout period | #88 |
| ventilation lung | #89 |
| severe hf | #89 |
| adequate treatment | #89 |
| tests test | #89 |
| matisse | #89 |
| cytokine release | #89 |
| smoking incidence | #89 |
| vte venous thromboembolism | #89 |
| rates major bleeding | #89 |
| unexplained recurrent | #89 |
| stroke bleeding | #89 |
| costs patient | #89 |
| beta blockers | #89 |
| reversal strategies | #89 |
| anticoagulants dabigatran | #89 |
| ddimer | #89 |
| safety noacs | #89 |
| new patients | #90 |
| outweighs | #90 |
| 2293 | #90 |
| primary thromboprophylaxis | #90 |
| pediatric venous | #90 |
| vka dabigatran | #90 |
| popliteal vein | #90 |
| thrombophilic risk factors | #90 |
| fibrinolytic factors | #90 |
| venous thrombosis risk | #90 |
| thrombosis women | #91 |
| perfusion ratio | #91 |
| pyridines pyridones | #91 |
| inconvenience | #91 |
| anticoagulants doacs | #91 |
| agents hemorrhage | #91 |
| 60 95 | #91 |
| cdrs | #91 |
| 20210 | #91 |
| thromboembolism pregnancy | #91 |
| combined clinical | #92 |
| thrombotic disease | #92 |
| single intravenous | #92 |
| prophylaxis incidence | #92 |
| anticoagulation reversal | #93 |
| incidence knee | #93 |
| 95 years | #93 |
| direct thrombin inhibitors | #93 |
| compression patients | #93 |
| rivaroxaban edoxaban | #93 |
| scenario analyses | #93 |
| test result | #94 |
| 1027 | #94 |
| atherogenic lipid | #94 |
| children vte | #94 |
| 125 patients | #94 |
| patients symptomatic | #94 |
| hf severity | #94 |
| vte surgery | #94 |
| heparins | #94 |
| viia rfviia | #95 |
| european consensus statement | #95 |
| direct oral anticoagulant | #95 |
| 2 levels | #95 |
| randomised crossover study | #96 |
| 6 12 months | #96 |
| xii deficiency | #96 |
| symptomatic vte | #96 |
| fondaparinux treatment | #96 |
| risk symptomatic | #96 |
| efficacy rivaroxaban | #96 |
| ddimer level | #96 |
| studies evaluated | #97 |
| haemophilia patients | #97 |
| invasive testing | #97 |
| abnormal perfusion | #97 |
| fibrin generation | #97 |
| doacs risk | #97 |
| symptomatic pulmonary embolism | #97 |
| tpa release | #97 |
| pyrazoles pyridones | #97 |
| difference rates | #97 |
| 2875 | #98 |
| hypercoagulable | #98 |
| major bleed | #98 |
| simplify | #98 |
| supervised exercise therapy | #98 |
| essential thrombocythaemia | #98 |
| pregnancy postpartum period | #98 |
| activated protein apc | #98 |
| 16slice | #98 |
| hirudin | #99 |
| acute dvt | #99 |
| 2·0 | #99 |
| probast | #99 |
| perfusion scintigraphy | #99 |
| unselected | #99 |
| risk arterial | #99 |
| lmwh warfarin | #99 |
| previews | #100 |
| 1116 | #100 |
| fatty foods | #100 |
| patient groups | #100 |
| doubleblind trial | #100 |
| gbd 2010 | #100 |
| prevention recurrent | #100 |
| warfarin patients | #100 |
| 3 trials | #100 |
| increasing levels | #100 |
| aptts | #101 |
| factor vii factor | #101 |
| morpholines | #101 |
| factor viia | #101 |
| 40 microg | #102 |
| low pretest probability | #102 |
| 265 patients | #102 |
| enoxaparin fondaparinux | #102 |
| alternative diagnosis | #102 |
| pts patients | #102 |
| venous thromboembolism women | #102 |
| endogenous thrombin | #103 |
| 338 | #103 |
| adjudicated | #103 |
| doppler method | #103 |
| pregnancy puerperium | #103 |
| cteph patients | #103 |
| therapeutic consequences | #103 |
| arthroscopic anterior | #103 |
| separate analyses | #104 |
| fibrin degradation products | #104 |
| oral factor | #104 |
| diagnostic imaging humans | #104 |
| term treatment | #104 |
| assay variation | #104 |
| apparent increase | #104 |
| antithrombin iii | #104 |
| absolute increase | #104 |
| recurrence women | #104 |
| heparin pregnancy | #104 |
| partial restoration | #104 |
| 7 children | #105 |
| conventional therapy patients | #105 |
| 1089 | #105 |
| embryo loss | #105 |
| 2479 | #106 |
| thrombosis age | #106 |
| chest ray | #106 |
| elevated levels | #106 |
| thromboprophylaxis patients | #106 |
| blind double | #106 |
| fibrinolytic systems | #106 |
| study total | #106 |
| 314 | #106 |
| thrombophilia | #106 |
| hospitalized patients hf | #106 |
| essentials | #106 |
| thromboembolic | #107 |
| definition classification | #107 |
| vte risk | #107 |
| topic recurrence | #107 |
| ddimer levels | #107 |
| survival cancer patients | #107 |
| simplified version | #107 |
| specific subgroups | #108 |
| human volunteers | #108 |
| grade 1c | #108 |
| cardiovascular death stroke | #108 |
| noncancer patients | #108 |
| patients cancer | #108 |
| post thrombotic syndrome | #108 |
| factor mutation | #109 |
| 500μg | #109 |
| synthetic pentasaccharide | #109 |
| 1235 | #109 |
| 039 | #109 |
| routine coagulation | #109 |
| embolism treatment | #109 |
| thrombin antithrombin | #109 |
| evaluation studies | #109 |
| anticoagulants cohort | #109 |
| viia | #109 |
| subsequent pregnancy | #110 |
| inferiority trial | #110 |
| embolism quality | #110 |
| vka doac | #110 |
| cancer activity | #110 |
| thrombosis treated | #110 |
| primary safety | #110 |
| antiplasmin | #110 |
| negative predictive 100 | #111 |
| predefined | #111 |
| humans intermittent | #111 |
| obstetric complications | #111 |
| anticoagulants biomarkers | #111 |
| comparison control | #111 |
| siset | #111 |
| treatment risk factors | #111 |
| recurrence treatment | #112 |
| publication anticoagulants | #112 |
| efficacy prevention | #112 |
| chromogenic | #112 |
| patients 70 | #112 |
| patients ventricular dysfunction | #112 |
| rivaroxaban enoxaparin | #112 |
| risk rivaroxaban | #112 |
| thromboembolic diseases | #112 |
| epidemiology risk factors | #112 |
| emergency situations | #112 |
| topic guidelines | #112 |
| inappropriate treatment | #113 |
| heterozygous carriers | #113 |
| nonionic contrast | #113 |
| metabolic response | #113 |
| patients nephrotoxicity | #113 |
| lmwh risk | #113 |
| total knee replacement | #114 |
| 0·0 | #114 |
| study centre | #114 |
| dialysers | #114 |
| cancerassociated vte | #114 |
| postphlebitic syndrome | #114 |
| patients intermediate | #114 |
| hyperhomocysteinaemia | #115 |
| 393 | #115 |
| global public | #115 |
| patients recurrent | #115 |
| fibrinogen vwf | #115 |
| positive predictive values | #115 |
| effects tnf | #116 |
| heparin warfarin | #116 |
| reference standard | #116 |
| major bleeding 95 | #116 |
| agents heparin | #116 |
| vte data | #116 |
| topic dabigatran | #116 |
| anticoagulants arthroplasty | #116 |
| life treatment | #116 |
| women severe preeclampsia | #116 |
| computed tomography patients | #116 |
| protein resistance | #117 |
| arthroscopies | #117 |
| vte children | #117 |
| women caesarean | #117 |
| vte complications | #117 |
| 2460 | #117 |
| fibrinolytic parameters | #117 |
| protein inhibitor pci | #117 |
| arterial thrombosis patients | #118 |
| patients extensive | #118 |
| 2744 | #118 |
| autopsyconfirmed | #118 |
| 4118 | #118 |
| proximal dvt | #118 |
| incidence pulmonary embolism | #119 |
| compared warfarin | #119 |
| humans leg | #119 |
| compression stockings | #119 |
| patients doac | #119 |
| thrombosis study | #120 |
| lactoferrin leukocyte | #120 |
| mortality diseases | #120 |
| acquired deficiency | #120 |
| rivaroxaban patients | #120 |
| months follow | #120 |
| healthy humans | #120 |
| dabigatran factor | #120 |
| risk thromboembolism | #120 |
| previous vte | #120 |
| patients prostatic cancer | #121 |
| thrombocytopenia thrombosis | #121 |
| anti factor | #122 |
| studies venous | #122 |
| patients 6 | #122 |
| fatal pulmonary embolism | #122 |
| oral hormonal | #122 |
| heparin hirudin | #123 |
| heparin | #123 |
| placebo standard | #123 |
| factor xia | #123 |
| minor bleeding | #123 |
| early dynamics | #123 |
| acute infection | #123 |
| 100 patients | #123 |
| venous thromboembolism pregnancy | #123 |
| treatment data | #124 |
| ft4 levels | #124 |
| atherogenic lipid profile | #124 |
| statin risk | #124 |
| association level | #124 |
| vte lmwh | #124 |
| thrombophilia pregnancy | #124 |
| skin perfusion | #125 |
| bayer | #125 |
| peripheral arterial disease | #125 |
| fibrinolysis inhibitor | #125 |
| nonsignificantly | #125 |
| treatment indication | #125 |
| intravenous heparin | #125 |
| diseases mortality | #125 |
| incidence thrombosis | #125 |
| thromboembolism recurrence | #125 |
| elevated liver enzymes | #125 |
| puerperal disorders | #125 |
| distal dvt | #126 |
| upper extremity | #126 |
| doacs treatment | #126 |
| occurrence vte | #127 |
| patients permanent | #127 |
| thromboprophylaxis lmwh | #127 |
| performance scores | #127 |
| marder | #127 |
| patients ventilation | #127 |
| unacceptably | #127 |
| resistance apc | #128 |
| venous thromboembolism risk | #128 |
| patients conventional therapy | #128 |
| treatment months | #128 |
| prevention | #128 |
| direct factor | #128 |
| 50 age | #128 |
| development vte | #128 |
| riete registry | #129 |
| 060 | #129 |
| ctrough | #129 |
| mortality cancer patients | #129 |
| elevated biomarkers | #129 |
| 1041 | #129 |
| anticoagulants antithrombins | #130 |
| plaster cast | #130 |
| 220 | #130 |
| day 10 | #130 |
| 194 patients | #130 |
| hospital discharge records | #130 |
| internists | #130 |
| patients episode | #130 |
| tests specificity | #131 |
| 05 patients | #131 |
| pooled incidence | #131 |
| linear interpolation | #131 |
| long‐term clinical outcomes | #131 |
| obviating | #131 |
| rivaroxaban versus | #132 |
| postpartum period women | #132 |
| hypocoagulability | #132 |
| hoc analysis | #132 |
| avidin | #133 |
| 80 anticoagulants | #133 |
| started | #133 |
| direct inhibitors | #133 |
| fxa inhibitors | #133 |
| cha2ds2vasc | #133 |
| enoxaparin treatment | #133 |
| embolism acute | #134 |
| risk pad | #134 |
| selectin levels | #134 |
| instituted | #134 |
| rco vwf | #134 |
| pulmonary angiography patients | #134 |
| prevalence dvt | #135 |
| activator plasminogen | #135 |
| bnp concentration | #135 |
| anticoagulant prophylaxis | #135 |
| followup patients | #136 |
| months anticoagulation | #136 |
| clinical prediction | #136 |
| east asian patients | #136 |
| 0056 | #136 |
| severe pph | #136 |
| apixaban edoxaban | #136 |
| thrombotic syndrome | #136 |
| acquired thrombophilia | #137 |
| sequential application | #137 |
| 99 patients | #137 |
| point‐of‐care | #137 |
| factor prothrombin | #137 |
| diagnostic work | #137 |
| phase 3 trials | #137 |
| 2283 | #137 |
| studies mortality | #138 |
| enhanced factor | #138 |
| national guidelines | #138 |
| complete inhibition | #138 |
| intravascular coagulation dic | #138 |
| bleeding warfarin | #138 |
| antidote | #138 |
| 95 major bleeding | #139 |
| 2465 | #139 |
| reproducibility risk | #139 |
| direct inhibitor | #139 |
| 3 weeks | #139 |
| risk fatal | #139 |
| factor viii factor | #139 |
| patients comparison | #139 |
| oral anticoagulant treatment | #139 |
| 20 iu | #140 |
| distal deep | #140 |
| human activated | #140 |
| 12 95 | #140 |
| 80 cohort | #140 |
| 0114 | #140 |
| vwf rco | #140 |
| dvt incidence | #140 |
| ottawa | #140 |
| thromboembolic disorders | #141 |
| antidotes | #141 |
| pharmacy records | #141 |
| carriership | #142 |
| thrombin potential | #142 |
| active malignancy | #143 |
| jugular veins | #143 |
| ischaemic events | #143 |
| geneva | #143 |
| warfarin administration | #143 |
| points 95 | #143 |
| treatment pulmonary | #143 |
| escherichia humans | #143 |
| pregnancy female humans | #144 |
| fatal pulmonary | #144 |
| management vte | #144 |
| topic practice patterns | #144 |
| postoperative venous | #144 |
| compared treatment | #144 |
| doac treatment | #144 |
| filters venous | #145 |
| dose rivaroxaban | #145 |
| serial testing | #145 |
| thrombosis model | #145 |
| hyperthyroxinemia | #145 |
| referred patients | #145 |
| patient populations | #145 |
| death cancer patients | #146 |
| derived microvesicles | #146 |
| months treatment | #146 |
| protein factor | #146 |
| tissue factor pathway | #147 |
| personal fees | #147 |
| intention treat | #148 |
| antithrombotic drugs | #148 |
| partial thromboplastin | #148 |
| long‐acting | #148 |
| embolism diagnosis | #148 |
| rebuttal | #148 |
| acute medical illness | #148 |
| 2076 | #148 |
| 10 years patients | #148 |
| procoagulant | #149 |
| diagnostic score | #149 |
| thrombocyte | #149 |
| risk subgroups | #149 |
| individual patient data | #149 |
| 0·45 | #149 |
| vte hospitalization | #149 |
| relevant publications | #149 |
| dimer level | #150 |
| additional imaging | #151 |
| enoxaparin unfractionated heparin | #151 |
| humans injections | #151 |
| coagulation dic | #151 |
| patient eligibility | #152 |
| longterm treatment | #152 |
| patients primary outcome | #152 |
| continuous venovenous | #152 |
| bleeding patients | #152 |
| point systems | #153 |
| extracorporeal circuit | #153 |
| thrombosis prevention | #153 |
| hypercoagulable state | #153 |
| cardiopulmonary bypass surgery | #153 |
| activity mortality | #154 |
| angioplasty patients | #154 |
| active cancer | #154 |
| thrombosis factor | #154 |
| direct thrombin | #154 |
| dimer levels | #154 |
| bleeding scores | #154 |
| fiia | #155 |
| states venous | #155 |
| curve sensitivity | #155 |
| tomography patients | #155 |
| thromboembolic event | #155 |
| drug factor | #155 |
| warfarin apixaban | #155 |
| stockings | #156 |
| fvl | #156 |
| daily oral | #156 |
| enoxaparin dose | #156 |
| patients gastrointestinal | #156 |
| coagulant activity | #156 |
| 09 | #156 |
| recurrent symptoms | #156 |
| vte treatment | #156 |
| prophylaxis patients | #157 |
| hemodynamically | #157 |
| increased thrombin | #157 |
| cross‐sectional survey | #157 |
| months chemotherapy | #158 |
| underlying malignancy | #158 |
| 2126 | #158 |
| 97 | #158 |
| duration anticoagulation | #158 |
| dfl | #158 |
| increased risk thrombosis | #159 |
| adjusted relative risk | #159 |
| 145 patients | #160 |
| thrombotic disorders | #160 |
| 120 minutes | #160 |
| plasma dimer | #160 |
| children fh | #160 |
| schering | #160 |
| guidelines prevention | #160 |
| antithrombotic efficacy | #160 |
| antagonists patients | #161 |
| prophylactics | #161 |
| pvo | #161 |
| 2206 | #162 |
| women time | #162 |
| patients imaging | #162 |
| incidence vte | #162 |
| lysine analogues | #162 |
| lmwh therapy | #163 |
| 198 patients | #163 |
| rates vte | #163 |
| coagulation blood | #163 |
| factors bleeding | #163 |
| imaging test | #163 |
| strain gauge | #163 |
| venous thrombus | #163 |
| increased plasma levels | #163 |
| justified | #164 |
| observer variability | #164 |
| 028 | #164 |
| inborn humans | #164 |
| age comorbidity | #164 |
| subhazard | #165 |
| mutation factor | #165 |
| relatives patients | #165 |
| patients enoxaparin | #165 |
| stockings compression | #166 |
| pravastatin therapy | #166 |
| viii factor | #166 |
| management venous thromboembolism | #166 |
| microvascular thrombosis | #166 |
| strategies patients | #166 |
| phlebography | #166 |
| 3658 | #167 |
| recurrent thrombosis | #167 |
| ankle brachial abi | #167 |
| thrombin venous | #167 |
| recurrent acute | #168 |
| cstatistics | #168 |
| treatment 3 months | #168 |
| cvcs | #168 |
| double heterozygosity | #168 |
| warfarin | #168 |
| syndrome pts | #168 |
| current clinical practice | #168 |
| preexistent | #169 |
| 3 12 | #169 |
| risk profile | #169 |
| fold increased | #169 |
| postthrombotic syndrome pts | #169 |
| therapeutic range | #169 |
| patients infections | #169 |
| postoperative blood loss | #170 |
| interobserver agreement | #170 |
| cart patients | #170 |
| thrombosis cancer | #170 |
| heavy menstrual bleeding | #170 |
| venous thrombotic events | #171 |
| aged algorithms | #171 |
| recombinant factor | #171 |
| adamts‐13 | #171 |
| 57 years | #171 |
| patients blood transfusion | #172 |
| antifibrinolytic | #172 |
| lmw heparin | #172 |
| clinical trials patients | #172 |
| risk factors patients | #172 |
| vaginal bleeding | #172 |
| pulmonology | #172 |
| bleeds | #173 |
| inr | #173 |
| hospitalized medical patients | #173 |
| pulmonary | #173 |
| arterial occlusions | #174 |
| bleeding tendency | #174 |
| clinically bleeding | #174 |
| patients initial | #174 |
| laboratory monitoring | #174 |
| fragment 1 | #175 |
| vte common | #175 |
| data control | #175 |
| arterial venous | #175 |
| reocclusion | #175 |
| mitsubishi | #177 |
| picotamide | #177 |
| prothrombin | #177 |
| aspirin ticlopidine | #178 |
| hyperthyroidism hypothyroidism | #178 |
| short‐ | #178 |
| intention analysis | #178 |
| 122 | #178 |
| baseline day | #179 |
| oral female humans | #179 |
| noninferior | #179 |
| vte event | #179 |
| concomitance | #179 |
| additional risk factors | #180 |
| ventilation perfusion | #180 |
| thromboplastin time | #180 |
| referral bias | #180 |
| isth | #180 |
| patients deficiency | #180 |
| aged partial | #181 |
| testing patients | #182 |
| antithrombin | #182 |
| acute episode | #182 |
| painkillers | #182 |
| hyperhomocysteinemic | #183 |
| biological variation | #183 |
| 2–4 | #183 |
| patients major | #183 |
| prognosis pulmonary | #184 |
| antithrombin iii atiii | #184 |
| 4150 | #184 |
| n110 | #184 |
| thromboinflammation | #184 |
| subsequent diagnosis | #184 |
| coagulation factors | #184 |
| risk bleeding | #184 |
| pregnancy vte | #184 |
| incidental | #184 |
| treat analysis | #184 |
| vte age | #185 |
| deficient patients | #185 |
| brain natriuretic | #186 |
| live birth rate | #186 |
| patients thromboprophylaxis | #186 |
| anticoagulated | #186 |
| studies heparin | #186 |
| patients intensive units | #186 |
| symptomatic | #186 |
| hemostatic effects | #186 |
| safety apixaban | #187 |
| risk composite | #187 |
| cutoff level | #187 |
| antifibrinolytic agents | #187 |
| patients haemophilia | #187 |
| humans international | #188 |
| 926 | #188 |
| absolute rate | #188 |
| prevalence cancer | #188 |
| ratio inr | #188 |
| doacs vkas | #188 |
| spontaneous rupture | #188 |
| 64slice | #189 |
| viia female | #189 |
| riete | #189 |
| clinical validity | #189 |
| fibrinolysis | #189 |
| patients netherlands | #189 |
| willebrand factor antigen | #189 |
| heparin administration | #189 |
| blood loss patients | #189 |
| thrombosis patients | #190 |
| anticoagulant drugs | #190 |
| current views | #190 |
| ccus | #190 |
| ischemic event | #190 |
| acute thrombosis | #191 |
| gogh | #191 |
| 07 | #191 |
| attending physicians | #191 |
| venous outflow | #191 |
| score patients | #191 |
| 1495 | #192 |
| 058 | #192 |
| stroke systemic | #192 |
| endothelial cell activation | #193 |
| coagulation assays | #193 |
| blood coagulation | #194 |
| heparin patients | #194 |
| anticoagulation | #194 |
| prothrombin activation | #194 |
| 070 | #194 |
| target range | #195 |
| antixa levels | #195 |
| antagonist treatment | #195 |
| recurrent ischemic events | #195 |
| 65 months | #195 |
| risk major | #195 |
| 29 95 | #196 |
| abnormal test | #196 |
| complications cardiovascular | #196 |
| coagulation status | #196 |
| vii rfviia | #198 |
| difference treatment | #198 |
| vwf adamts13 | #198 |
| treatment groups patients | #198 |
| sew2871 | #198 |
| ate | #198 |
| coagulation monitoring | #199 |
| cachectin | #199 |
| patient diagnosis | #199 |
| patients 12 months | #200 |
| incidence cardiovascular events | #200 |
| obese controls | #200 |
| screening patients | #200 |
| patients abnormal | #201 |
| validation sets | #201 |
| thrombin factor | #201 |
| vte incidence | #201 |
| thromboembolic disease | #201 |
| johnson | #202 |
| arterial thrombosis | #202 |
| 17 95 | #202 |
| peritoneovenous | #202 |
| worldwide survey | #203 |
| symptomatic pad | #203 |
| heparin dose | #203 |
| induced activation | #203 |
| invitees | #203 |
| antithrombotic agents | #204 |
| levonorgestrel | #204 |
| 0 95 | #205 |
| stroke systemic embolism | #205 |
| period time | #205 |
| thrombophilia risk | #205 |
| low incidence | #205 |
| extended thromboprophylaxis | #205 |
| varese | #206 |
| patients anticoagulant therapy | #206 |
| venous ultrasonography | #206 |
| fgt | #206 |
| data synthesis | #206 |
| 06 | #207 |
| methods consecutive | #207 |
| fviii | #207 |
| death female humans | #207 |
| algorithms anticoagulants | #207 |
| imt patients | #207 |
| desogestrel | #207 |
| objectively | #207 |
| systematic review studies | #207 |
| platelet activation patients | #207 |
| cardiologist | #207 |
| thrombocythaemia | #208 |
| bleeding compared | #208 |
| patients hypothyroidism | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| antixa activity | #210 |
| women frequency | #210 |
| tgt | #210 |
| hirudins | #210 |
| ioxaglate | #211 |
| toxaemia | #211 |
| stocking | #211 |
| systemic embolism patients | #211 |
| anticoagulation management | #212 |
| atrial fibrillation study | #212 |
| plasminogen activator activity | #213 |
| heparitin sulfate | #213 |
| correct interpretation | #214 |
| topic practice | #214 |
| dabigatran dose | #214 |
| standard duration | #215 |
| current developments | #215 |
| factors vte | #215 |
| thrombin inhibition | #215 |
| studies rivaroxaban | #215 |
| deamino | #216 |
| community hospital | #216 |
| duplex venous | #216 |
| betatg | #216 |
| warfarin stroke | #216 |
| studies difference | #217 |
| diagnostic algorithm | #217 |
| mildest | #217 |
| undergoing total | #217 |
| obviates | #217 |
| npv 100 | #218 |
| g20210a | #218 |
| plasminogen activator inhibitor | #218 |
| cstatistic | #218 |
| conclusive evidence | #218 |
| cancer | #219 |
| patients cart | #219 |
| 077 95 | #219 |
| deamino arginine | #219 |
| viii female | #220 |
| vii factor | #220 |
| techniques female | #220 |
| hip replacement surgery | #220 |
| data extraction | #220 |
| postoperative vte | #221 |
| healthy human subjects | #221 |
| hmvec | #221 |
| preventive measures | #221 |
| heparin humans | #221 |
| apc resistance | #222 |
| vte events | #222 |
| proximally | #222 |
| 1541 | #223 |
| 1 january | #223 |
| pulmonologists | #223 |
| substantial proportion | #223 |
| engl | #223 |
| topic factor | #224 |
| subsequent cancer | #224 |
| protein pathway | #224 |
| thromboendarterectomy | #224 |
| org | #225 |
| balloon coronary anticoagulants | #225 |
| neoplasms prospective | #225 |
| kruskalwallis | #225 |
| thrombosis warfarin | #225 |
| inr monitoring | #226 |
| vascular events patients | #226 |
| extremity amputation | #226 |
| 16 95 | #226 |
| 0·67 | #226 |
| acute medical | #227 |
| tests diagnosis | #227 |
| 35 ± | #227 |
| haemostasis | #227 |
| mild hyperhomocysteinemia | #228 |
| ipe | #228 |
| dalteparin | #229 |
| cgp | #229 |
| residual thrombus | #229 |
| scant | #229 |
| 037 | #230 |
| advocated | #230 |
| urosepsis | #231 |
| ft4 | #231 |
| resource utilisation | #231 |
| major orthopaedic surgery | #231 |
| severe preeclampsia | #231 |
| equinox | #231 |
| thiazoles | #231 |
| habitual abortion | #231 |
| patients discontinuation | #231 |
| 6 studies | #231 |
| patients warfarin | #232 |
| aspirin dipyridamole | #232 |
| cancer prevalence | #233 |
| dimer | #233 |
| recurrence risk factors | #233 |
| humans netherlands | #233 |
| anticoagulant effects | #233 |
| endogenous thrombin potential | #233 |
| surgical embolectomy | #233 |
| effective alternative | #234 |
| doac | #235 |
| prothrombotic state | #235 |
| graduated compression | #235 |
| venous thromboembolic events | #236 |
| humans meta | #236 |
| brain natriuretic peptide | #236 |
| treatment continuation | #237 |
| myocardial infarction 95 | #237 |
| oral anticoagulants | #237 |
| patients vkas | #238 |
| 6500 | #238 |
| 009 | #238 |
| predictive tests | #238 |
| rational approach | #239 |
| anticoagulants aspirin | #239 |
| factor tnf | #239 |
| crossover study | #239 |
| factor viii fviii | #239 |
| patients initial treatment | #240 |
| arterial venous thrombosis | #240 |
| 045 | #241 |
| aspirin heparin | #241 |
| hip knee arthroplasty | #241 |
| time therapeutic range | #242 |
| bleeding incidence | #242 |
| pivotal trials | #243 |
| patients intermittent claudication | #243 |
| prothrombin fragment | #243 |
| iohexol | #244 |
| n89 | #245 |
| vte risk factors | #245 |
| children neonates | #246 |
| vte cases | #246 |
| casecontrol | #246 |
| thrombogenesis | #246 |
| 23 95 | #247 |
| antithrombotic | #247 |
| warfarin aged | #247 |
| lipoproteina levels | #247 |
| patients solid tumours | #248 |
| coronary anticoagulants | #248 |
| treatment compared | #248 |
| anti activity | #248 |
| committees | #248 |
| bleeding rates | #249 |
| score risk | #249 |
| multiple comorbidities | #249 |
| diagnostic models | #249 |
| protein risk | #250 |
| fv leiden | #250 |
| ioxaglic | #250 |
| ischemic strokes | #250 |
| microthrombosis | #251 |
| 8595 | #251 |
| finalized | #251 |
| patients contraindications | #251 |
| simplification | #252 |
| somit | #252 |
| vkas doacs | #252 |
| incidence | #253 |
| thrombin thrombosis | #253 |
| agents anticoagulants | #254 |
| treatment duration | #254 |
| palga | #255 |
| fibrinolytic activity | #255 |
| haul | #256 |
| activation humans | #256 |
| medea | #256 |
| bleeding risk | #257 |
| q24h | #257 |
| continuous intravenous | #257 |
| cost‐effectiveness | #257 |
| activity assay | #257 |
| clinical utility | #257 |
| patient subgroups | #258 |
| fibrin degradation | #258 |
| ctpa | #258 |
| unpublished data | #259 |
| 30 50 | #259 |
| dvt risk | #260 |
| sspe | #260 |
| noncarriers | #261 |
| toxicosis | #261 |
| thrombus size | #261 |
| heparin dosing | #261 |
| patients hospitalization | #262 |
| optimal duration | #263 |
| risk pulmonary | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| einstein | #267 |
| pbac | #267 |
| endotoxaemia | #268 |
| statins risk | #268 |
| propeptide | #269 |
| malignancy patients | #269 |
| relation time | #269 |
| versus aspirin | #269 |
| randomised cross | #269 |
| lysis time | #269 |
| single test | #270 |
| protein patients | #270 |
| discontinuing | #270 |
| exclusion | #270 |
| orthopaedic patients | #271 |
| 3·0 | #271 |
| thrombosis inflammation | #271 |
| platelet serotonin | #271 |
| protein apc | #271 |
| hormonal replacement therapy | #271 |
| vte recurrence | #272 |
| groups levels | #272 |
| clopidogrel ticlopidine | #272 |
| patients combination | #272 |
| bleeding patient | #272 |
| efficacy analysis | #273 |
| ankle brachial | #273 |
| months 12 | #274 |
| risk levels | #274 |
| prevalence pad | #274 |
| cleavage sites | #274 |
| performance score | #275 |
| international normalized | #275 |
| parenteral nutrition patients | #275 |
| antithrombotic agent | #276 |
| fourth quartile | #276 |
| time aptt | #277 |
| smoking hypertension | #277 |
| normalized ratio | #278 |
| imaging sensitivity | #278 |
| dose reduction | #278 |
| rco | #279 |
| aptt | #279 |
| blood test | #279 |
| partial thromboplastin time | #280 |
| exclusion criteria | #280 |
| hospitalized medical | #280 |
| obviate | #280 |
| propositi | #280 |
| intracranial hemorrhage patients | #280 |
| patients presence | #281 |
| thromboplastin | #282 |
| diagnostic test | #282 |
| diagnostic sensitivity | #283 |
| thyroid diseases | #283 |
| presentation patients | #283 |
| neutrophil degranulation | #283 |
| puerperal | #283 |
| noninferiority margin | #284 |
| test characteristics | #284 |
| outpatient treatment | #284 |
| departments | #284 |
| favor | #284 |
| animals anticoagulants | #284 |
| major orthopaedic | #285 |
| gentamicin treatment | #286 |
| patients apixaban | #286 |
| 2630 | #286 |
| plasma bnp | #286 |
| clinically | #287 |
| patients pancreatic cancer | #287 |
| levels measured | #287 |
| subdistribution | #287 |
| disseminated intravascular | #287 |
| 227 | #288 |
| premature atherosclerosis | #288 |
| md patients | #288 |
| oral combined | #288 |
| cvt patients | #289 |
| substantiation | #289 |
| clot lysis | #289 |
| vte rates | #289 |
| vte women | #289 |
| thrombin time | #290 |
| n59 | #290 |
| 0·50 | #290 |
| oral contraceptives | #291 |
| current clinical | #291 |
| extracted data | #291 |
| 016 | #291 |
| carriers mutation | #291 |
| willebrand disease vwd | #292 |
| 1603 | #292 |
| 2 studies | #292 |
| activator inhibitor | #292 |
| pentasaccharide | #293 |
| 1000 personyears | #293 |
| adverse outcome patients | #293 |
| plasmin activity | #293 |
| patients dabigatran | #293 |
| cardiac troponin ctnt | #294 |
| tissuetype plasminogen activator | #294 |
| patients rivaroxaban | #294 |
| lower extremities | #294 |
| extremity dvt | #295 |
| scenario analysis | #295 |
| 1025 | #295 |
| classified | #296 |
| coagulation factor viii | #296 |
| peripheral vascular | #296 |
| observer agreement | #297 |
| routine monitoring | #297 |
| recurrent miscarriage | #298 |
| specificity npv | #298 |
| thrombocytes | #298 |
| episode patients | #298 |
| patients inr | #299 |
| inferiority | #300 |
| 041 | #301 |
| heparitin | #301 |
| aged neoplasms | #302 |
| thromboglobulin | #302 |
| toxemia | #302 |
| 155 patients | #302 |
| subclinical thyroid dysfunction | #302 |
| 1214 | #304 |
| absolute difference | #304 |
| rivaroxaban dabigatran | #305 |
| medline embase | #306 |
| prophylactic administration | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| hematologic pregnancy | #310 |
| surgery day | #310 |
| thrombotic | #310 |
| vte pregnancy | #310 |
| percentage points | #311 |
| antithrombins blood | #311 |
| patients 100 | #311 |
| clinical presentation | #311 |
| 105 patients | #311 |
| 598 | #312 |
| leg male | #312 |
| obesity risk factor | #313 |
| negative reactions | #313 |
| hereditary thrombophilia | #313 |
| vte 95 | #313 |
| diagnosis | #314 |
| puerperium | #315 |
| postpartum haemorrhage | #315 |
| cardiologists | #315 |
| funding | #315 |
| heparin aspirin | #315 |
| apixaban versus | #316 |
| therapeutic dose | #316 |
| adjudicators | #317 |
| patients followup | #317 |
| 0·92 | #318 |
| deciding | #318 |
| failure rates | #319 |
| decision model | #319 |
| safety outcomes | #319 |
| catheter thrombosis | #320 |
| combined administration | #320 |
| 1731 | #320 |
| influenza infections | #320 |
| bnp levels | #320 |
| patients pregnancy | #320 |
| ventricular dysfunction patients | #321 |
| additional data | #322 |
| intermediate phenotype | #322 |
| patients noacs | #322 |
| difference risk | #322 |
| inrs | #324 |
| peripheral arterial | #324 |
| glaxosmithkline | #324 |
| convincing evidence | #325 |
| mortality odds ratio | #325 |
| pulmonary embolus | #326 |
| mechanical heart valves | #326 |
| blood coagulation factor | #326 |
| 122 patients | #326 |
| surgery trauma | #327 |
| clinical | #327 |
| association vte | #329 |
| thrombotic event | #331 |
| pregnancy outcome women | #331 |
| incidence bleeding | #331 |
| vitamin administration | #331 |
| new oral | #332 |
| analysis trials | #333 |
| embase databases | #333 |
| 95 percent | #333 |
| n69 | #333 |
| 95 confidence limits | #334 |
| minor effects | #334 |
| complicate | #334 |
| incidences | #334 |
| fibrillation benzimidazoles | #335 |
| patients healthy volunteers | #335 |
| rationale design | #335 |
| septicaemia | #336 |
| pulmonary perfusion | #336 |
| central venous catheter | #336 |
| 065 | #337 |
| 2 points | #337 |
| plethysmographic | #337 |
| recurrent | #337 |
| total hip replacement | #337 |
| 035 | #337 |
| aged netherlands | #338 |
| fatal bleeding | #338 |
| outpatient management | #338 |
| coagulation abnormalities | #338 |
| noacs warfarin | #339 |
| prospective clinical study | #339 |
| placebo trials | #339 |
| antithrombotic effects | #340 |
| patients 12 | #340 |
| 024 | #340 |
| coagulation markers | #341 |
| 217 | #341 |
| activatable | #341 |
| knee arthroscopy | #342 |
| noac patients | #342 |
| pretest | #344 |
| patients covid19 infection | #344 |
| vte prevention | #345 |
| antithrombotic strategies | #345 |
| splanchnic vein thrombosis | #345 |
| rfviia | #345 |
| embolisms | #346 |
| diagnosis vte | #346 |
| activated protein resistance | #347 |
| patients thrombosis | #347 |
| 073 | #347 |
| cochrane central | #348 |
| 044 | #348 |
| bsf | #349 |
| 2575 | #349 |
| chads2 | #349 |
| tafia | #350 |
| trousseau | #350 |
| randomized studies | #350 |
| brain predictive | #350 |
| factor viii | #351 |
| 013 | #351 |
| versus warfarin | #351 |
| selection bias | #352 |
| factor activation | #352 |
| dermatan sulphate | #352 |
| anticoagulants noacs | #352 |
| 1590 | #353 |
| oral anticoagulant therapy | #353 |
| relative efficacy | #353 |
| 5075 | #353 |
| vein | #353 |
| international normalized ratio | #354 |
| aged pulmonary | #354 |
| patients gp | #355 |
| studies diagnostic accuracy | #355 |
| protein deficiency | #356 |
| post hoc | #357 |
| intestinal microbiome | #357 |
| categorised | #357 |
| tests prospective studies | #357 |
| 127 patients | #358 |
| pilots | #360 |
| sucra | #360 |
| intermittent claudication | #361 |
| consensus agreement | #362 |
| treatment risk | #362 |
| anticoagulation patients | #364 |
| conventional therapy | #365 |
| humans risk | #365 |
| topic female | #366 |
| bleeding rate | #366 |
| prediction models | #367 |
| infrainguinal | #368 |
| time recurrence | #368 |
| patients 3 | #368 |
| thrombin inhibitor | #369 |
| patients acl reconstruction | #370 |
| influenza infection | #370 |
| 6week | #370 |
| venous stasis | #371 |
| endotoxin infusion | #371 |
| 055 | #372 |
| 803 | #372 |
| knee surgery | #373 |
| aprotinin blood | #373 |
| patients svt | #373 |
| recombinant activated | #373 |
| clinical suspicion | #373 |
| human cytomegalovirus infection | #374 |
| helical computed tomography | #374 |
| patients scores | #374 |
| hmb | #375 |
| subcutaneous | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| contraceptives oral | #380 |
| stroke venous | #380 |
| ethinyloestradiol | #381 |
| tafi | #381 |
| antitnf | #382 |
| prefilter | #383 |
| multivariate regression analysis | #384 |
| thromboembolic complications | #384 |
| reassessed | #384 |
| standardized questionnaire | #384 |
| 0·8 | #384 |
| alpha2m | #385 |
| systemic activation | #385 |
| bleeding events | #386 |
| surrogate outcome | #386 |
| conference proceedings | #386 |
| cumulative incidences | #387 |
| sensitivity npv | #387 |
| antithrombins | #387 |
| major orthopedic | #388 |
| delegates | #388 |
| referred | #389 |
| systemic embolism | #389 |
| safety rivaroxaban | #389 |
| 880 | #389 |
| apixaban warfarin | #390 |
| vitt | #390 |
| tinzaparin | #390 |
| drug prescription | #391 |
| comparison patients | #391 |
| increased bleeding | #391 |
| postop | #391 |
| biosis | #391 |
| abi | #391 |
| topic female humans | #392 |
| time presentation | #392 |
| patients chest | #392 |
| kappa values | #393 |
| factors thrombosis | #393 |
| pulmonary emboli | #394 |
| clinical score | #394 |
| injections intravenous | #394 |
| background patients | #394 |
| 007 | #395 |
| 95 12 | #396 |
| bleeding event | #396 |
| popliteal | #396 |
| replacement surgery | #397 |
| hirudins humans | #397 |
| embolic events | #397 |
| factors factor | #397 |
| 665 | #397 |
| risk score patients | #399 |
| heparin induced | #400 |
| patients risk | #400 |
| echography | #400 |
| risk factors asthma | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| increased risk vte | #403 |
| dabigatran | #403 |
| controversy | #403 |
| massive pulmonary embolism | #405 |
| treatment patient | #406 |
| thrombolytic agents | #406 |
| 075 | #406 |
| 2215 | #406 |
| factor levels | #408 |
| oral anticoagulant | #408 |
| biologic effects | #410 |
| safety combination | #411 |
| patients assigned | #411 |
| noacs patients | #411 |
| fviii levels | #411 |
| transfusion patients | #412 |
| major risk factor | #412 |
| 20 microg | #412 |
| euthyroidism | #414 |
| maastricht | #414 |
| coagulation patients | #414 |
| aged odds | #415 |
| xii | #415 |
| hypocortisolism | #415 |
| dose heparin | #416 |
| deserve | #416 |
| intravascular coagulation | #416 |
| pai1 levels | #416 |
| 95 10 | #417 |
| comparable | #417 |
| data risk | #417 |
| 95 | #418 |
| pretest probability | #418 |
| carotid femoral | #418 |
| dermatan | #419 |
| 269 | #419 |
| risk factors thrombosis | #419 |
| ototoxicity | #420 |
| xia | #420 |
| fibrillation risk | #421 |
| tests radiography | #422 |
| 1989 | #422 |
| 2850 | #422 |
| fibrillation clinical | #422 |
| fibrinolysin | #423 |
| subanalysis | #424 |
| fviia | #424 |
| prevalence patients | #425 |
| fii | #426 |
| adjunct | #426 |
| randomised double | #426 |
| cancer cohort | #426 |
| activated factor | #427 |
| consecutive | #427 |
| plg | #428 |
| daily practice | #428 |
| conferences | #428 |
| excessive bleeding | #428 |
| idiopathic myelofibrosis | #429 |
| daily clinical practice | #429 |
| patients testing | #429 |
| prolactin levels | #429 |
| undergoing elective | #429 |
| 1904 | #430 |
| bleeding complications | #431 |
| rule | #431 |
| heparinoids | #431 |
| 04 | #432 |
| incidence length | #433 |
| outpatients | #433 |
| ncb | #434 |
| patients systematic review | #434 |
| firstdegree relatives patients | #436 |
| blood cultures | #436 |
| 059 | #437 |
| bolus injection | #437 |
| composite point | #439 |
| dose adjustment | #439 |
| proven | #439 |
| prostatic cancer | #439 |
| women compared | #439 |
| concomitant medications | #441 |
| highrisk populations | #441 |
| 074 | #442 |
| rate vte | #442 |
| standard therapies | #444 |
| –control study | #444 |
| prespecified | #445 |
| patients atrial fibrillation | #446 |
| febrile patients | #446 |
| female fibrinolytic | #447 |
| hellp | #449 |
| 58 | #449 |
| utrecht | #449 |
| patients parenteral nutrition | #449 |
| 3 12 months | #450 |
| prevalence distribution | #450 |
| stigmatisation | #451 |
| category | #451 |
| pipecolic | #452 |
| fatal disease | #453 |
| thrombin generation | #453 |
| noninvasive tests | #453 |
| aspirin risk | #453 |
| portal blood | #454 |
| 30 40 | #454 |
| factor xii | #454 |
| placebo day | #454 |
| 026 | #455 |
| 12week | #455 |
| microthrombi | #455 |
| dichotomized | #456 |
| fviii vwf | #456 |
| squibb | #457 |
| onwards | #457 |
| dicumarol | #457 |
| anti levels | #458 |
| iii complexes | #458 |
| hazard ratio 95 | #458 |
| recommend | #460 |
| svt | #460 |
| plasma lipoprotein | #460 |
| gastrointestinal cancer | #461 |
| factor fxa | #461 |
| expert consensus document | #462 |
| hip arthroplasty replacement | #462 |
| curve biomarkers | #462 |
| guidelines patients | #463 |
| haemolysis | #463 |
| studies ultrasonography | #464 |
| patients values | #464 |
| gp iib | #464 |
| month follow | #465 |
| diabetes stroke | #466 |
| cancerassociated thrombosis | #466 |
| thrombin formation | #467 |
| accuracy detection | #467 |
| patients nsaids | #468 |
| prophylaxis | #468 |
| intimamedia thickness | #468 |
| teaching hospitals | #469 |
| bmi≥30 | #469 |
| eligible studies | #469 |
| inr patients | #470 |
| roc analysis | #470 |
| 077 | #470 |
| test probability | #470 |
| hemihepatectomy | #470 |
| placebo recipients | #471 |
| prophylactic anticoagulation | #472 |
| case control study | #472 |
| hypercoagulability | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| intermittent pneumatic | #475 |
| endotoxemia | #475 |
| heterozygote humans | #475 |
| plethysmograph | #475 |
| patients heparin | #475 |
| 15 95 | #475 |
| atria | #477 |
| haemophiliacs | #479 |
| 08 | #479 |
| patients score | #479 |
| versus standard | #480 |
| acutely | #481 |
| hit patients | #481 |
| thrombosis cvt | #481 |
| postoperative blood | #482 |
| transportability | #482 |
| 1162 | #482 |
| advisory | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| diagnostic efficacy | #485 |
| patients hematologic malignancies | #485 |
| awaited | #486 |
| secondary prophylaxis | #487 |
| composite scores | #487 |
| silent | #488 |
| travel | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| hemophilic | #493 |
| p00007 | #493 |
| treatment period | #493 |
| new therapy | #493 |
| pan troglodytes | #493 |
| residual risk | #493 |
| vcf | #494 |
| activated protein | #495 |
| dose oral | #496 |
| replacement hip arthroplasty | #496 |
| heterozygote | #496 |
| favour | #496 |
| topic risk factors | #497 |
| 271 | #497 |
| risk factors stroke | #498 |
| blockages | #498 |
| willebrand disease | #498 |
| discriminative ability | #498 |
| hip knee | #501 |
| ptp | #502 |
| nri | #502 |
| ft4 tsh | #503 |
| deficiencies | #503 |
| subcategories | #503 |
| rapid decrease | #504 |
| nondiagnostic | #505 |
| patients referred | #505 |
| 1107 | #505 |
| complications pulmonary | #505 |
| net clinical | #506 |
| 310 | #506 |
| oftentimes | #507 |
| day surgery | #507 |
| nonionic | #507 |
| inhibitors rivaroxaban | #508 |
| aminocaproates | #509 |
| guidelines diagnosis | #509 |
| contraceptives | #509 |
| 13 95 | #509 |
| coagulation tests | #509 |
| degradation products | #510 |
| angiography patients | #510 |
| thrombosis animals | #510 |
| new oral anticoagulants | #510 |
| viii fviii | #511 |
| 019 | #512 |
| epiphenomenon | #512 |
| serial | #513 |
| 056 | #514 |
| highintensity | #514 |
| interim analysis | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| thrombophilia thrombosis | #518 |
| thrombotic diseases | #518 |
| protein antithrombin | #518 |
| sensitivity diagnosis | #518 |
| bleeding outcomes | #518 |
| treatment cancer patients | #519 |
| groups treatment | #519 |
| study sensitivity | #520 |
| duration intensity | #521 |
| 8090 | #521 |
| 1599 | #521 |
| warfarin therapy | #524 |
| fixed doses | #525 |
| general practitioner | #525 |
| 062 | #527 |
| cindices | #528 |
| cancer age | #528 |
| 051 | #529 |
| convincing | #529 |
| 378 | #529 |
| 923 | #529 |
| health female | #530 |
| fatal | #530 |
| betaalanine | #531 |
| thrombosis hemostasis | #531 |
| medically patients | #531 |
| humans postoperative | #531 |
| ≥50 years | #532 |
| 068 | #532 |
| thrombosis risk | #532 |
| intensive units icu | #532 |
| therapy cancer | #534 |
| factor thrombin | #534 |
| 730 | #536 |
| factor pathway | #537 |
| patients idiopathic | #538 |
| humans neoplasms | #538 |
| 449 | #538 |
| concise | #539 |
| comprehensive search | #539 |
| ddavp | #539 |
| cbo | #539 |
| clinical review | #540 |
| diagnostic accuracy studies | #540 |
| diagnosis acute | #540 |
| bleeding episodes | #543 |
| 234 | #543 |
| vascular obstruction | #543 |
| thrombotic risk | #543 |
| conventional treatment | #543 |
| patients eligible | #543 |
| pad abi | #544 |
| 00 | #544 |
| coagulative | #544 |
| jak2 mutation | #544 |
| hellp syndrome | #545 |
| perc | #545 |
| v617f | #545 |
| prospective cohort study | #545 |
| association statin | #546 |
| screening strategies | #546 |
| prothrombin complex | #547 |
| bureau | #547 |
| primary | #548 |
| overt | #549 |
| adequate | #549 |
| 95 difference | #549 |
| reviewers | #550 |
| percent patients | #550 |
| platelet inhibitors | #550 |
| 1103 | #550 |
| cancer type | #550 |
| conduction anesthesia | #550 |
| 500 patients | #552 |
| management bleeding | #552 |
| studies sensitivity | #552 |
| amsterdam | #552 |
| day patients | #552 |
| careful | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| factor vii | #558 |
| 66 patients | #558 |
| vivo treatment | #558 |
| orthopedic surgery | #559 |
| bleeding time | #559 |
| limulus | #561 |
| female humans tests | #563 |
| board directors | #563 |
| patients transfusion | #563 |
| risk development | #563 |
| anamnesis | #564 |
| appears | #564 |
| hip replacement | #564 |
| hyperfibrinolysis | #565 |
| increasing risk | #565 |
| solid tumours | #566 |
| cardiac troponins | #566 |
| withholding | #566 |
| roc curves | #568 |
| patients 2 years | #568 |
| n46 | #568 |
| alpha1antitrypsin | #571 |
| levothyroxine | #571 |
| aggravation | #572 |
| ctnt | #573 |
| revascularization procedures | #574 |
| menstrual bleeding | #574 |
| cutoff point | #574 |
| subcutaneously | #575 |
| women proportion | #575 |
| major bleedings | #575 |
| progression cancer | #577 |
| patients vka | #578 |
| endothelial barrier | #578 |
| pharma | #579 |
| endotoxin | #579 |
| thiophenes | #579 |
| notice | #580 |
| diagnostic tools | #580 |
| 99 | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| unselected patients | #584 |
| dummy | #584 |
| coagulation disorders | #585 |
| 094 | #585 |
| chondroitin sulfates | #586 |
| feasibility safety | #588 |
| major orthopedic surgery | #588 |
| helminth proteins | #589 |
| malignancy | #590 |
| healthy human | #590 |
| thrombophilias | #590 |
| beta alanine | #590 |
| reversal agents | #590 |
| massive pulmonary | #592 |
| doppler ultrasound | #592 |
| conventional management | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| ldf | #597 |
| replacement knee | #597 |
| major hemorrhage | #597 |
| severe bleeding | #597 |
| patency rates | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| tests sensitivity | #600 |
| loss surgical | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| events occurred | #604 |
| clinical characteristics patients | #604 |
| comorbid conditions | #604 |
| diagnostic studies | #606 |
| activated coagulation | #607 |
| patients antibodies | #607 |
| initial increase | #607 |
| 0·3 | #607 |
| treatment acute | #608 |
| pfizer | #609 |
| arbitrage | #609 |
| tissue factor | #609 |
| airline | #610 |
| 100 years | #610 |
| benefit risk | #610 |
| patients death | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| leg | #615 |
| reluctant | #615 |
| patients bariatric surgery | #615 |
| complications risk | #616 |
| arterial disease | #617 |
| treatment rivaroxaban | #617 |
| occurred | #618 |
| 467 | #618 |
| stroke atrial fibrillation | #618 |
| compared placebo | #620 |
| fh patients | #620 |
| patients elevated | #621 |
| advisory committees | #621 |
| 1002 | #622 |
| sgs | #623 |
| thyrotoxic | #623 |
| thrombocytopenia hit | #623 |
| cochrane central register | #625 |
| peptide bnp | #625 |
| stopped | #626 |
| topic practice guidelines | #626 |
| stroke warfarin | #627 |
| 66 | #628 |
| 5000 | #628 |
| women risk factors | #628 |
| warfarin risk | #628 |
| physical training | #629 |
| referral patients | #629 |
| human subjects | #629 |
| diagnostic algorithms | #629 |
| sanofi | #630 |
| absolute | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| outweigh | #635 |
| uneventful | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 14 95 | #640 |
| 95 allcause mortality | #640 |
| proceedings | #641 |
| study quality | #641 |
| 3050 | #642 |
| predictive performance | #642 |
| neutrophilia | #643 |
| threatening bleeding | #643 |
| primary outcome measure | #647 |
| association mortality | #647 |
| necessitating | #648 |
| statin treatment | #648 |
| studies efficacy | #648 |
| 036 | #651 |
| thrombolysis patients | #651 |
| fixed | #651 |
| troglodytes | #652 |
| organisations | #652 |
| hemorrhagic stroke | #653 |
| fxa | #653 |
| 127 | #655 |
| patients review | #657 |
| bleeding death | #659 |
| coronary stent implantation | #659 |
| 69 | #659 |
| haematoma | #660 |
| coagulation proteins | #661 |
| physical examination | #661 |
| tertiles | #661 |
| haemophilia | #662 |
| clinical presentations | #662 |
| 95 studies | #663 |
| 1028 | #663 |
| provoked | #664 |
| long term treatment | #664 |
| sepsis shock | #665 |
| deep | #666 |
| phase iii studies | #666 |
| guideline adherence | #667 |
| patients completed | #667 |
| onethird | #667 |
| presence patients | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| patients cteph | #673 |
| elevated plasma | #673 |
| managing | #674 |
| hospitalization hf | #674 |
| inhibitor 1 | #675 |
| il6 levels | #675 |
| clotting factors | #675 |
| highincome countries | #676 |
| prothrombotic | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| pulmonary endarterectomy | #681 |
| medicine humans | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| ambulatory patients | #692 |
| patients bleeding | #692 |
| graduated | #693 |
| myocardial infarctions | #693 |
| activator pa | #693 |
| intracranial bleeding | #694 |
| precise mechanisms | #694 |
| administer | #694 |
| composite outcome | #694 |
| 1718 | #695 |
| combined oral contraceptives | #696 |
| moyamoya | #696 |
| stroke prevention patients | #696 |
| difference 95 | #698 |
| participant data | #698 |
| ratio male | #698 |
| compression devices | #700 |
| episode | #700 |
| diagnostic errors | #702 |
| therapeutic management | #702 |
| prothrombin gene | #702 |
| surgery risk | #703 |
| veins venous | #703 |
| patients confirmed | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| directors | #709 |
| clinical expression | #709 |
| starters | #711 |
| gastrointestinal bleeding | #712 |
| 048 | #712 |
| medical patients | #712 |
| gynaecology | #712 |
| radionuclide imaging | #713 |
| 1098 | #714 |
| neurosurgical patients | #714 |
| rate death | #714 |
| intravenous bolus | #715 |
| rivaroxaban stroke | #716 |
| menstrual period | #716 |
| cancer groups | #717 |
| adequately | #717 |
| solid cancer | #718 |
| 10 30 | #718 |
| falsely | #718 |
| plasminogen | #719 |
| reagent kits | #719 |
| pulmonary medicine | #720 |
| nordisk | #721 |
| pyrazoles pyridines | #721 |
| clinical judgment | #721 |
| accp | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| follow period | #726 |
| abnormal | #726 |
| gentamicins | #727 |
| 59 patients | #727 |
| diagnostic therapeutic | #728 |
| orthopaedic surgery | #728 |
| diagnostic tests | #730 |
| gentamicin | #732 |
| leeches | #732 |
| oral contraception | #733 |
| tumor necrosis factor | #733 |
| relative risk 95 | #734 |
| patients levels | #735 |
| hull | #735 |
| disease pad | #735 |
| clinical prediction rule | #736 |
| atrial fibrillation risk | #736 |
| tests retrospective studies | #736 |
| post hoc analysis | #739 |
| 6 12 | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| unclear | #742 |
| early pregnancy loss | #742 |
| 040 | #742 |
| topic predictive | #743 |
| molecular weight | #744 |
| betathromboglobulin | #744 |
| illness time factors | #744 |
| patients 50 years | #746 |
| antithrombin activity | #746 |
| 285 | #746 |
| etp | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| fibrin formation | #754 |
| advisable | #754 |
| primary patients | #755 |
| 95 risk factors | #756 |
| answer | #756 |
| hf risk | #756 |
| pneumatic compression | #756 |
| 95 combination | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| loe | #759 |
| 85 | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| proportion women | #763 |
| 435 | #763 |
| cprs | #764 |
| start treatment | #764 |
| hip surgery | #765 |
| 689 | #767 |
| risk pregnancy | #767 |
| aspirin clopidogrel | #767 |
| 732 | #768 |
| method drug | #769 |
| relevant | #770 |
| 566 | #770 |
| groups patients | #770 |
| graft patency | #772 |
| baseline values | #772 |
| patients criteria | #773 |
| subcutaneous injections | #774 |
| bmi patients | #774 |
| 1·5 | #776 |
| 992 | #777 |
| dose intravenous | #778 |
| dose warfarin | #778 |
| study groups | #778 |
| patients 65 years | #778 |
| miscarriage | #779 |
| 066 | #780 |
| thromboembolism prophylaxis | #780 |
| plasmin generation | #780 |
| patients hyperthyroidism | #780 |
| age ≥ | #782 |
| factor ixa | #785 |
| onefifth | #785 |
| abnormalities patients | #786 |
| topic disease models | #787 |
| cteph | #787 |
| polypharmacy | #787 |
| general practitioners | #787 |
| 100 personyears | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| recombinant tissue | #793 |
| mechanical heart | #793 |
| inactivators | #795 |
| 047 | #795 |
| risk factors risk | #795 |
| patient years | #796 |
| patency | #796 |
| studies prevalence | #797 |
| eligible | #797 |
| netherlands | #797 |
| lupus anticoagulant | #798 |
| femoropopliteal | #798 |
| patients lower | #799 |
| theme | #799 |
| estrogen therapy | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| randomized patients | #804 |
| subclinical | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| adverse outcomes patients | #806 |
| fibrillation blood | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| hypertension cteph | #809 |
| efficacy patients | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| flights | #816 |
| factor vwf | #816 |
| 0·4 | #818 |
| irrespective | #820 |
| vehicle control | #820 |
| health predictive | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| prevention patients | #823 |
| reduction mortality | #823 |
| single administration | #824 |
| coc | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| cardioembolic stroke | #828 |
| gp | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| 93 | #833 |
| antithrombotic treatment | #833 |
| myers | #833 |
| abortion habitual | #835 |
| oral adult | #836 |
| plough | #836 |
| noac | #837 |
| versus placebo | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| antithrombotic therapy | #846 |
| 49 | #846 |
| multidetector row | #847 |
| 072 | #847 |
| advise | #848 |
| recurrence risk | #849 |
| patients diagnosis | #850 |
| caesarean | #850 |
| area roc curve | #852 |
| pre‐eclampsia | #853 |
| 30 patients | #853 |
| reference method | #853 |
| advanced prostate | #854 |
| clopidogrel aspirin | #855 |
| fibrin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| pyridones | #870 |
| 6 month | #870 |
| individual participant | #872 |
| longterm clinical outcomes | #872 |
| tasman | #873 |
| favoring | #873 |
| thromboembolic pulmonary | #874 |
| imaging reproducibility | #874 |
| targeted inhibition | #874 |
| titles | #875 |
| plasminogen activation | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| dabigatran rivaroxaban | #878 |
| risk thromboembolic | #878 |
| 57 | #879 |
| anticoagulants atrial | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| domiciliary | #894 |
| male mexico | #894 |
| 084 | #894 |
| loading dose | #896 |
| p011 | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| 064 | #908 |
| factor activity | #908 |
| subcutaneous administration | #909 |
| documented | #911 |
| patients clinical trials | #911 |
| initially | #912 |
| haemostatic | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| combined approach | #916 |
| haemodialysis patients | #916 |
| 317 | #917 |
| 022 | #918 |
| thromboembolic events | #918 |
| chronic thromboembolic | #919 |
| standard patients | #920 |
| antagonist oral | #920 |
| randomeffects model | #920 |
| ultrasound examination | #921 |
| loss patients | #921 |
| optimal dose | #921 |
| estimate male | #923 |
| practise | #923 |
| study medication | #925 |
| multifactorial disease | #925 |
| total hip | #926 |
| 902 | #928 |
| safer | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| treatment placebo | #934 |
| wording | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| subgroup patients | #938 |
| 60 patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| stroke atrial | #944 |
| echocardiographically | #944 |
| women preeclampsia | #944 |
| emboli | #945 |
| predictive values | #946 |
| ssc | #946 |
| anticoagulation treatment | #947 |
| knee replacement | #948 |
| diagnostic | #948 |
| extensive disease | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| registro | #956 |
| dic | #956 |
| cancer humans | #956 |
| network metaanalysis | #956 |
| venous insufficiency | #957 |
| reassuring | #957 |
| efficacy | #958 |
| day1 | #958 |
| combined oral | #961 |
| retropubic | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| reference lists | #966 |
| inhibitor1 | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| hoc | #973 |
| antiplatelet | #973 |
| prevalence characteristics | #973 |
| risk allcause mortality | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| female fibrinogen | #976 |
| vascular humans | #976 |
| fvii | #978 |
| false negative | #979 |
| 071 | #980 |
| 50 100 | #980 |
| onset aged aged | #980 |
| early gestation | #984 |
| 426 | #986 |
| randomised trials | #987 |
| prophylactic treatment | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| missed | #991 |
| rises | #991 |
| seminar | #992 |
| academic medical center | #992 |
| counteracted | #993 |
| normal lung | #993 |
| treatment bleeding | #994 |
| 226 | #999 |
| aged | #999 |
| justification | #1000 |
| thromboembolic risk | #1000 |
| lower extremity | #1000 |
| tissue type | #1001 |
| rivaroxaban apixaban | #1002 |
| parenteral administration | #1002 |
| eclamptic | #1003 |
| interleukin 6 | #1005 |
| hyperprolactinaemia | #1005 |
| extended | #1005 |
| pyridines | #1006 |
| 50 patients | #1007 |
| orthosis | #1007 |
| easier | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| ticlopidine | #1018 |
| pounds | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| cha2ds2 vasc | #1023 |
| years risk | #1023 |
| international prospective | #1024 |
| humans randomized | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| firstdegree relatives | #1030 |
| decision analysis | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| cardiovascular event | #1033 |
| relatives | #1033 |
| risk hemorrhage | #1033 |
| 052 | #1035 |
| male netherlands | #1037 |
| graft occlusion | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| patients severe asthma | #1047 |
| vwf levels | #1047 |
| examiner | #1050 |
| patients massive | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| mean±sd | #1054 |
| 221 | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| 179 | #1060 |
| birth rate | #1060 |
| coagulant | #1060 |
| 610 | #1061 |
| pad | #1061 |
| published literature | #1062 |
| primary data | #1062 |
| false | #1064 |
| prekallikrein | #1065 |
| 150 | #1065 |
| 00008 | #1066 |
| 101 | #1066 |
| live birth | #1066 |
| lysosphingolipid | #1067 |
| cut | #1067 |
| pmol | #1068 |
| register controlled | #1070 |
| 95 increased risk | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| laboratory diagnosis | #1074 |
| thorax | #1074 |
| systematic search | #1078 |
| advocate | #1080 |
| 063 | #1080 |
| drawbacks | #1082 |
| f1 | #1087 |
| longterm therapy | #1087 |
| bandages | #1089 |
| clarifications | #1095 |
| stopping | #1095 |
| idarucizumab | #1096 |
| diagnostic utility | #1096 |
| mandated | #1096 |
| 083 | #1099 |
| 1223 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| peptide brain | #1107 |
| clinical protocols | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| haemodialysis | #1116 |
| bypass grafts | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| resistance factor | #1123 |
| probands | #1123 |
| new developments | #1124 |
| advised | #1125 |
| new perspectives | #1126 |
| 445 | #1126 |
| cip | #1127 |
| heparininduced thrombocytopenia | #1127 |
| patients pad | #1128 |
| judged | #1132 |
| discretion | #1132 |
| statistic | #1133 |
| ≤10 | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| superior efficacy | #1141 |
| 635 | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| roc curve | #1150 |
| refusal | #1150 |
| medline | #1151 |
| medical records | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| blood loss | #1156 |
| anticoagulation therapy | #1156 |
| patients influenza | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| published guidelines | #1163 |
| bristol | #1163 |
| hyperhomocysteinemia | #1164 |
| stable angina | #1164 |
| intermittent | #1164 |
| safety concerns | #1164 |
| viii | #1164 |
| thromboembolism risk | #1165 |
| age 65 years | #1165 |
| angiogram | #1167 |
| perioperative bleeding | #1172 |
| glucocorticoid treatment | #1172 |
| crossover design | #1172 |
| atherosclerotic disease | #1172 |
| practice guideline | #1173 |
| occlusive diseases | #1173 |
| 5 years patients | #1176 |
| macroglobulin | #1176 |
| findings patients | #1178 |
| analysis studies | #1178 |
| 79 | #1179 |
| conceive | #1181 |
| concealed | #1181 |
| patients obesity | #1182 |
| unaware | #1182 |
| hospitalized patients | #1182 |
| combined therapy | #1186 |
| conclusive | #1186 |
| occult | #1189 |
| degree relatives | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| cardiotonic agents | #1199 |
| mandate | #1199 |
| international society | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| quantitative trait locus | #1204 |
| 015 | #1204 |
| categorized | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| multicenter randomized | #1214 |
| pph | #1214 |
| 103 | #1218 |
| scores patients | #1221 |
| warranted | #1221 |
| patient treatment | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| 64 patients | #1224 |
| peak levels | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| blind | #1227 |
| sixfold | #1227 |
| metabolic syndrome patients | #1228 |
| consensus guidelines | #1228 |
| trial background | #1229 |
| peptide hydrolases | #1229 |
| radionuclide | #1229 |
| 65 patients | #1230 |
| rules | #1232 |
| doubles | #1232 |
| aspirin | #1234 |
| coronary angiography patients | #1238 |
| milliliter | #1238 |
| postoperative hemorrhage | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| matter lesions | #1252 |
| ml1 | #1252 |
| subgroups | #1252 |
| artery pulmonary | #1254 |
| search strategy | #1257 |
| extensive | #1257 |
| oral vitamin | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| troponins | #1266 |
| visiting | #1266 |
| entity | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| intensive patients | #1274 |
| equally | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| 75 years | #1281 |
| routine screening | #1281 |
| statin users | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| janssen | #1295 |
| perfusion defects | #1295 |
| scan | #1295 |
| predictive | #1297 |
| hemofiltration | #1297 |
| insufficiently | #1298 |
| cardiovascular complications | #1299 |
| low prevalence | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| pf4 | #1303 |
| 61 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| risk difference | #1312 |
| apoa | #1312 |
| cyproterone | #1312 |
| 1st | #1312 |
| adamts13 activity | #1313 |
| tests severity | #1314 |
| 0·7 | #1314 |
| current strategies | #1314 |
| atrial fibrillation | #1316 |
| claudication | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| lipoproteina | #1325 |
| glycoprotein gpiib | #1325 |
| patients coronavirus disease | #1326 |
| vascular diseases | #1329 |
| beneficial | #1329 |
| antibodies monoclonal antibodies | #1329 |
| thyroid disorders | #1330 |
| plasminogen activators | #1330 |
| low moderate | #1330 |
| 77 | #1331 |
| coagulation cascade | #1331 |
| 6 months patients | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| 91 | #1342 |
| likelihood ratio | #1342 |
| venous catheters | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| antitrypsin | #1347 |
| surgical trauma | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| allcause mortality 95 | #1359 |
| experimental model | #1359 |
| 15 patients | #1359 |
| limb salvage | #1363 |
| arsenal | #1363 |
| vwf | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| noninferiority | #1385 |
| dl1 | #1385 |
| 224 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| patients control subjects | #1400 |
| record linkage | #1400 |
| equipoise | #1402 |
| antisense oligonucleotide | #1402 |
| 82 | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| 1886 | #1405 |
| patients advanced cancer | #1405 |
| pregnancy loss | #1406 |
| obese patients | #1406 |
| 515 | #1408 |
| categories | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| 6 weeks | #1419 |
| 7 weeks | #1419 |
| thrombotic complications | #1419 |
| 3 6 | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| university hospitals | #1422 |
| followup data | #1422 |
| 061 | #1424 |
| daily | #1424 |
| ≥55 | #1424 |
| eightfold | #1425 |
| randomised controlled trials | #1427 |
| 080 | #1427 |
| casecontrol study | #1430 |
| rgs | #1430 |
| outcome pregnancy | #1438 |
| imaging radiopharmaceuticals | #1439 |
| 096 | #1439 |
| principal | #1443 |
| 78 | #1443 |
| 1123 | #1445 |
| weight bmi | #1446 |
| drug levels | #1446 |
| outcome studies | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| confusion | #1454 |
| population patients | #1454 |
| aged blood | #1455 |
| platelet factor | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| funded | #1466 |
| actual | #1466 |
| 0·9 | #1468 |
| avoided | #1468 |
| 26 patients | #1469 |
| heart failure hf | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| prevalences | #1473 |
| 1215 | #1473 |
| centrally | #1474 |
| systemic infection | #1477 |
| probability | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| analysis randomized | #1485 |
| cushing syndrome | #1485 |
| phase iii trials | #1486 |
| methodologic | #1486 |
| general practice | #1491 |
| patients control | #1495 |
| procoagulant activity | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| growing body | #1514 |
| adverse outcome | #1514 |
| proximal | #1516 |
| ganz | #1520 |
| patients 10 | #1520 |
| pregnancy postpartum | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| contraindicated | #1527 |
| thrombotic events | #1527 |
| time study | #1529 |
| score | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| patients severe sepsis | #1552 |
| live births | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| pfa | #1564 |
| enfermedad | #1564 |
| iii topic | #1565 |
| topic | #1566 |
| treatment prevention | #1566 |
| cushings syndrome | #1568 |
| hyperlipoproteinemia type | #1568 |
| deficient | #1568 |
| 95ci | #1568 |
| aged biomarkers | #1571 |
| plasminogen activator | #1575 |
| 36 | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| study entry | #1586 |
| thyroid dysfunction | #1586 |
| cocs | #1586 |
| activation markers | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| total mortality | #1594 |
| 1·1 | #1594 |
| translates | #1597 |
| placebo | #1598 |
| noncancer | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| 162 | #1613 |
| general surgery | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| tests reproducibility | #1616 |
| postpartum period | #1616 |
| prospective cohort studies | #1616 |
| factors tomography | #1616 |
| positive effects | #1616 |
| 155 | #1618 |
| perinatal outcome | #1618 |
| imaging tomography | #1619 |
| female hemostasis | #1619 |
| cvd patients | #1619 |
| proportion | #1620 |
| uncertain | #1621 |
| 12month followup | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| incidentally | #1632 |
| venous disease | #1632 |
| pa patients | #1632 |
| fresh frozen plasma | #1633 |
| clinical patients | #1633 |
| double | #1639 |
| study outcomes | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| ctni | #1644 |
| stroke prevention | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| dorsiflexion | #1651 |
| 997 | #1651 |
| 35 years | #1652 |
| ≤4 | #1652 |
| thrombin activity | #1653 |
| studies data | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| homocysteine levels | #1670 |
| disease adult | #1670 |
| thrombi | #1674 |
| daily dosing | #1676 |
| inpatient treatment | #1676 |
| plasma level | #1677 |
| deficiency | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| steroidal anti | #1686 |
| unreliable | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| 033 | #1712 |
| yielded | #1712 |
| intravenous | #1715 |
| hemorheology | #1715 |
| bronchospasm | #1720 |
| hematologic malignancies | #1720 |
| mb | #1721 |
| diagnostic evaluation | #1721 |
| female femoral | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| conference | #1726 |
| 107 | #1726 |
| derived microparticles | #1729 |
| volunteer | #1730 |
| 021 | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| clinical scores | #1735 |
| east asian | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| patients ventricular | #1745 |
| 691 | #1745 |
| table | #1745 |
| profession | #1746 |
| hyperinsulinaemia | #1747 |
| risk cardiovascular events | #1747 |
| apc | #1749 |
| turp | #1749 |
| homozygosity | #1750 |
| pselectin | #1750 |
| replacement | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| audiometry | #1760 |
| assessor | #1760 |
| treatment recommendations | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| human insulin | #1764 |
| fx | #1764 |
| duplicate | #1769 |
| arteriosclerosis | #1770 |
| initial management | #1770 |
| hemorrhage | #1770 |
| allcause death | #1774 |
| 2 6 | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| clinical consequences | #1790 |
| selfmanagement | #1790 |
| microparticle | #1793 |
| reid | #1793 |
| vascular surgical | #1794 |
| cardiac troponin | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| aggregation inhibitors | #1802 |
| 020 | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| tumor necrosis | #1812 |
| slc6a4 | #1812 |
| 95 specificity | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| conjoint | #1819 |
| economic evaluation | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| screening middle | #1825 |
| preference | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| compressibility | #1837 |
| definite | #1837 |
| kaplanmeier estimate | #1838 |
| cushing | #1838 |
| severe sepsis | #1839 |
| 1 week | #1842 |
| central venous | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| explanations | #1852 |
| hydroxyethyl starch | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| thromboses | #1892 |
| shrs | #1892 |
| diagnostic techniques | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 5 10 | #1897 |
| 067 | #1897 |
| contraindications | #1900 |
| tnf | #1901 |
| diagnostic testing | #1901 |
| extremity | #1901 |
| clt | #1905 |
| induced thrombocytopenia | #1906 |
| plaster | #1906 |
| hazard ratio | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| efficacy treatment | #1910 |
| referral | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 793 | #1920 |
| 13 patients | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| 868 | #1923 |
| stroke 95 | #1923 |
| biotin | #1924 |
| 55 years | #1924 |
| trials patients | #1926 |
| venous pressure | #1926 |
| intracranial hemorrhage | #1927 |
| μg | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| nonfatal | #1934 |
| glucocorticoid | #1934 |
| 3months | #1935 |
| relative risks | #1935 |
| acute | #1936 |
| 17 | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| femoral vein | #1950 |
| safety effectiveness | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| observer | #1962 |
| investigators | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| fibrin clot | #1973 |
| surgical blood | #1973 |
| 48 hours | #1973 |
| renewed | #1976 |
| potent inhibitor | #1976 |
| topic clinical trials | #1978 |
| hyperaldosteronism | #1981 |
| specificity ultrasonography | #1981 |
| 771 | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| 1·0 | #1986 |
| treatment cancer | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| prospero | #1992 |
| 018 | #1992 |
| drug drug therapy | #1994 |
| cmax | #1994 |
| cvt | #1995 |
| computerized | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| autopsy | #2000 |
| 3 months patients | #2000 |
| transient increase | #2000 |
| clinical severity | #2000 |
| 53 | #2003 |
| pneumonia patients | #2006 |
| 7 patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| angina unstable | #2017 |
| mongrel | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| patients lung | #2033 |
| 097 | #2033 |
| pertechnetate | #2036 |
| costs cost | #2041 |
| medical record | #2041 |
| abstracts | #2042 |
| undergoing major | #2042 |
| questioned | #2043 |
| prediction rule | #2045 |
| thrice | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| superior vena cava | #2051 |
| quartiles | #2051 |
| inadequately | #2052 |
| pregnancy trimester | #2053 |
| 277 | #2053 |
| controversial | #2055 |
| stent implantation | #2056 |
| adherence guidelines | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| varies | #2063 |
| requested | #2063 |
| biological neoplasms | #2064 |
| clinical indications | #2064 |
| hemostatics | #2070 |
| mcnemar | #2074 |
| 188 | #2074 |
| national institute | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| media thickness | #2087 |
| bypasses | #2087 |
| 03 | #2089 |
| versions | #2091 |
| 114 | #2092 |
| square distribution | #2092 |
| tissue plasminogen | #2093 |
| preformed | #2099 |
| reference range | #2099 |
| 038 | #2100 |
| lifetime risk | #2101 |
| desmopressin | #2101 |
| 59 | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| substantial | #2109 |
| 031 | #2109 |
| 1966 | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| unnecessary | #2118 |
| independently | #2118 |
| exists | #2119 |
| initial | #2119 |
| development validation | #2120 |
| coronary stent | #2122 |
| clinicaltrialsgov | #2122 |
| 11 | #2122 |
| original | #2125 |
| acl reconstruction | #2125 |
| patients cardiovascular disease | #2127 |
| topic surveys | #2127 |
| chose | #2129 |
| controlled | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| congress | #2134 |
| protamines | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| live | #2145 |
| clot | #2145 |
| professionals | #2146 |
| bodyweight | #2146 |
| pancreatic cancer patients | #2157 |
| oestrogens | #2160 |
| committee | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| advanced cancer | #2183 |
| 674 | #2183 |
| fifty | #2185 |
| 2 × | #2185 |
| giant cell arteritis | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| pravastatin | #2205 |
| increased patients | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| neutrophil elastase | #2212 |
| diagnosis differential | #2212 |
| doubled | #2213 |
| pao2 | #2219 |
| 364 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| 94 | #2225 |
| differential female | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| clots | #2257 |
| hivinfected patients | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| hyperthyroidism | #2265 |
| stroke aged | #2265 |
| 12 | #2266 |
| metaanalysis | #2267 |
| 6 months | #2267 |
| reverses | #2273 |
| patients developed | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| setting | #2284 |
| based case | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| tests | #2314 |
| metaanalysis studies | #2314 |
| nephelometry | #2316 |
| initial therapy | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| humans myocardial | #2324 |
| method female | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| inhibitor | #2344 |
| lacked | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| 099 | #2375 |
| risk bias | #2375 |
| patients active | #2376 |
| hemostasis | #2377 |
| predictable | #2377 |
| enrolling | #2379 |
| acute coronary syndromes | #2379 |
| 187 | #2381 |
| anticardiolipin | #2382 |
| dosing regimen | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| 757 | #2401 |
| patients liver cirrhosis | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| postinjection | #2413 |
| periodicals | #2413 |
| protein | #2413 |
| risk estimates | #2414 |
| 22 | #2415 |
| sphingosine1 | #2415 |
| study drug | #2424 |
| internal medicine | #2424 |
| 32 | #2425 |
| sensitivity 100 | #2426 |
| guidelines | #2426 |
| legs | #2430 |
| 002 | #2430 |
| 0048 | #2430 |
| coagulants | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| prolonging | #2434 |
| ptca | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| 719 | #2448 |
| turbidimetry | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| watchful | #2464 |
| prognostic patients | #2464 |
| potential benefits | #2466 |
| therapy acute | #2468 |
| nephrotoxic | #2468 |
| 477 | #2469 |
| comprised | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| cancer population | #2476 |
| current review | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| 648 | #2485 |
| pathway inhibitor | #2485 |
| treatment efficacy | #2489 |
| 829 | #2490 |
| 1015 | #2490 |
| chest | #2493 |
| duration | #2493 |
| 25 | #2495 |
| illness tomography | #2503 |
| 616 | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| drug female humans | #2516 |
| 479 | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| neutrophil extracellular traps | #2521 |
| 463 | #2521 |
| 152 | #2523 |
| accurate diagnosis | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 0046 | #2537 |
| 164 | #2537 |
| 874 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| hydroxyethyl | #2560 |
| haematology | #2560 |
| hours | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| kits | #2574 |
| humans logistic | #2574 |
| 73 | #2574 |
| prevalence | #2575 |
| pill | #2575 |
| patients total | #2577 |
| translate | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| 591 | #2585 |
| efficacious | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| manifest | #2605 |
| burden disease | #2605 |
| metaregression | #2606 |
| parenteral | #2606 |
| fatal outcome | #2608 |
| patients 2 | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| aviation | #2620 |
| cost analysis | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| trials rcts | #2635 |
| coincided | #2635 |
| chondroitin | #2635 |
| 10 day | #2637 |
| 345 | #2641 |
| attractive | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| c677 | #2662 |
| benzimidazoles | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| 516 | #2683 |
| outcome ultrasonography | #2683 |
| initial dose | #2685 |
| iii | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| aso | #2691 |
| 594 | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| management strategies | #2732 |
| dose low | #2732 |
| cart | #2736 |
| 595 | #2737 |
| 427 | #2739 |
| classifications | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| predetermined | #2746 |
| 848 | #2746 |
| patients asthma | #2747 |
| baseline characteristics | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| management acute | #2768 |
| 143 | #2768 |
| confounded | #2769 |
| expert consensus | #2772 |
| antithyroid | #2772 |
| alpha animals | #2772 |
| active control | #2775 |
| inpatient | #2776 |
| thrombomodulin | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| 402 | #2802 |
| consecutive series | #2802 |
| reaching | #2805 |
| cirrhosis patients | #2805 |
| international | #2809 |
| standardized | #2811 |
| secondary | #2811 |
| embolic | #2812 |
| follow studies | #2813 |
| 406 | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| antiplatelet drugs | #2826 |
| bid | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| recurrence rate | #2835 |
| contacting | #2835 |
| ketoprostaglandin | #2836 |
| helminth | #2836 |
| crossover | #2839 |
| kruskal | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| doppler ultrasonography | #2852 |
| iii trials | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| new treatment | #2857 |
| post discharge | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| trimester pregnancy | #2880 |
| excessive | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| systematic review metaanalysis | #2897 |
| 21 | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| feasible | #2903 |
| slight | #2903 |
| severe asthma | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| lowrisk patients | #2917 |
| leading death | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| proportions | #2928 |
| 993 | #2928 |
| clear | #2932 |
| risk stratification patients | #2934 |
| 2400 | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 010 | #2960 |
| 270 | #2960 |
| 20 | #2961 |
| exercise therapy | #2962 |
| followup | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| lecture | #2984 |
| declare | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| pneumatic | #2991 |
| point | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| antigen levels | #3015 |
| factors surveys | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| nested case | #3025 |
| early recognition | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 50 years | #3040 |
| 419 | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| nomogram | #3063 |
| 80 | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| subsequently | #3076 |
| 2 4 | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| angioplasty | #3088 |
| chronic renal failure | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| trimester | #3110 |
| benchmark | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| lifelong | #3122 |
| wallis | #3122 |
| oac | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| levels risk | #3142 |
| 082 | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| idiopathic | #3153 |
| 507 | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| diethylstilbestrol | #3194 |
| pregnancy women | #3194 |
| pacientes | #3197 |
| plasmin | #3198 |
| 945 | #3198 |
| tenth | #3199 |
| therapy risk | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| suggested | #3219 |
| cancer types | #3219 |
| 153 | #3223 |
| intravenous infusion | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| recombinant | #3241 |
| meetings | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| bivalirudin | #3251 |
| 198 | #3251 |
| 29 | #3253 |
| hypothyroid | #3253 |
| scoring | #3255 |
| judgement | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| tumor markers | #3289 |
| coumarin | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| reduces | #3330 |
| 465 | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| inpatients | #3344 |
| cerebrovascular disease | #3344 |
| 362 | #3349 |
| evaluating | #3349 |
| spontaneous abortion | #3354 |
| diagnosing | #3354 |
| 273 | #3355 |
| diagnosis cancer | #3356 |
| common complication | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| 301 | #3379 |
| concluded | #3379 |
| humans lower | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| function patients | #3389 |
| calf | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| 553 | #3403 |
| tunica | #3403 |
| acute treatment | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| preventive | #3419 |
| randomisation | #3419 |
| surgical patients | #3420 |
| study risk | #3420 |
| hypothesised | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| 168 | #3452 |
| prevalence incidence | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| differ | #3470 |
| 34 | #3470 |
| intensive chemotherapy | #3471 |
| patients receive | #3472 |
| pregnancy complications | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| antiphospholipid | #3485 |
| cancer metastasis | #3485 |
| increased morbidity | #3486 |
| asymptomatic | #3487 |
| lower leg | #3487 |
| paradox | #3490 |
| personyears | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| treat | #3506 |
| hemorrhagic complications | #3506 |
| inhibitors | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| discusses | #3522 |
| confirmed | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| lupus | #3533 |
| human cytomegalovirus | #3533 |
| areas covered | #3537 |
| guidance | #3541 |
| societies | #3541 |
| 113 | #3544 |
| gastro | #3551 |
| current practice | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| necessity | #3596 |
| prognosis prospective | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| treated | #3619 |
| platelet function | #3619 |
| interval | #3622 |
| platelet activation | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| kappa | #3629 |
| q3 | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| bypass surgery | #3642 |
| undergo | #3642 |
| homozygote | #3642 |
| externally | #3645 |
| p006 | #3645 |
| occlusions | #3646 |
| 1960 | #3649 |
| 30 | #3649 |
| interindividual variability | #3651 |
| fibrillation | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| optimal management | #3671 |
| outcome administration | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| diagnostic process | #3721 |
| drug monitoring | #3721 |
| pharmacodynamics | #3725 |
| inhibitors humans | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| effective | #3739 |
| humans intracranial | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| randomised | #3754 |
| deterioration | #3754 |
| objectives | #3759 |
| 8 patients | #3762 |
| subgroup analyses | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| clinicians patients | #3774 |
| computed ultrasonography | #3774 |
| inherited | #3775 |
| 517 | #3778 |
| interpretable | #3778 |
| 483 | #3782 |
| thyroid hormones | #3789 |
| aminoglycosides | #3789 |
| total knee arthroplasty | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| vessel wall | #3804 |
| compelling | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| patients lung cancer | #3815 |
| 330 | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| irs | #3856 |
| meeting | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| review data | #3860 |
| acquired resistance | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| cancer survival | #3884 |
| optimisation | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| difference | #3890 |
| 351 | #3890 |
| 184 | #3890 |
| 10000 | #3902 |
| halflives | #3903 |
| methylamines | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| specificity tomography | #3915 |
| angiography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| case fatality | #3946 |
| 405 | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| p004 | #3961 |
| dichotomy | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| uncontrolled | #3970 |
| risk cancer | #3970 |
| austrian | #3971 |
| behalf | #3971 |
| cardiovascular events | #3972 |
| 2nd | #3975 |
| data studies | #3975 |
| quality assurance | #3980 |
| pregnancy | #3982 |
| 986 | #3982 |
| continuous infusion | #3983 |
| unstable | #3986 |
| flying | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| 296 | #4045 |
| introduction | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| pcc | #4077 |
| bariatric | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| oligosaccharides | #4089 |
| natriuretic peptide | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| cutoff | #4099 |
| indications | #4099 |
| activation | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| withdrawn | #4137 |
| 008 | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| 2030 | #4171 |
| patients prostate cancer | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 485 | #4212 |
| 411 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 289 | #4226 |
| 121 | #4226 |
| trough | #4229 |
| p0005 | #4230 |
| crosssectional analysis | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| cox regression | #4242 |
| patients mortality | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 455 | #4340 |
| 102 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| managed | #4350 |
| potential risk factors | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| minutes | #4383 |
| rapid | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| slice | #4394 |
| concurrently | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| negative | #4407 |
| bowel diseases | #4407 |
| 71 | #4407 |
| general | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| splanchnic | #4417 |
| lacking | #4417 |
| dose aspirin | #4419 |
| immunoassays | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| 192 | #4459 |
| vascular surgery | #4459 |
| proband | #4461 |
| cytomegalovirus infection | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| clinical manifestations | #4486 |
| cd18 | #4486 |
| pancreatic cancer | #4487 |
| inadequate | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| activation platelet | #4503 |
| comprises | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| calculating | #4571 |
| cerebrovascular disorders | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| preserves | #4594 |
| attenuating | #4594 |
| gradual | #4595 |
| eventually | #4595 |
| 204 | #4596 |
| simplified | #4596 |
| 4000 | #4601 |
| 4 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| acetylsalicylic acid | #4613 |
| vii | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| risks benefits | #4640 |
| hospital costs | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| 003 | #4658 |
| habitual | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| myelofibrosis | #4670 |
| 171 | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| day | #4680 |
| fh | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| ranging | #4698 |
| unchanged | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| baseline patients | #4775 |
| chronic renal | #4775 |
| acute coronary | #4784 |
| 44 | #4785 |
| scheduled | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| definition | #4861 |
| acl | #4861 |
| efficiency | #4869 |
| gpiib | #4870 |
| nonvalvular atrial fibrillation | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| total | #4891 |
| antiplatelet therapy | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| tests prognosis | #4906 |
| preparations | #4906 |
| served | #4910 |
| fmd | #4913 |
| chlamydophila | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| dose | #4976 |
| manufacturers | #4976 |
| albeit | #4982 |
| orthopedics | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| references | #5006 |
| 389 | #5006 |
| reminder | #5009 |
| epoprostenol | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| 156 | #5040 |
| screening test | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| evaluable | #5089 |
| regarded | #5089 |
| relation | #5090 |
| hip fractures | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| vivo studies | #5124 |
| bay | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| 0018 | #5130 |
| ischaemic stroke | #5130 |
| 131 | #5131 |
| female | #5131 |
| transfused | #5134 |
| contrast media | #5136 |
| balancing | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| disagreement | #5157 |
| shortly | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| 11 patients | #5170 |
| predispose | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| emergencies | #5233 |
| articles | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| pooling | #5289 |
| 365 | #5289 |
| aware | #5300 |
| thrombus | #5301 |
| 36 patients | #5301 |
| urokinase | #5302 |
| atherogenesis | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| acute ischemic stroke | #5341 |
| reagent | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| male | #5363 |
| schedule drug | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| 247 | #5490 |
| occurrences | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| 260 | #5497 |
| patient risk | #5497 |
| discomfort | #5499 |
| continuing | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| erythema | #5539 |
| limitation | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| receptor1 | #5563 |
| established | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| 46 | #5573 |
| reduce risk | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| equivalent | #5598 |
| circulating levels | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| reclassification | #5644 |
| 80 years | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| semiquantitative | #5771 |
| milder | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| mpo | #5804 |
| incidence rates | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| aircraft | #5819 |
| 1000 | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| atrial | #5852 |
| true | #5852 |
| 088 | #5854 |
| attending | #5856 |
| women pregnancy | #5857 |
| 290 | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| occurrence | #5894 |
| reliable | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| 22 patients | #5928 |
| aged platelet | #5928 |
| graded | #5934 |
| revision | #5938 |
| premenopause | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| 43 | #5962 |
| rcts | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| topics | #6101 |
| type iii | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| generation | #6160 |
| ffa | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| mortality morbidity | #6228 |
| terminated | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| colleagues | #6273 |
| practitioners | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 63 | #6340 |
| 135 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| roche | #6405 |
| factor gene | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| accuracy | #6501 |
| peripheral artery disease | #6501 |
| cancer cell | #6502 |
| incidence risk | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| triiodothyronine | #6524 |
| washout | #6524 |
| 318 | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| cochrane | #6532 |
| highrisk patients | #6532 |
| increased incidence | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| exogenous | #6538 |
| bowel | #6538 |
| aspirin patients | #6540 |
| thirteen | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| pancreatic neoplasms | #6641 |
| genetic testing | #6641 |
| individual | #6650 |
| complications | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| hazard ratios | #6729 |
| recognised | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| 385 | #6766 |
| body temperature | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| defined | #6780 |
| 2 groups | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| reached | #6803 |
| premedication | #6803 |
| plasma proteins | #6807 |
| response relationship | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| adverse event | #6912 |
| disturbances | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| 246 | #6976 |
| intensity | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| shock septic | #6995 |
| 222 | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| computed | #7104 |
| betacoronavirus covid19 | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| withdrawal | #7204 |
| 5year | #7204 |
| acting | #7210 |
| cardiovascular disease cvd | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| vldl | #7250 |
| treatment children | #7250 |
| hematocrit | #7255 |
| 199 | #7257 |
| retrospective cohort study | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| modest | #7290 |
| sensitivity analysis | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| ischemic stroke | #7338 |
| pectoris | #7338 |
| 1c | #7352 |
| interleukin6 | #7352 |
| p0001 | #7356 |
| standardised | #7356 |
| myocardial infarction | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| urgently | #7522 |
| angina | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| cinahl | #7578 |
| comorbid | #7578 |
| 191 | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| 29 patients | #7647 |
| epidemiological studies | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| 18 | #7705 |
| medical conditions | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| 110 | #7802 |
| manufacturer | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| 31 patients | #7828 |
| label | #7828 |
| hormone replacement | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| academic | #7878 |
| tramadol | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| urogenital | #7939 |
| highrisk | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| 600 | #8051 |
| preventable | #8051 |
| medical | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| training | #8120 |
| patients heart | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| imaging studies | #8141 |
| investigational | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| parenteral nutrition | #8204 |
| confidence | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| renal function | #8228 |
| impairment | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lowest | #8250 |
| lists | #8250 |
| version | #8260 |
| 125i | #8264 |
| activated | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| endothelium vascular | #8338 |
| postulated | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| absence presence | #8382 |
| 2 years | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| 28 patients | #8415 |
| occur | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| procedures operative | #8463 |
| transient ischemic | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| evaluate | #8501 |
| covariate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| adolescent | #8582 |
| 146 | #8582 |
| row | #8590 |
| carotid arteries | #8596 |
| thirty | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| 15 years | #8624 |
| fish oil | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| 1 2 | #8723 |
| hold | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| practical | #8756 |
| endovascular | #8756 |
| cardiovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| hydroxymethylglutaryl | #8837 |
| convenient | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| micrograms | #8914 |
| planned | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| proportional hazards | #8945 |
| signs symptoms | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| options | #9002 |
| patients placebo | #9002 |
| comprise | #9005 |
| chemoprevention | #9005 |
| societies medical | #9007 |
| clinical events | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| diagnose | #9080 |
| mps | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| time points | #9147 |
| valve prosthesis | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| pci | #9230 |
| dyspnea | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| hazards | #9264 |
| illness surveys | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| positive | #9286 |
| rabbit | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| p0004 | #9355 |
| patients negative | #9355 |
| preceded | #9376 |
| loss | #9378 |
| 014 | #9380 |
| higher incidence | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| kidney failure | #9638 |
| primary point | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| easily | #9817 |
| precise | #9817 |
| coa reductase | #9828 |
| nmol | #9828 |
| classification | #9836 |
| craniotomy | #9839 |
| 212 | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| nonhuman primates | #9871 |
| heterozygotes | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| 2003 | #9941 |
| degradation | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| pancreatic | #9997 |
| 12 hours | #9997 |
| casecontrol studies | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| protective | #10045 |
| obstacles | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| investigations | #10199 |
| cell activation | #10199 |
| cardiovascular risk factors | #10209 |
| clinical data | #10213 |
| medical therapy | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| hospitalization | #10293 |
| blood transfusion | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| 032 | #10336 |
| dilution | #10336 |
| 667 | #10337 |
| worldwide | #10337 |
| aorta | #10352 |
| greatly | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| p0003 | #10408 |
| outcome measures | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| reductase inhibitors | #10432 |
| circulation | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| patients age | #10461 |
| priority | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| 1991 | #10491 |
| style | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| patients moderate | #10570 |
| ray | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| antisense | #10583 |
| recurrences | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| microvascular | #10605 |
| 159 | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| concerned | #10674 |
| held | #10674 |
| pulmonary vascular | #10690 |
| discriminate | #10697 |
| term | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| airways | #10903 |
| diagnoses | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| ischemic | #11057 |
| neutropenia | #11057 |
| summarizes | #11062 |
| attained | #11062 |
| ethical | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| inability | #11108 |
| location | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| humans kidney | #11281 |
| cerebrovascular | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| placebo treatment | #11533 |
| occlusion | #11533 |
| multicenter study | #11542 |
| outflow | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| baseline | #11624 |
| younger patients | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| thirds | #12057 |
| dietary intake | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| causality | #12208 |
| lung | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| switzerland | #12409 |
| inflammatory response | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| guide | #12540 |
| requires | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| prostatic | #12708 |
| 45 | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| instance | #13041 |
| oral administration | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| escalation | #13107 |
| cancer risk | #13107 |
| physical | #13112 |
| vomiting | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| accurate | #13563 |
| pulmonary hypertension | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| competence | #13708 |
| vascular | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| explanation | #13773 |
| pelvic | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| members | #14033 |
| risk death | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| situations | #14084 |
| focus | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| 6 patients | #14391 |
| min1 | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| statistics | #14637 |
| renal insufficiency | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| validity | #14787 |
| independent predictor | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| decrease | #15201 |
| copd | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| drug | #15278 |
| disorders | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| women age | #15474 |
| randomised controlled trial | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| effectively | #15813 |
| examination | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| discuss | #15997 |
| severely | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| develop | #16513 |
| prevented | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| cooperative | #17262 |
| lung neoplasms | #17262 |
| estimated | #17274 |
| acute phase | #17288 |
| largest | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| ventricular function | #18296 |
| metastases | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| 2002 | #20050 |
| gestational | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| persistent | #20562 |
| elisa | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| attenuated | #21137 |
| operative | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| majority | #21894 |
| 139 | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| naive | #23767 |
| adverse | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| commonly | #27411 |
| mass bmi | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
रिपोर्ट चलाएं | |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| के लिए जाना जाता है Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL-Index: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| के लिए जाना जाता है Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| के लिए जाना जाता है Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL-Index: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| के लिए जाना जाता है Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL-Index: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| के लिए जाना जाता है Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL-Index: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| के लिए जाना जाता है Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| के लिए जाना जाता है Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL-Index: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| के लिए जाना जाता है Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL-Index: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| के लिए जाना जाता है Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL-Index: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| के लिए जाना जाता है Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL-Index: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| के लिए जाना जाता है Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL-Index: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| के लिए जाना जाता है Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| के लिए जाना जाता है Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL-Index: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| के लिए जाना जाता है Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
के लिए प्रमुख लोग Pulmonary Embolism
दुनिया में शीर्ष kols
एक खोज वाक्यांश का चयन करें pulmonary embolism , pulmonary embolism patients , pulmonary embolism 95 , pulmonary embolism diagnosis , pulmonary embolism treatment
Harry Roger Büller:विशेषज्ञ प्रभाव
जिसके लिए अवधारणाएंHarry Roger Büllerप्रत्यक्ष प्रभाव है:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:कोल इम्पैक्ट
अन्य लेखकों के काम से संबंधित अवधारणाएं जिनके लिएfor which Harry Roger Büller प्रभाव है:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
क्या यह आपकी प्रोफ़ाइल है? अपनी प्रोफ़ाइल का दावा करें यूआरएल कॉपी करें अपनी प्रोफ़ाइल के लिए लिंक एम्बेड करें |